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Uterine leiomyosarcoma (ULMS) is an aggressive malignancy characterized by 
marked chemoresistance, frequent relapses, and poor outcome. Despite efforts to 
improve survival over the past several decades, only minimal advances have been 
made. Hence, there is an urgent and unmet need for better understanding of the 
molecular deregulations that underlay ULMS and development of more effective 
therapeutic strategies.  
 
This work identified several common deregulations in a large (n=208) tissue 
microarray of ULMS compared to GI smooth muscle, myometrium, and leiomyoma 
controls. Our results suggest that significant loss of smooth muscle and 
gynecological differentiation markers is common in ULMS, a finding that could help 
render improved ULMS diagnosis, especially for advanced disease. Similarly to 
reports in other malignancies, we found that several cancer-related proteins were 
differentially expressed; these could be useful together as biomarkers for ULMS.  
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Notably, we identified significant upregulation and overexpression of the mTOR 
pathway in ULMS, examined the possible contribution of tyrosine kinase receptor 
deregulation promoting mTOR activation, and unraveled a role for pS6RP and 
p4EBP1 as molecular disease prognosticators. The significance of mTOR activation 
in ULMS and its potential as a therapeutic target were further investigated. 
Rapamycin abrogated ULMS cell growth and cell cycle progression in vitro but 
induced only sight growth delay in vivo. Given that effective mTOR therapies likely 
require combination mTOR blockade with inhibition of other targets, coupled with 
recent observations suggesting that Aurora A kinase (Aurk A) deregulations 
commonly occur in ULMS, the preclinical impact of dually targeting both pathways 
was evaluated. Combined therapy with rapamycin (an mTORC1 inhibitor) and 
MLN8237 (an investigational Aurk A inhibitor) profoundly and synergistically 
abrogated ULMS growth in vitro. Interestingly, the superior effects were noted only 
when MLN8237 was pre-administered. This novel therapeutic combination and 
scheduling regimen resulted in marked tumor growth inhibition in vivo. Together, 
these data support further exploration of dual mTOR and Aurk A blockade for the 
treatment of human ULMS.  
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Introduction 
Soft tissue sarcoma  
Soft tissue sarcomas (STS) are a complex group of rare malignancies (about 1% of 
all tumors) that are diagnosed in 9,500-10,520 individuals per year.1-3 Arising from 
cells of mesenchymal origin, STS can originate from almost any anatomic locus 
within the body in several tissue types including smooth and striated muscle, fat, 
and nerves, irrespective of age.4,5 Classification of STS is based on the presumed 
cell of origin and hence, subtype names are reflective of cell of origin. For example, 
the subtype name “leiomyosarcoma” can be broken down into “leio” – meaning 
smooth, “myo” – meaning muscle, and “sarcoma” – meaning mesenchymal-derived 
malignancy; as their name implies, leiomyosarcoma are tumors of smooth muscle 
origin. There are currently more than 50 recognized histological subtypes of STS 
that can be divided into 2 groups: simple or complex karyotype STS.4,6 STS with 
simple karyotypes have specific genetic alterations (i.e. translocations or point 
mutations) that are a major contributor to sarcomagenesis while complex karyotype 
STS have a wide array of multiple genetic alterations.7 STS frequently metastasize 
and are generally chemoresistant, resulting in 5-year survival rates of only 50%.5,8-10 
   
Leiomyosarcoma (LMS)  
Leiomyosarcoma account for about 1/7 to 1/4 of all STS11-13 and are a more 
common soft tissue sarcoma subtype, followed in frequency by malignant fibrous 
histiocytoma and liposarcoma.12 As their name suggests, leiomyosarcomas are 
malignancies of smooth muscle origin and can occur throughout the body wherever 
smooth muscle is present. The most common sites for leiomyosarcoma are the 
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retroperitoneum, extremities, and uterus; as much as 40% of leiomyosarcoma in 
women occur within the uterus corpus.4,12 Many studies report a strong predilection 
for the development of leiomyosarcoma in African Americans versus Caucasians. 
The African American:Caucasian rate ratio is 1.2 for all leiomyosarcoma; in African 
American versus Caucasian women, this ratio is increased to 1.7.12 Extra-uterine 
leiomyosarcoma incidence increases with age in a linear fashion whereas uterine 
leiomyosarcoma incidence is greatest around pre- to menopausal ages (40-60 
years of age).12 As a whole, leiomyosarcoma are aggressive, chemoresistant, and 
have a propensity to recur and metastasize.  
 
Uterine Leiomyosarcoma (ULMS)  
Uterine leiomyosarcoma (ULMS) arise from smooth muscle walls of the uterus and 
represent the most common subtype of uterine sarcoma, a group of infrequent but 
highly devastating diseases.14,15 Although ULMS account for only 1-2% of all uterine 
malignancies, they are the cause of >25% of all uterine cancer-related deaths.16 
The disease most frequently manifests during the fourth to sixth decade of life with 
slight predilection towards African American women.14 ULMS are highly aggressive 
and recur or metastasizes in as many as 73% of patients.1 Even in patients with 
early stage (I or II) ULMS, a recurrence rate of nearly 40% is observed (14.3% with 
isolated pelvic recurrence, 65.7% with distant metastases, and 20.0% with disease 
in both loci).17,18 Metastatic lesions are most commonly found in the lungs, liver, 
bone, extremity tissues and skin (especially scalp).19 In addition, case report studies 
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have identified ULMS metastases in the brain, thyroid, breast, pancreas, and 
heart.20-24 
 
Symptoms, diagnosis, and staging 
Women with ULMS typically present asymptomatically in early stages, but abnormal 
vaginal bleeding, pain, and/or a palpable pelvic mass may be present.15 Such 
symptoms closely mimic those of leiomyomas (uterine fibroids), common and 
benign uterine growths that occur in nearly 2/3 of women and are frequently 
observed as multiple lesions lining the uterus.25 For this reason, it is often hard to 
distinguish a single ULMS lesion within a uterus containing multiple fibroids. 
Fibroids are usually treated by observation alone until they become symptomatic, at 
which time hormone-based therapies, myomectomy, or total abdominal 
hysterectomies are utilized.16,26-29 
 
The diagnosis of ULMS can be difficult to establish due to many contributing factors.  
In women who have previously opted for surgical resection of presumed 
leiomyomas, diagnosis of ULMS is often made incidentally upon surgical specimen 
review by pathologists post-resection.30 About 0.1% of leiomyomas that are 
presumed benign are actually found to be ULMS and extensive studies have shown 
that leiomyoma is a distinct entity which does not degenerate into ULMS.28 Another 
confounding factor in ULMS diagnosis is the “watch and wait” policy for the 
treatment of leiomyoma, which often delays ULMS diagnosis.28,30 
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Diagnosis of ULMS may be indicated or supported by several imaging techniques 
including ultrasound, computerized tomography (CT) or positron emission 
tomography/CT (PET/CT).31 ULMS are usually visualized via ultrasound as large, 
oval shaped lesions; bizarre and inhomogeneous internal echo patterns; necrotic 
tumor centers are often noted. PET imaging uses radio labeled18-
fluorodeoxyglucose ([18F]FDG) that is taken up in areas of high metabolic activity 
within the body, especially in tumors. It is often combined with CT to obtain both 
anatomical and morphological features of the study area.32,33 Although the 
technique cannot readily detect very small or low-grade lesions, PET/CT or CT are 
regularly performed during diagnosis and follow-up to aid in the diagnosis of 
recurrent and metastatic ULMS in the lungs and abdomen/retroperitoneum.30  
 
The next step towards confirming a diagnosis of ULMS is by obtaining biopsies 
and/or resection specimens, which are sent to pathology for histological evaluation 
and confirmation of ULMS diagnosis. ULMS generally appear as large oval-shaped 
nodules that are firm to the touch and yellow or tan in color.30 Centralized necrosis 
and hemorrhaging is frequently observed.30,34 Several studies have shown that 
large size (>15-10cm), extrauterine extension, and infiltrating borders are common 
features of ULMS.15,35,36 ULMS are comprised of spindle shaped cells with 
elongated nuclei and are characterized by large numbers of atypical nuclei, high 
mitotic indices, alterations in chromosome copy number, and complex 
karyotype.30,37,38 Ferenczy et al. performed a comparative ultrastructural 
microscopy-based study ULMS and found they have very large, irregularly shaped 
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nuclei; multiple nuclei were often observed within the same cell and randomly 
dispersed chromatin and dense nucleoli were present.39 Noted increases in mitotic 
activity and nuclear pleomorphism were observed in ULMS as well as reduced 
collagenous stroma and myofilament bundles, which were also increasingly 
disorganized.39  
 
Once radiological, then histological and pathological data have been compiled, 
physicians can classify each patient into stages. ULMS staging is performed as per 
The International Federation of Gynecology and Obstetrics (FIGO) classification 
system incorporating tumor, lymph node, and metastatic status in a four-stage 
schema (Table 1). Staging helps physicians to stratify tumors based on the criteria 
above and provides a starting point for rational therapeutic interventions. 
 
Treatment 
Therapeutic interventions for ULMS are varied and first/second line therapies differ 
depending on tumor stage classification. For all resectable primary ULMS, surgery 
is regarded as the mainstay of treatment; aggressive wide margin resection is 
standard. Most commonly, complete hysterectomy with bilateral salpingo-
oophorectomy is performed.40 However, several studies indicate that ovarian 
preservation does not negatively affect overall survival, and therefore, it is 
sometimes considered in women of childbearing age to avoid premature onset of 
menopause.30,40 Additionally, the risk of ovarian metastasis is low (about 4%), with 
many of these being low-grade, hormone-sensitive LMS.30,41-44  
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Table 1. FIGO staging for ULMS 
TNM FIGO Stage Definition 
Primary Tumor (T) 
 TX    Primary tumor cannot be assessed 
 T0    No evidence of primary tumor 
 T1 I  Tumor confined to uterus 
T1a IA  Tumor <5cm  
T1b IB  Tumor>5cm 
 T2 II  Tumor confined to uterus and pelvis 
T2a IIA  Tumor involves adnexa 
T2b IIB  Tumor involves other pelvic tissues  
 T3 III  Tumor infiltrates abdominal cavity 
T3a IIIA  Infiltration at one site 
T3b IIIB  Infiltration at more than one site 
 T4 IV  Tumor growth distant from uterus 
T4a IVA  Tumor invades bladder or rectum 
Regional Lymph Nodes (N) 
 NX    Regional lymph nodes not assessed 
 N0    No regional lymph node metastasis 
 N1 IIIC  Regional lymph node metastasis 
Metastases (M) 
 M0    No distant metastasis 
 M1 IVB 
    
 Distant metastasis (excluding 
 pelvic and abdominal) 
        
Overall Diagnosis (TNM combined staging) 
 Stage I T1 N0 M0    
 Stage IA T1a N0 M0    
 Stage IB T1b N0 M0    
 Stage II T2 N0 M0    
 Stage IIIA T3a N0 M0    
 StageIIIB T3b N0 M0    
 Stage IIIC T1, T2, T3 N1 M0    
 Stage IVA T4 Any N M0    
 Stage IVB Any T Any N M1     
Adapted from American Joint Committee on Cancer 2010. 
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Several comprehensive studies have shown that unlike epithelial-derived 
malignancies, sarcomas do not have a propensity for lymph node involvement.45 In 
a large cohort study of 1396 ULMS patients Kapp et al. demonstrated lymphatic 
spread in only ~3-7% of ULMS.36 While lymphatic involvement is more frequent in 
advanced stage tumors, ULMS metastases regularly occur in its absence.36 Neither 
adnexectomy or lymphanedenectomy were found to be prognostic factors favoring 
survival, and fewer than 25% of ULMS patients therefore undergo regional 
lymphanedenectomy.36  
 
Early stage ULMS treatment 
For early stage tumors (stages I and II), surgery is regarded as the first-line therapy. 
Following surgery with clear margins, patients are generally placed on a “watch and 
wait” policy and do not undergo chemotherapeutic treatment, as it shows no clear 
clinical benefit.17,30,40  If clear margins are not obtained or an aggressive 
chemotherapy approach is warranted, patients may consider radio- or 
chemotherapy.  
 
The use of adjuvant radiation therapy to the pelvis may be considered, as some 
studies suggest it may reduced the risk of local recurrence.46 In a 103 patient trial, 
Reed et al. administered pelvic radiation to stage I and II ULMS patients over the 
course of 5 weeks; no significant benefits were observed.47 However, the efficacy of 
radiation therapy in this setting remains controversial and most studies agree that 
there is little to no therapeutic benefit.46-48 Hormonal agents such as tamoxifen are 
largely ineffective versus aggressive ULMS and may even accelerate 
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sarcomagenesis.49,50 Chemotherapeutic agent doxorubicin also offered no overall or 
recurrence-free survival benefit.18 However, adjuvant gemcitabine and docetaxel 
combination therapy yielded significant improvement in survival over historical rates. 
In a study conducted by Hensley et al., 59% of stage I or II ULMS patients were 
progression-free at 2 years; the median progression-free survival while on 
gemcitabine/docetaxel combination therapy was 39 months.51 In early stage 
disease, most studies agree that radiation and chemotherapy have minimal to no 
added benefit. Additionally, radio- or chemotherapy may be considered. 
 
Locally advanced and recurrent ULMS treatment 
Many ULMS patients will be diagnosed with locally advanced (stage III) disease, 
where the tumor extends beyond the uterus. Additionally, numerous others will 
experience relapse and recurrent tumors will emerge. Surgery is generally regarded 
as the only curative modality in both subsets of patients, but achieving clear 
margins is often difficult or not possible. In such cases, additional therapies may be 
used to reduce tumor size, which may sometimes allow for surgery.35 
 
Radiation therapy is sometimes employed in locally advanced or recurrent ULMS, 46 
but appears to have little to no impact on progression-free or overall survival.46,48 
Despite having little to no curative effects, radiation therapy can be used effectively 
in palliative care setting for large tumors in terminal patients.42 Doxorubicin 
(adriamycin) is one of the best-studied and clinically administered chemotherapies 
in ULMS. It acts by inhibiting topoisomerase II and thus, DNA replication.52 
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Doxorubicin has been modestly effective against ULMS with response rates of 
about 25% and may decrease the likelihood of recurrence (61% in placebo-dosed 
patients compared with 41% in doxorubicin-treated patients), however, it did not 
significantly effect progression-free or overall survival.18,53-55 Several other 
monotherapies have shown minimal success in ULMS therapy (Table 2). Given the 
overall lack of response to monotherapies, combination therapies have been 
examined in locally advanced/recurrent ULMS including ifosfamide/doxorubicin and 
docetaxel/gemcitabine. Studies in advanced recurrent ULMS (and metastatic 
ULMS) using a docetaxel/gemcitable combination yielded the most efficacious 
results (36% response) in the treatment of recurrent ULMS and are discussed as 
part of the following section.56,57 
 
Metastatic ULMS treatment 
Metastatic ULMS are highly invasive, rapidly proliferating, and aggressive lesions 
that most frequently develop in the lungs, where patients often develop multiple 
bilateral lesions.18 In these lesions surgery, when possible, represents the first-line 
therapeutic approach. Burt et al. report that aggressive metastasectomies 
significantly extend overall survival, however, they do not extend disease-free 
survival and more than 80% of women with pulmonary metastasectomies 
experienced recurrence.58 The study concluded that long-term survival could be 
achieved through repeated and aggressive pulmonary metastasectomy for patients 
with recurring ULMS pulmonary metastases.58 Surgical resection for 
extrapulmonary metastases is also advantageous and can enhance the probability 
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Table 2. Monotherapy regimens for ULMS treatment 
Author (year)  Therapy/Regimen  Study  Cohort Disease Stabilization  
Partial/Complete 
Response  (n)  
Sutton (1992)  Ifosfamide  (1.5mg/m2 for 5 days) 
Uterine 
sarcoma & 
ULMS, 
 Phase II 
ULMS/uterine sarcomas 
without prior 
chemotherapy  
- 17% 35 
Sutton (1999)  Paclitaxel  (175mg/m2 every 3 weeks  
ULMS,  
Phase II 
Recurrent or advanced 
ULMS without prior 
chemotherapy  
24% 9% 33 
Gallup (2003)  Paclitaxel  (175mg/m2 every 3 weeks) 
ULMS,  
Phase II 
Recurrent or advanced 
ULMS without prior 
chemotherapy  
23% 8% 48 
Look (2004)  
Gemcitabine 
 (1000mg/m2 every 3 weeks 
on days 1, 8, 15) 
ULMS,  
Phase II 
Recurrent or persistent 
ULMS after progression 
on chemotherapy 
16% 21% 42 
Anderson (2005)  
Temozolomide  
(50-75mg/m2 daily for 6 of 8 
weeks) 
ULMS Recurrent or metastatic, unresectable ULMS  33% 8-14% 13 
Wade (1990) Tamoxifen  ULMS All stages of ULMS  - 4% 28 
Amant  (2009)  Trabectedin  (1.5mg/m2 every 3 weeks) 
Uterine 
sarcoma 
Metastatic high grade 
uterine sarcoma after 
progression on 
chemotherapy  
64% 45% 11 
Omura (1985)  Doxorubicin  (60mg/m2 every 3 weeks) 
Uterine 
sarcoma 
Stage I or II uterine 
sarcoma  
no difference 
in survival 
no difference in 
recurrence 28 
Sutton (2005)  Liposomal Doxorbicin (50mg/m2 every 4 weeks) 
ULMS,  
Phase II 
Recurrent or advanced 
ULMS after progression 
on local therapy 
32% 16% 32 
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of long term survival in ULMS patients.59 Resection is regarded as the only 
curative therapy; moderate successes have been achieved with chemotherapies. 
Radiation therapy can also be effective in palliative care for metastatic ULMS, but 
offers no clear curative benefits.46 
 
While surgical resection is the only curative treatment in metastatic ULMS, it is 
not practical or even possible for most patients; so aggressive chemotherapy 
regimens often represent the best and primary course of therapy. Whether alone 
or in combinations, chemotherapeutic regimens can be mildly successful in 
extending survival for ULMS patients with metastatic lesions. Several single-
agent regimens such as docetaxel, temazolamide, and cisplatin, have been 
utilized in ULMS therapy, albeit with very little success (Table 2).18,55,60-68 
Notably, single-agent trabectadin is sometimes used in cases of advanced and 
metastatic ULMS. While trabectadin offers minimal response rates of 16%, 
several studies indicate that it can significantly stabilize disease for progression-
free responses in about 53% of patients for three months and about 35% of 
patients for six or more months, suggesting that trabectadin may offer additional 
benefit in selected patients.69-71  
 
Given the overall lack of appreciable response to monotherapies, a number of 
combined agent approaches in ULMS have emerged (Table 3).56,57,72-76 For 
example, combined doxorubicin/ifosfamide therapy yielded a 30.3% overall 
response rate; a low, but considerably better result than that of either therapy 
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alone.62 Currently, the most successful therapy for advanced and metastatic 
ULMS utilizes a combined gemcitabine/docetaxel approach.57,75 As a first-line 
approach, gemcitabine/docetaxel yielded complete response in only 4.8% of 
patients and partial response in 31% of patients, resulting in an overall response 
rate of 35.8%. In addition, 26.2% of the other study patients experienced disease 
stabilization while receiving the combined therapy and the median overall 
survival was extended by >16 months (range 4-41 months).57 A similar study 
utilizing gemcitabine/docetaxel combination therapy as a second-line therapeutic 
approach for women with metastatic ULMS who previously experienced tumor 
progression on cytotoxic therapies (mostly doxorubicin-based) showed slightly 
less favorable, albeit measureable effects. Complete response was observed in 
6.3% of patients and partial response in 20.8% of patients; the overall response 
rate was 27% (n=48 evaluable cases). Notably, 73% of patients had a 
progression-free interval of at least 12 weeks and 52% were progression-free for 
at least 24 weeks.56 Overall, gemcitabine/docetaxel combination therapy 
currently represents the most effective chemotherapy regimen for ULMS. While 
the minimally improved response rates that are observed with administration of 
this therapy are superior to those of other clinically approved chemotherapeutic 
agents, it is critical to emphasize that only about one of every three women with 
ULMS will show any positive response to this therapy; for the remaining two-
thirds, efficacious chemotherapies have not yet been identified. 
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Table 3. Combination therapies for the treatment of ULMS 
Author (year)  Therapy/Regimen  Study Cohort Stable Disease 
Partial/Complete 
Response  (n) 
Hensley (2002)  gemcitabine/docetaxel LMS, Phase II 
Unresectable LMS after 
progression with ≥ 2 prior 
chemotherapies. 
21% 53% 34 
Hensley (2008)  gemcitabine/docetaxel ULMS, Phase II 
 Advanced ULMS with no 
prior chemotherapy 26% 36% 39 
Hensley (2008)  gemcitabine/docetaxel ULMS, Phase II 
Unresectable metastatic 
ULMS after progression 
on first line chemotherapy 
50% 27% 48 
Blum (1993)  doxorubicin/ifosfamide STS, Phase III Metastatic STS - 34% 88 
Edmonson (1993)  doxorubicin/mitomycin/cisplatin STS, Phase III 
Advanced (recurrent, 
residual, or metastatic) 
STS  
- 32% 84 
Santoro (1995)  doxorubicin/ifosfamide STS, Phase III 
Advanced STS with no 
prior chemotherapy - 28% 221 
Patel (1998)  doxorubicin/ifosfamide STS Primary STS or Metastatic STS  - 66% 33 
Maki (2007)  Gemcitabine/docetaxel  STS Metastatic STS  - 16% 119 
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ULMS Outcome  
Women diagnosed with ULMS often face an ongoing battle and eventually, a 
grim fate (Table 4). High rates of recurrence and metastasis, regardless of 
adjuvant treatment, coupled with short disease free time intervals (usually <six 
months to one year), make ULMS a very deadly disease.17 Kapp et al. reported 
5-year disease specific survival for women diagnosed by stage as: stage I - 
75.8%, stage II – 60.1%, stage III – 44.9% and stage IV – 28.7%.36 Others cite 5-
year survival rates as low as 8% for women diagnosed with stage II-IV ULMS.44 
A 1971 report indicates a 5-year survival rate of 20.7% with a high level of 
recurrence.14 More than 35 years later, reports indicate 5-year overall survival 
rates at only 20-60% regardless of stage at diagnosis. While the long term 
survival rate approaches 90% for the much more common endometrial 
adenocarcinoma,77 the ULMS 5-year survival rates are far less encouraging 
despite several decades of research efforts towards identifying molecular 
underpinnings of the disease.78,79 
 
In summary, complete wide margin surgical resection in ULMS often confers 
significant postoperative morbidity and chemotherapy/radiation-based 
interventions offer very low response rates in uterine leiomyosarcoma and bring 
clinical benefit to only a small subset of patients. Several chemotherapy 
monotherapies and combined treatment regimens have been evaluated with 
inconsistent resultant efficacy and 18,47,60,61,63-68,80-82 despite research efforts over 
the past several decades, very little improvement in ULMS survival rates has 
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Table 4. Recurrence-free, metastasis-free, and disease specific survival in 
ULMS. 
Author (year) Stage (n=) 
Recurrence 
Rate 
Metastasis 
Rate 5-yr survival 
Salazar (1978)  
Stage I 
Stages II-IV 
- 
 
- 
 
(Overall) 
56% 
7% 
George (1986)  All stages (n=81) 
(2-year) 
23% (19/81) 
(2-year) 
38% (31/81) 
(Overall) 
~35% 
Larson (1990)  
Stage I (n=97) 
Stage II (n=11) 
Stage III (n=27)  
Stage IV (n=8) 
(5-year, all 
stages) 
 
63.6% 
(49/77) 
(5-year, all 
stages) 
 
54.5% (42/77) 
(Overall) 
39% 
~18% 
~7% 
0% 
Major (1993)  
Stage I (n=49) 
Stage II (n=2) 
Stage III (n=5) 
Stage IV (n=3) 
(Overall, all 
stages) 
 
13.5% (8/59) 
(Overall, all 
stages) 
 
64.4% (38/59) 
(Overall, all 
stages) 
 
31% 
Gadducci (1996)  
Stage I/II (n=126) 
Stage III (n=16) 
Stage IV (n=6) 
(5-year) 
13% (12/90) 
56.3% (9/16) 
33.3% (2/6) 
(5-year) 
33.3% (30/90) 
62.5% (10/16) 
83.3% (5/6) 
(DSS) 
61.1% 
0% 
0% 
Nordal (1997)  
 
Stage I 
Stage IV 
Total (n=475) 
- 
 
- 
 
(Overall) 
65% 
0% 
 
Blom (1998)  
Stage I/II (n=29) 
Stage III/IV (n=20) 
68% (19/29) 
- 
- 
- 
(DSS) 
42% 
0% 
Mayerhofer (1999)  
Stage I (n=49) 
Stage II (n=5) 
Stages III/IV (n=17) 
- 
 
 
- 
 
 
(Overall) 
~78% 
~0% 
~12% 
Ferrer (1999)  All stages (n=43) - 
- 
 
(DSS) 
55.4% 
Pautier (2000)  
 
Stage I (n=45) 
Stage II (n=10) 
Stage III (n=7) 
Stage IV (n=14) 
(5-year, all stages) 
 
~80% 
(Overall) 
 
 
~35% 
 
 
 
 
Giuntoli (2003) 
 
 
 
 
Stage I (n=130) 
Stage II (n=13) 
Stage III (n=18) 
Stage IV (n=41) 
 
 
 
 
 
- 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
(DSS) 
~60% 
~47% 
~34% 
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~20% 
Livi (2003)  All Stages (n=72) - - 
(Overall) 
18.8% 
Wu (2006)  
 
Stage I (n=51) 
Stage III/IV (n=10) 
(5-year) 
29.3% 
50% 
(5-year) 
66.7% 
60% 
(Overall) 
73.6% 
43% 
Kapp (2008)  
Stage I (n= 951) 
Stage II (n=43) 
Stage III (n=99) 
Stage IV (n=303) 
- 
 
 
- 
 
 
(DSS) 
75.8% 
60.1% 
44.9% 
28.7% 
 
 
 
been achieved. It is clear that the development of novel, efficacious therapies through 
a better understanding of molecular deregulations and identification of potential drug 
targets is essential towards improving survival in ULMS patients. 
 
 
Molecular underpinnings of ULMS 
 
Over the past several decades, a number of studies have been conducted to examine 
the molecular underpinnings of ULMS. To develop more effective anti-ULMS 
therapies, a better understanding of molecular drivers and genetic/epigenetic 
aberrations in the disease must be acquired.  
 
Genetic/epigenetic 
Several genetic/epigenetic aberrations and molecular alterations have been identified 
in small ULMS patient cohort studies. Many ULMS have regions of amplifications or 
loss that may contribute to their malignant phenotype. Studies, including comparative 
genomic hybridization (CGH) arrays, have revealed amplifications or deletions in 
1q21, 1p12-13, 1p31-32, 5p14, 8q, 10, 12q13-15, 12q31, 13q, 17p11, 19p13, and 
20q13 regions.83-85 A few genes of interest in these regions include amplification of 
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Ras oncogenes (RAB3B - 1p31-21, RAP1A – 1p12-13) and the MET 
protooncogene.86,87 In one study, specific gains and losses of gene copy number were 
evaluated by CGH array in seven ULMS samples and averages of 4.86% gain and 
15.1% loss were identified.83 The study reports substantial gain in chromosomes 
seven and twelve at 7q36.3, 7q33–q35, 12q13–12q15, and 12q23.3. Homozygous 
loss was identified in chromosomes one, two, six, nine, and fourteen at 1p21.1, 
2p22.2, 6p11.2, 9p21.1, 9p21.3, 9p22.1, 14q32.33, and 14q32.33 qter.83 Genes 
associated with regions of gain were HMGIC, SAS, MDM2, PDGF-β, KLK2, and TIM1 
genes. Those associated with regions of loss included: LEU1, ERCC5, THBS1, DCC, 
MBD2, SCCA1, FVT1, CYB5, and ETS2/E2.83 Another CGH array by Packenham et 
al. compared ULMS (n=8) versus leiomyoma (n=14).88 The study showed that only 
2/14 leiomyoma showed genetic alterations whereas all ULMS had multiple regions of 
gains and losses. Gain on chromosome 1 (both arms) was most common in ULMS 
and occurred in 5/8 samples.88 Additional studies have suggested a 291kb region on 
16q24 and a 2.5Mb region on 1p36.32 loss and gain of regions in chromosomes 1, 7, 
and 15. Regions gained were associated with three genes implicated in 
tumorigenesis: TCF12, ABL2, and MET.89 Other genes of potential interest in this 
region include CBFA2T2 and FANCA, both of which are implicated in acute myeloid 
leukemia.90,91 Amplification of 17p11 and 7q31.2 were also identified and contain 
MYCOCD and MAP2K4 genes and the gene for a protein that may activate the AKT 
pathway named calveolin, respectively.89 A region of was also identified in 13q14.2, 
which contains the RB1 gene encoding the Rb tumor suppressor protein.89 Overall, a 
study in recurrent ULMS confirmed findings from several groups and overall, found 
that well over half of ULMS samples had clonal chromosomal abnormalities.87  
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Genetic mutations could also lead to a tumorigenic phenotype and have been 
identified in ULMS. For example, p53, a critical tumor suppressor, was found to be 
mutated in more than one-third of leiomyosarcoma.92 Fumarate hydrase mutations 
have also been identified in and may predispose patients to ULMS.93 Additionally, 
mutations in several key proteins such as Jak1, MDM2 and TSC2 have been 
observed in ULMS.94-96 A combination of amplification in oncogenic regions, loss in 
tumor suppressor regions, and genetic mutations may contribute to ULMS. 
 
Epigenetic regulation of ULMS has also been minimally evaluated. Several genes 
encoding tumor suppressor proteins can be epigenetically downregulated in cancer 
and are implicated in tumorigenesis. For example, Xing et al. showed that BRCA1 
downregulation in ULMS is likely due to BRCA1 promoter methylation.97  Also, loss of 
PTEN has been shown to activate the AKT/mTOR pathway in leiomyosarcoma and is 
suggested to be a driving force of tumorigenesis.98 Methylation of the PTEN promoter 
region has been previously implicated in PTEN loss in other cancer and could be a 
contributing cause of PTEN loss in ULMS.99 However, a single LMS study did not 
show any significant PTEN promoter methylation, suggesting that PTEN methylation 
may not be as prevalent in LMS/ULMS as in other cancers.99 The p16 protein and 
tumor suppressor is reported to be reduced or lost in some ULMS. Xu et al. examined 
the methylation status of INK4A (the gene that encodes p16 protein) compared to p16 
expression in a series of 38 LMS compared against 10 leiomyomas and 5 normal 
smooth muscle samples.100 In total, almost one-quarter of LMS had hypermethylated 
INK4A promoter regions; samples with hypermethylated promoter regions also had 
absent or faint positive p16 staining, suggesting that 5’ CPG methylation to the 
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promoter region of INK4A may be a significant cause of diminished expression of p16 
protein in LMS.100 A number of epigenetic deregulations could occur in ULMS and 
may contribute to leiomyosarcomagenesis, however, additional studies are required to 
confirm existing reports and identify novel epigenetic regulations. 
 
Gene Alterations  
Studies have been conducted to identify genes differentially expressed in ULMS/LMS 
compared with myometrium and leiomyoma. Skubitz et al. examined genes 
associated with malignant transformation in ULMS/LMS compared against 
myometrium and leiomyoma.101 Several differentially expressed genes were 
identified, including many that were overexpressed in ULMS/LMS compared to 
leiomyoma and myometrium. Genes that had increased expression by ≥10-fold were: 
interleukin-17B, proteolipid 1, doublecortin, osteoponin, pituitary tumor transforming 1, 
calpain 6, and ubiquitin conjugating enzyme E2C. A number of additional genes were 
enriched five to ten-fold in ULMS/LMS compared to other tissues including those 
encoding for CDC2 associated protein CKS2, cellular retinoic acid binding protein 2, 
cyclin-dependent kinase inhibitor 2A (CDKIN2A), diaphanous (Drosophila homolog) 3, 
forkhead box M1B, popeye protein 2, protein regulator of cytokinesis (PRC-1), 
suppression of tumorgenicity 5 (STS 5) and topoisomerase II-α.101  
 
Other potential deregulations 
In addition to genomic/epigenetic expression profiling, a handful of studies have 
examined several proteins that are potentially over- or under-expressed in ULMS 
compared with myometrium or leiomyoma controls including c-Myc, MET, IGF and 
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IGFR, PTEN, Rb, MMP1 and MMP2, and PDGFR-α.38,84,85,89,102-105 Together, 
evidence suggests that ULMS has deregulations in critical pathways.106 Small cohort 
studies have identified several potential genetic, epigenetic, and molecular 
aberrations that may contribute to the aggressive ULMS phenotype; however, few 
large scale studies have been conducted to date, so global conclusions cannot be 
drawn at this time. Comprehensive, large-cohort studies could confirm previous 
findings and provide insight into the molecular deregulations that contribute to and 
underlay ULMS. 
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The mTOR!Pathway in ULMS 
 
Molecular aberrations can play a role in pathway deregulation and contribute to 
tumorigenesis. Several groups have reported mTOR pathway activation in cancer, 
sarcoma, and even LMS, suggesting that it may be a critical pathway in cancer and 
lending evidence to suggest that it could be deregulated in ULMS.98,107  
 
mTOR : biochemistry and function 
The protein mTOR (mammalian target of rapamycin) lies at the crux of the 
PI3K/AKT/mTOR signaling cascade and controls cell survival, growth, migration, and 
cell cycle progression through regulation of mRNA translation.108,109 mTOR, also 
known as FRAP1, is a 289kDa serine/threonine kinase that functions mainly in two 
unique complexes: mTORC1 and mTORC2 (Figure 1A).102,103,110-112 The primary 
differences between mTORC1 and mTORC2 are that mTORC1 complexes with raptor 
and is sensitive to mTOR inhibitor rapamycin, while mTORC2 binds in a complex with 
rictor and is rapamycin insensitive.113,114 Several domains within the mTOR protein 
have been identified including HEAT repeat, FAT, FRB, FATC, and Ser/Thr kinase 
domains (Figure 1B).110 mTOR is a member of the TOR (target of rapamycin) family; 
only one TOR protein exists in mammals compared to two in yeast and one in 
Drosophila.115,116 The TOR proteins are evolutionarily conserved to some extent and 
share approximately 40-60% homology between mammals, yeast, worms, and 
drosophila.116-119 This pronounced homology preservation among several different 
species further indicates that the protein confers essential functions in cell  
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Figure 1. mTOR is a critical signaling molecule. A) mTOR functions in two distinct 
complexes, mTORC1 and mTORC2. B) mTOR has several domains that lend 
towards its functionality. (Adapted and reprinted by permission from Macmillan 
Publishers Ltd: [Nature Reviews Neuroscience] Bove, J. et al., Fighting 
neurodegeneration with rapamycin: mechanistic insights, copyright 2011).110 
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growth. Moreover, mTOR knockdown results in embryonic lethality just after 
implantation due to developmental abnormalities and points further to the critical role 
of mTOR in growth regulation.120,121  
 
mTOR has four predominant phosphorylation sites, Ser1261, Thr2446, Ser2448, and 
Ser2481.122 Phosphorylation at Ser1261 is thought to be the only site that directly 
regulates mTOR activity.122 Additionally, Ser2481 is shown to be 
autophosphorylated.123 The status of this autophosphorylation has been linked to 
mTOR activity, although the mechanisms by which this occurs are largely 
unknown.124,125 Activated AKT is responsible for phosphorylation of residues Thr2446 
and Ser2448, presumably through AKT activation induced by a S6 kinase feedback 
loop that is described later in this chapter. The function(s) of these latter 
phosphorylations remain unclear.126,127  
 
mTORC1 plays a critical role in protein translation and regulation of the AKT/mTOR 
pathway. Consisting of mTOR, raptor (regulatory-associated protein of mTOR) and 
GβL/LST8, the complex relays PI3K/AKT signals downstream and regulates 
translational effects from such signaling. As part of mTORC1, mTOR phosphorylates 
two main downstream targets, ribosomal protein S6 kinase (S6K) and eukaryotic 
initiation factor binding protein 1 (4E-PB1; Figure 2).128 Phosphorylation of S6K 
occurs at Thr389 by mTORC 1 and Thr229 by PDK1, thereby activating the protein,  
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Figure 2. mTORC1 downstream signaling. mTORC1 phosphorylates at Thr389 to 
activate the 70S6K; further activation by PDK1 at Thr229 fully activates the protein. 
Activated 70S6K phosphorylates and activates S6RP, which signals downstream to 
regulate translation of 5’TOP-containing mRNAs and ultimately, enhancement of cell 
growth and metabolism. Phosphorylation of 4EBP1 is inhibitory and results in 
abrogation of 4EBP1-binding to eIF4E translation initiation factor, resulting in unbound 
eIF4E and enhanced translation. 
 
 
which in turn activates 4eIF4B, a molecule involved in translation, and S6RP.127,129-132 
Through this pathway, S6K regulates translation of 5’TOP-containing mRNAs.133 
Cumulatively, S6K activation via phosphorylation results in enhancement of cell 
growth and metabolism. mTOR also phosphorylates 4E-BP1 in an inhibitory manner, 
which results in abrogation of 4EBP1 binding to translation initiation factor eIF4E and 
promotes translation initiation.134 Together, the effects of mTOR inhibition on 
downstream targets are prevention of the translation of mRNA critical in cell cycle 
advancement from G1 to S phase, thereby trapping cells in G1.38,109,134,135  
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mTORC1 regulates protein translation by several complex mechanisms. Eukaryotic 
translation is a three-step process involving temporally oriented initiation, elongation, 
and termination steps. Many initiation and elongation steps in protein translation are 
regulated by mTOR and its downstream effectors. For example, translation initiation 
factors (eIFs) help to mediate recruitment of mRNA to the 40S ribosome unit and also 
help to bring methionyl-tRNA molecules to the sites of translation, which recognize the 
start codon and initiate translation.136 One particularly important eIF, eIF4E, binds to 
the 5’ of the mRNA and coupled with the activities of several additional proteins such 
as scaffold protein eIF4G and DNA helicase eIF4A, elF4E forms a complex that binds 
to mRNA and initiates translation. The binding site for eIF4G located within eIF4E also 
serves as a binding site for 4E-BP1.136 When bound to eIF4E, 4E-PB1 occupies the 
binding site for eIF4G, thereby abrogating binding and assembly of the translation 
complex and subsequent initiation of mRNA translation.136 Activated mTOR (via the 
mTORC1 complex) phosphorylates 4E-BP1, inactivating 4E-BP1 which results in 
eIF4E and eIF4G binding, complex formation, and initiation of translation. 
Interestingly, mTORC1, but not mTORC2, phosphorylates 4E-BP1 at Thr37 and 
Thr46, which are not sufficient to inhibit the molecule, but are required to prime 4E-
BP1 for additional phosphorylations at Ser65 and Thr70.136 These latter 
phosphorylations are near the eIF4E binding site on 4E-BP1. Thus, when 4E-BP1 is 
hyperphosphorylated, it abrogates binding to eIF4E and blocks the inhibitory effects 
that 4E-BP1 exerts on eIF4E.136 Functioning eIF4E forms a complex and initiates 
translation of many pro-tumorigenic molecules such as c-myc, HIF-1α, VEGF, and 
cyclin D1.129,137 In addition to shorter term increases in mRNA translation initiated by 
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growth/hormone signaling molecules via the mTOR pathway, the pathway can also 
mediate longer term translation capabilities of the cell by upregulating transcription of 
translational machinery.138,139  
  
mTOR has additional functions beyond regulation of mRNA translation, including cell 
cycle regulation, exerting anti-apoptotic effects, and promoting angiogenesis. 
Inhibition or sequestering of mTOR can also induce autophagy in several models, 
including mice and human cells.140,141 For example, mTOR controls G1 to S cell cycle 
progression by inhibiting cyclin D1 turnover as well as enhancing p27 
degradation.139,142,143 It can also regulate apoptosis by activation of S6K, which has 
been shown to localize at the mitochondrial membrane. There, it phosphorylates BAD, 
a pro-apoptotic protein that is inhibited via phosphorylation. Through this interaction, 
mTOR promotes cell survival through inhibition of pro-apoptotic signaling molecules. 
Additionally, mTOR also enhances intracellular levels of pro-survival molecule 
survivin.144 Although mTOR functions primarily in the cytoplasm, there is evidence to 
suggest that it also has functions as a cytoplasmic-nuclear shuttling protein.145  
 
mTOR regulation  
The mTOR pathway is regulated predominantly via extracellular signaling molecules 
(i.e. hormones and mitogens) through PI3K (Figure 3).  
 
PI3K/PTEN 
PI3K is an important intracellular signaling molecule that phosphorylates 
phosphatidylinositol-4,5-bis-phosphate (PIP2) to PIP3 at the cellular membrane.146  
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Figure 3. The mTOR pathway. A schema of the canonical PI3K/AKT/mTOR 
pathway. PI3K is a cell signaling molecule that is activated by a series of tyrosine 
kinase receptors on the cellular membrane. Once activated, PI3K causes the 
conversion of PIP2 to PIP3, which recruits AKT to the cellular surface. PTEN tumor 
suppressor acts by converting PIP3 to PIP2, thereby reducing PI3K signaling. AKT is 
later fully activated by the mTORC2 complex by phosphorylation at a second site. 
Activated AKT phosphorylates TSC2, thereby activating Rheb and subsequently, 
mTOR. mTORC1 has two main downstream targets, S6K and 4EBP1. 
Phosphorylation of these targets leads to enhanced translation, cell proliferation, and 
promotion of cell survival.  
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PI3K serves as a primary signaling relay molecule, receiving growth signals from 
activated tyrosine kinase receptors (IGF-1R, c-KIT, PDGFR, EGFR, MET, etc.) on the 
cell surface and transmitting them to intracellular downstream components.147 
Through interaction with their pleckstrin homology domains, PIP3 brings 3-
phosphoinositide-dependent protein kinase 1 (PDK1) and AKT to the cellular 
membrane. Upon interaction with PIP3, PDK1 is activated and phosphorylates AKT at 
Thr308.148,149 Phosphorylation of AKT at Thr308 results in partial activation of AKT. 
AKT is phosphorylated further by mTORC2 at Ser473 in the amino terminal domain of 
AKT to achieve full activation.112,150,151 Relative levels of intracellular PIP2 and PIP3 
are also regulated by phosphatase and tensin homolog (PTEN), which is an important 
tumor suppressor and regulator of the mTOR pathway.152 As a phosphatase, PTEN 
converts PIP3 to PIP2 via dephosphorylation, thus limiting PI3K signaling.146  
 
TSC1/2 
The tuberous sclerosis proteins (TSC1 and TSC2) are tumor suppressors that 
regulate the mTOR pathway.153 TSC1 and TSC2 heterodimerize to form the TSC1/2 
complex, which acts as a GTPase-activating protein to inhibit GTP-binding protein 
rheb (Ras homolog enriched in brain).150 In the absence of functional TSC1/2, GTP-
bound Rheb can bind to and directly activate mTOR.154-156 TSC1/2 activity is 
regulated directly by fully activated AKT, which can phosphorylate TSC2 at Ser939 
and Thr1462, thereby inhibiting the complex and activating rheb and subsequently, 
mTOR.150,157,158 TSC2 can also be phosphorylated by other signaling molecules such 
as MAP kinase pathway protein ERK1/2, which phosphorylates TSC2 at Ser 664 and 
Ser1798.159-161 Evidence also suggests that S6 kinase can phosphorylate TSC2, 
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suggesting a positive feedback regulation.162 Phosphorylation of TSC2, regardless of 
the responsible kinase, results in inactivation of GTPase-activating activity, 
enhancement of rheb activation, and promotion of downstream mTOR activation and 
signaling.160,162-165  
 
Intracellular factors 
mTORC1 can also be regulated intracellularly by both amino acid and energy levels. 
While the mechanisms surrounding regulation via amino acid levels are largely yet to 
be elucidated, experiments show that these effects are likely indirect.166-168 
Exhaustion of cellular ATP levels can also downregulate mTOR signaling through 
mechanisms that remain elusive, but may involve LKB1. Evidence suggests that the 
mechanism likely involves AMPK inactivation via phosphorylation by LKB1, leading to 
rheb and mTORC1 inhibition.169 The LKB1 energy sensing pathway is thought to be 
parallel to the PI3K pathway.170  
 
Feedback and regulatory loops 
The mTOR pathway is a complex pathway and has several feedback and regulatory 
loops. First, mTORC2, can phosphorylate and partially activate AKT, contributing to 
full AKT activation and ultimately, activation of the mTORC1 complex.171 This positive 
feedback loop is triggered upon inhibition of mTORC1. Second, mTOR/S6K are also 
known to participate in a negative feedback loop with PI3K/AKT via the insulin 
receptor substrate 1 (IRS1). In this loop, S6K is thought to phosphorylate IRS, thereby 
inactivating the protein.171  
 
!! 30!
 mTOR in cancer  
Aberrant mTOR signaling and subsequent cell proliferation and survival effects are 
thought to be important in tumorigenesis and cancer progression. The 
PI3K/AKT/mTOR pathway is highly activated and implicated in the pathogenesis of 
several malignancies, including lung, skin, thyroid, colon, prostate, and endometrial 
cancers.172-180  
 
Notably, several studies have identified high mTOR pathway activity in human soft 
tissue sarcomas. Iwenofu et al. reported that in a 20 patient cohort with high grade, 
metastatic sarcomas, more than half (11 patients) had high pS6RP expression before 
beginning treatment.181 Additionally, Dobashi et al. immunohistochemically evaluated 
140 bone and soft tissue sarcomas for AKT/mTOR pathway activation and concluded 
elevated AKT and mTOR expression was evident in 61% and 66% of tumors, 
respectively.182 Staining of a tissue microarrays for proteins in the PI3K/AKT/mTOR 
pathway showed that the pathway was highly active in human myxoid/round cell 
liposarcoma, epithelioid sarcoma, and malignant peripheral nerve sheath tumors.183 
184,185 
 
In vitro, many studies have identified AKT/mTOR pathway 
upregulation/overexpression in cancers in general and in sarcoma specifically. A 
study in ovarian carcinoma cells show elevated pAKT levels and targeting of the 
AKT/mTOR pathway in this model inhibited cell proliferation.186 Dobashi et al. 
examined a panel of bone and soft tissue sarcomas using immunoblotting and 
showed prominent activation of AKT as well as mTOR downstream targets S6K and 
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4EBP1.182 In a panel of STS cell lines, Zhu et al. demonstrated that STS cells highly 
express phosphorylated AKT.187  
 
Elevated activity of mTOR pathway proteins have been observed, identified as 
potential prognostic factor(s), and correlated to outcome in multiple cancers, including 
sarcoma.109,188-191 In hepatocellular carcinoma, Feng et al. showed that there is a 
correlation between phospho-mTOR levels, tumor size, and metastasis potential.180 In 
rhabdomysarcoma, high levels of AKT were associated with poor disease-free and 
overall survival.191 A patient-based study in sarcoma found that activation status of the 
AKT/mTOR pathway was significantly associated with poorer survival.109 Additional 
studies found that enhanced AKT activation in sarcoma significantly correlated with a 
higher probability of developing metastases182 and that enhanced AKT/mTOR 
pathway activity was associated with shorter recurrence-free and poorer overall-
survival in childhood rhabdomyosarcoma.191 Several other studies have shown that 
intratumoral expression of the mTOR pathway in cancer associated with 
tumorigenesis, progression, recurrence, metastases, and poor prognosis.137,192-195 
 
mTOR in LMS/ULMS 
mTOR pathway hyperactivation has been identified in many cancer types, including 
sarcoma; however, relatively few studies on the AKT/mTOR pathway have been 
conducted in LMS and to the best of our knowledge pathway activation/deregulation 
has not yet been reported in human ULMS. Evidence to suggest that the AKT/mTOR 
pathway is highly active in LMS stems from a study by Hernando et al., who proposed 
that elevated activation of the mTOR pathway played a defining role in the 
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development of LMS.98 Using GEM mouse models, researchers conditionally knocked 
out PTEN, an important tumor suppressor that suppresses the mTOR pathway. PTEN 
knock out led to rapid development of leiomyosarcoma in the mouse model, likely due 
to elevated activation of the mTOR pathway, suggesting that mTOR activation was a 
driving force in leiomyosarcomagenesis in these mice and suggesting potential roles 
for PTEN deletion and subsequent mTOR pathway activation in the formation of 
human ULMS.98 As part of larger studies in STS, there is also some evidence of 
AKT/mTOR pathway hyperactivation in LMS.107,187,196 As part of a larger in vitro STS 
study, our group reported elevated pAKT in Mes-Sa and SKLMS1 (uterine sarcoma 
and leiomyosarcoma of gynecological origin, respectively).187 Very few studies using 
LMS or ULMS cell lines/strains have been conducted and therefore, little is currently 
understood. 
 
Causes of mTOR pathway deregulation 
There are several possible deregulations that could lead to mTOR pathway activation 
in cancer. First, overexpression or mutation leading to hyperactivation of receptor 
tyrosine kinases (RTKs) could potentially induce high mTOR pathway signaling 
activation. In fact, overexpression/upregulation of several RTKs have been shown in 
carcinoma and in sarcoma.197-204 Many activating mutations or amplifications within 
pathway components such as PI3K, AKT, TSC1/2, and mTOR have been identified in 
cancer and could also significantly contribute to tumorigenesis.205-207 Loss or 
inactivation of tumor suppressors regulating a given pathway could also lead to 
hyperactivation. For example, Cowden’s syndrome is characterized by the loss of 
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PTEN due to gene mutation.208 As previously mentioned, PTEN expression can also 
be lost due to methylation of the PTEN promoter region.208  
 
Several scenarios could explain the elevated activity of the mTOR pathway observed 
in sarcoma and other cancers. While much research focuses on identifying the 
pathway as highly activated, fewer concentrate on possible explanations. Additional 
studies to identify deregulation(s) within the mTOR pathway that lead to increased 
pathway activation are essential to develop novel and more specific targeting 
therapeutic strategies for anti-cancer treatment, especially in ULMS, where little is 
currently known.  
 
Targeting mTOR in cancer: rapamycin and rapalogs 
mTOR pathway activation has been established in cancer and more specifically, in 
sarcoma. Many malignancies with PTEN loss of function (and therefore activated 
mTOR pathways) are very sensitive to mTOR inhibition and respond well to mTOR 
inhibitors.209,210 As such, the pathway represents an attractive axis for therapeutic 
targeting in anti-cancer therapies and has fueled development of several mTOR 
inhibitors.  
 
Rapamycin, a lactone-based macrocyclic compound, inhibits mTORC1 and abrogates 
many tumorigenic effects of the mTOR pathway (Figure 4). The potent mTOR 
inhibitor was originally discovered on Rapa Nui (Polynesian for “Easter Island”), where 
it was further isolated from Streptomyces hygroscopicus.211 Rapamycin, also known 
as sirolimus, was initially identified as an anti-fungal agent in the 1970s and nearly 
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two decades later was found to have significant activity as an 
immunosuppressant.109,211,212 After several years, it was identified as an anti-cancer 
agent in studies at the National Cancer Institute.213,214 Since FDA approval in 1999,  
 
 
Figure 4. The molecular structure of rapamycin 
 
 
 
rapamycin has been administered as an immunosuppressant for transplant patients; 
and over the past half-decade, in clinical applications for cancer patients.  
 
The mechanism of rapamycin-induced mTOR inhibition has been partially elucidated. 
Rapamycin binds with immunophilin FKBP12 to form a complex; the complex then 
binds to the amino terminal domain of mTOR and inhibits the protein.215 However, 
mTOR inhibition via rapamycin appears to be effective in inhibiting only mTORC 1 
(but not mTORC 2) complex and therefore does not affect mTORC2 signaling in many 
models.216  
 
Rapamycin has been tested extensively in vitro against several types of cancer cells, 
including sarcoma. Houghton et al. evaluated rapamycin against a panel of pediatric 
cancer cell lines and found that rapamycin effectively reduced cell proliferation in 
vitro.217 Using concentrations ranging from 0.01 – 100nM for cell growth assays, a 
median EC50 of about 0.7nM was found; almost half of all sarcoma lines tested 
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responded with ≥50% growth inhibition.217 Further, solid tumor pediatric sarcoma 
xenografts were treated with rapamycin to examine its efficacy in vivo using mouse 
models. Seventy five percent (27/36) of solid tumor xenografts achieved event-free 
survival while on rapamycin therapy.217 Preclinical studies using rapamycin in 
combination with an epidermal growth factor inhibitor (erlotinib) for the treatment of 
epithelioid sarcoma also resulted in improved therapeutic benefit compared with 
erlotinib administration alone in vitro and in vivo using mouse models.184 Rapamycin 
was also found to extend survival in an experimental bone metastases model.218  
 
Little is known about the role of mTOR inhibition in ULMS; however, several in vitro 
studies in LMS and STS suggest the possibility of a highly activated mTOR pathway 
in ULMS, which would render rapamycin-based therapy a viable therapeutic option. 
Human leiomyosarcoma cell lines (SKN [SKLMS1] and SK-UT-1) were used to test 
the effects of rapamycin in vitro.196 Rapamycin administration induced significantly 
reduced SKN cell proliferation and western blotting confirmed diminished levels of 
phosphorylated mTOR, 70S6K, and S6K. Notably, rapamycin did not induce 
apoptosis.196 
 
After publishing a single case report demonstrating the superior effects of rapamycin 
and gemcitabine in a patient with LMS,219 Merminsky et al. carried out a series of cell-
based experiments combining rapamycin with either common chemotherapy 
gemcitabine or the c-KIT/PDGFR inhibitor imatinib mesylate using several cancer 
models, including a cell line made from cervical leiomyosarcoma (SKLMS1).220 Of 
note, gemcitabine is a commonly used first-line chemotherapy in LMS and yielded 
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synergistic response when combined with rapamycin in a pancreatic cancer model.221 
However, in leiomyosarcoma, gemcitabine showed neither synergistic nor significant 
benefit in combination rapamycin versus single agent therapy with the exception of 
results at very short time points of less than 48h.220 In the same study, imatinib 
mesylate was also examined as combination therapy with rapamycin in 
leiomyosarcoma because of high PDGF expression found in SKLMS1 cells.220,222 
Further rationale for this combination can be derived from the work of Mohi et al., who 
showed that rapamycin and imatinib mesylate combination therapy yielded synergistic 
cell growth reduction effects in leukemia.223 Interestingly, monotherapy with imatinib 
mesylate was not effective in inhibiting SKLMS1 cell growth in vitro and combination 
therapy with rapamycin did not significantly reduce tumor cell growth and yielded 
results similar to rapamycin treatment alone, indicating that it may not be effective for 
the clinical treatment of ULMS.220  
 
At clinically relevant doses (5-10mg/m2 daily), rapamycin can induce toxicities 
including hypertriglyceridemia, thrombocytopenia, leucopenia, fever, and anemia, 
however, it is relatively well tolerated.224-227 Several clinical studies have tested 
rapamycin efficacy versus carcinomas;228-231 however, relatively few studies have 
been conducted in sarcomas.232 Extensive human studies have not been carried out 
with rapamycin given several limitations with the drug. Rapamycin has poor solubility 
in aqueous formulations for oral administration and shows problematic bioavailability 
profiles, presumably due to cytochrome P450 3A4/5 metabolism.134 To overcome 
these challenges, derivatives of rapamycin (rapalogs) have been developed. 
!! 37!
Currently, three rapamycin analogs (rapalogs) are FDA approved and extensively 
studied: CCI-779 (temsirolimus), AP23573 (deforolimus), and RAD-001 (everolimus).  
 
Temsirolimus 
Rapalog temsirolimus (CCI-779) was developed by Wyeth Pharmaceuticals and was 
approved by the FDA in 2007.  It differs from rapamycin by an additional esterdiol 
group and is approved by the FDA for the treatment of cancers including renal cell 
carcinoma. It has been evaluated in several clinical trials for lymphoma, glioblastoma 
multiforme, endometrial carcinoma, and metastatic breast cancer.233-236 In a recent 
phase II STS clinical trial of 41 total patients including nine with leiomyosarcoma and 
five with sarcomas of the uterus, pharmacokinetic studies indicated that >80% of 
patients achieved doses of temsirolimus sufficient to inhibit pS6K.237 Unfortunately, 
only 2 patients, including one with LMS, had partial responses while 95% (39/41) of 
STS patients experienced tumor progression while on temsirolimus therapy.237  
 
Temsirolimus was also tested against advanced leiomyosarcoma in a small cohort of 
six patients based on the premise that PTEN loss is a common mTOR pathway-
activating deregulation in LMS. In the study, 50% (3/6 patients) experienced disease 
stabilization while on therapy; the remainder, including the single patient with ULMS, 
had disease progression.238 Interestingly, the PTEN status of each patient was tested 
in this study; five of six patients did not show loss of PTEN as assessed via 
immunohistochemical methods, and PTEN status was not predictive of response to 
temsirolimus.238 A phase I trial of a novel oral temisirolimus formulation was 
conducted in a cohort of 24 STS patients, two of which had leiomyosarcoma.239 While, 
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none of the 19 evaluable patients had partial or complete responses, seven (about 1/3 
of study patients) had disease stabilization for several weeks, including one LMS 
patient.239 Taken together, these results suggest that temsirolimus may not be a 
viable monotherapy option in STS, but may possess useful anti-tumor activity against 
leiomyosarcoma.  
 
Ridaforolimus 
Ridaforolimus (AP23573, deforolimus, MK-8669) was developed by ARIAD 
Pharmaceuticals Inc. in an effort to overcome difficulties with rapamycin solubility for 
drug formulation. This rapamycin analog is water-soluble and has enhanced in vivo 
stability. Ridaforolimus is the most recently developed rapalog and has been 
examined briefly in SKLMS1 cells as part of a large cancer cell model panel. Rivera et 
al. showed inhibition of mTOR signaling in SKLMS1 using ridaforolimus at 
concentrations of 0.3-1nM, suggesting that leiomyosarcoma may be fairly sensitive to 
mTOR inhibition.240 In a wide array of cell models, they also showed that loss of 
PTEN did not correlate with cell sensitivity to ridaforolimus therapy.240    
 
In addition to cell-based models, ridaforolimus has been examined in several clinical 
trials including sarcoma. Chawla et al. evaluated the efficacy of ridaforolimus in a 
phase II clinical study in patients with advanced bone and soft tissue sarcomas that 
did not respond to several previous chemotherapy regimens.241 In total, 28.8% (n=61) 
achieved clinical benefit response for a median progression free survival of just 15.3 
weeks. 241  
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In October of 2011, ARIAD, in partnership with Merck Pharmaceuticals, filed a FDA 
New Drug Application for the use of ridaforolimus in metastatic STS and bone 
sarcomas in patients who responded well to chemotherapy. Ridaforolimus resulted in 
only mild toxicity in Phase I sarcoma clinical trials and inhibited mTOR downstream 
target p4EBP1.242 Preliminary results in STS showed that 28% of patients responded 
(complete response, partial response, or disease stabilization) for at least 16 weeks 
with ridaforolimus therapy.241 In another study, partial response was observed in 2% 
of patients and disease stabilization was identified in an additional 27%.243 Studies 
have also found that patients with high levels of pS6K are more likely to experience 
disease stabilization while on deforolimus and that pS6RP expression can be used to 
predict early tumor response to mTOR inhibition-based therapies such as 
deforolimus.181 Finally, a phase III trial (NCT00538239) is currently underway to 
determine the efficacy of this drug as long-term maintenance therapy.  
 
Everolimus 
Everolimus (RAD001, Zortress, Certican, Afinitor), owned by Novartis, has been 
minimally examined using animal modeling in LMS. Hernando et al. reported that the 
mTOR/AKT pathway is overexpressed in and drives leiomyosarcomagenesis in a 
transgenic mouse model with loss of PTEN.98 To determine if mTORC1 inhibition 
significantly prolonged life, everolimus was administered when tumors were 
detectable by MRI at 1 month of age. Everolimus had considerable effect on 
leiomyosarcoma in these models; average lifespan of mice in the control group was 
9.4±4.0 weeks compared to >37 weeks (at which time therapy was halted) in the 
everolimus-treated mice.98 Notably, downregulation of pAKT and pS6K was found in 
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these mice; reduced Ki67 expression and minimal TUNEL positivity compared with 
controls was also observed, suggesting cytostatic rather than cytotoxic effects.98  
 
Everolimus is currently approved by the FDA for the treatment of several cancers 
including pancreatic neuroendocrine tumors, astrocytomas, endometrial carcinoma, 
recurrent and metastatic breast cancer, and advanced kidney cancer.244-247 Notably, a 
patient with metastatic renal cell carcinoma achieved disease stabilization for >28 
months; a partial response with everolimus was identified after 28 months, supporting 
the use of mTOR inhibition in long-term maintenance for cancer.247  
 
Few studies have examined the efficacy of everolimus therapy in LMS or ULMS.  A 
pre-clinical and phase I trial combined everolimus mTOR inhibition with figitumumab 
IGF-1R kinase receptor inhibition in STS, demonstrating relatively favorable efficacy: 
toxicity ratios.248 In this study, disease stabilization was noted in 71% of patients and 
only 10% experienced disease progression while receiving combined therapy.248 
Nearly a quarter of the 21 patients enrolled in this trial had leiomyosarcoma. 
Everolimus and figitumumab combination therapy in these leiomyosarcoma patients 
yielded stable disease in three of four individuals with long-term disease stability in 
one patient.248 
 
Taken together, studies with mTOR inhibitors suggest that rapamycin and its analogs 
may have clinical benefit, chiefly by inducing disease stabilization, in certain subtypes 
of cancer such as LMS. The upregulation/overexpression of the mTOR pathway in 
LMS and the use of rapamycin or rapalogs in LMS is supported by multiple in vitro 
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and in vivo studies. Despite promising results in LMS, very little is known about 
possible deregulations in the mTOR pathway or the potential efficacy of mTOR 
inhibitors against human ULMS. Additional preclinical studies are necessary to 
examine pathway activation, identify potential deregulations, and test the efficacy of 
mTOR inhibitors in ULMS alone and in combination with other potential ULMS-
relevant therapies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!! 42!
Aurora A kinase 
Recently we have identified that ULMS overexpress gene products responsible for 
regulating centrosome structure and function, highlighting a role for Aurk A as a novel 
ULMS therapeutic target.249,250 Several lines of evidence support a role for Aurk A in 
cancer: 1) it was found to be amplified and/or over-expressed in multiple cancers 
including breast, ovarian, and hepatic carcinomas,251-253 2) forced Aurk A expression 
resulted in NIH3T3 fibroblast oncogenic transformation and induced aneuploidy in a 
nearly diploid breast cancer cell line,254 and 3) Aurk A interacts with and modifies the 
function of several key cancer-associated molecules such as BRCA1 and p53.255  
 
Aurora A Kinase 
Aurk A kinase is part of a family of serine/threonine kinases (Aurk A, Aurk B, and Aurk 
C) that are critical in cell cycle regulation, especially mitosis.256 Aurora kinases were 
originally discovered in Drosophila, where absence of this protein led to chromosomal 
separation failure with the subsequent formation of monopolar spindles. Because the 
defects occurred at the spindle poles, the proteins were named “Aurora” kinases 
because of the aurora borealis light displays that are occasionally seen at the poles of 
the Earth.257 The Aurora kinases are evolutionarily conserved in mammals and are 
also found in several other species (Table 5). Aurora kinases in mammals have an N-
terminal regulatory domain and a C-terminal catalytic domain.258 Although their 
regulatory domains are very different, the family members share >70% homology in 
their catalytically active domains (Figure 5).255  
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Figure 5. Aurora kinase protein domains. Functional domains in Aurora kinases A, 
B, and C. (Adapted and reprinted by permission from Macmillan Publishers Ltd: 
[Nature Reviews Cancer] Keen et al. Aurora-kinase inhibitors as anticancer agents, 
2004).258 
 
 
 
 
Table 5. Aurora kinases are conserved across several species. 
 
 !!
Species Aurk Kinases Names Author (Year) 
Drosophila 2 Aurk A, Aurk B Glover (1995)  
Saccharomyces 
cerevisiae 1 Ipl1 Chan (1993) 
Caenorhabditis 
elegans 2 AIR-1, AIR-2 Schumacher JM (1998) 
Xenopus 2 Eg2, AIRK2 Adams (2000) 
Mammals 3 Aurk A, Aurk B, Aurk C Nigg (2001)  
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Aurk A kinase  
Aurora A kinase (also called Aurk A kinase, BTAK, STK6, AIK, ARK1, AURA, STK7, 
STK15, Aurora 2, and MGC34538) is a 46kDa, 403 amino acid serine/threonine 
kinase that was first discovered in Drosophila in 1995; it is functional in cell cycle 
regulation257,259 and is located on human chromosome 10q13.2, a region that is often 
amplified in cancers.254,260 Aurk A kinase activity is directed towards arginine residues 
within the active loops of Aurk A substrates, making the protein an arginine-directed 
kinase.255 A threonine reside at amino acid 288 serves as the main site for activation 
of Aurk A kinase function, which requires phosphorylation of the T288 residue. Since 
resolution of the crystal structure of Aurk A in 2002 by Cheetham et al., it is now well 
established that Aurk A has two major domains; an amino terminal regulatory domain 
and a carboxy terminal catalytic domain.261 Similarly to many other serine/threonine 
kinases, the catalytic domain is comprised of two lobes adjoined by a hinge 
region.261,262 A carboxy terminal D-Box and amino terminal A-box are required for 
Aurk A degradation via ubiquitinylation by APC/C complex.263-265  
 
Unlike Aurk B and C family members, Aurk A has distinct localization, binding 
partners, and functions. Aurora A expression emerges in late S and early G2 phases 
and diminishes by the end of telophase with peak activity observed in G2-M 
transition.266,267 During the S to G2 transition, Aurk A begins to localize at the 
centrosomes; by metaphase, Aurk A is localized with spindle poles, microtubules and 
the microtubule organizing centers.268 Aurk A expression diminishes towards the end 
of mitosis when cyclin B expression is decreased.266  
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Aurk A kinase substrates  
Aurk A kinase is a key regulator of mitosis. To date, Aurk A has several identified 
substrates (Table 6).255,259,269-286 Aurk A exerts both kinase and non-kinase functions 
on these substrates, the majority of which are centrosome or spindle related proteins. 
Karthigeyan et al. reviews the interactions of all known Aurk A substrates in depth.255  
 
At this time, Aurk A mechanisms of action can be classified as kinase-independent or 
kinase-dependent.255 While most are kinase-dependent interactions, two kinase-
independent mechanisms have been identified, and interactions with several 
additional proteins remain to be elucidated.255 Centrosomin is a centrosomal protein 
critical in centrosomal assembly, maturation, and function in both drosophila 
melanogaster and mammalian cells.287,288 Terada et al. showed that Aurk A binds to 
the carboxy terminal domain of centrosomin and are mutually dependent on one 
another for proper localization to spindle poles.288 The amino terminal domain of 
centrosomin binds to γ-tubulin, initiating microtubule nucleation and anchoring the 
tubulin to the centrosome.288 Aurk A also stabilizes n-Myc by inhibiting ubiquitin ligase 
SCfFbxw7 interaction, thereby allowing stability of n-Myc that is independent of growth 
factor signaling.289,290  
 
Several protein substrates of Aurk A kinase are phosphorylated by the protein at a 
consensus site of K/RXT/SI/L/V.291 Several of these Aurk A-regulated proteins are 
involved in transcriptional regulation. BRCA1 is a DNA repair molecule and E3 
ubiquitin ligase is phosphorylated by Aurk A at Ser308. Phosphorylation results in 
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Table 6. A list of known Aurk A binding partners and their functional consequences. 
(used with permission from Karthigeyan et. al)255  
 
First Author Protein Residue Affected Functional Consequence 
Toji (2004) Lats2  Ser83  Centrosome maturation  
Venoux(2008) ASAP  Ser625  Bioplar spindle assembly  
Mori (2007) NDEL1  Ser251  Microtubule reorganization, centrosome separation/maturation  
Sakai (2002) MBD3  Ser24  Undetermined  
LeRoy (2007) TACC3  Ser558  Regulates XMAP215  
Zhang (2008) MCAK  Ser196, Ser719 Loss of microtubule depolymerase activity  
Kemp (2004) SPD2  Undetermined  Enhanced microtubule depolymerase activity  
Geit (1999) Eg5  Ser543  Recruits SPD5, centrosome maturation  
Dutertre (2004) Cdc25B  Ser353  Microtubule organization  
Rong (2007) RASSF1A  Thr202, Ser203  M phase progression  
Wirtz-Peitz 
(2008) Par6  Undetermined  NUMB localization in cell division  
Du (2004) P160ROCK  Undetermined  Blocks transactivation  
Yu (2008) CFos  Undetermined  Undetermined  
Kunitoku (2003) CENP-A  Ser7  Kinetochore organization  
Huang (2002) CPEB  Ser174  Oocyte maturation  
Seki (2008) Plk1  Thr210  Centrosomal organization  
Yu (2005) HURP  
Ser627, 
Ser725, 
Ser757, Ser830  
Serum-independent growth acceleration  
Ouchi (2004) BRCA1  Ser308  Microtubule nucleation  
Katayama (2003) p53  Ser215, Ser315  Blocks transactivation, enhances proteosomal degradation 
Briassouli (2007) IkBa  Ser32, Ser36  Enhances NFkB activity  
Colon (2011) GSK-3β  Ser9  Enhanced β-catenin activity  
Colon (2011) N-Myc  Kinase independent  Stabilization of N-Myc  
Terada (2003) Centrosomin  
Kinase 
independent  Centrosome maturation  
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abrogated ligase activity and this interaction is thought to be critical in G2/M transition 
as well as centrosome-dependent microtubule nucleation.292,293 Aurk A also 
phosphorylates GSK-3β, resulting in accumulation of β-catenin in the nucleus. 
Nuclear β-catenin binds to LEF/TCF; together these proteins initiate transcription of 
several pro-growth molecules such as c-Myc and Cyclin D1.294,295 Tumor suppressor 
and transcription factor p53 is regarded as the gatekeeper of the human genome and 
is often mutated in cancers. Aurk A phosphorylates p53 at Ser315 and Ser215. 
Phosphorylation at Ser315 strengthens p53 and MDM2 interaction, leading to 
increased degradation of p53.296,297 Aurk A phosphorylation at Ser215 abrogates DNA 
binding ability and eliminates transcriptional activity of p53 including transcription of 
downstream targets such as p21 and PTEN.298  
 
Overall, Aurk A kinase is required for several centrosome and spindle assembly-
related functions in mitosis.268 Mutations in Aurk A can lead to centrosome separation 
failure and monopolar spindle development, resulting in improper cell 
division.257,299,300 Aurk A overexpression can produce chromosomal misalignment, 
defective mitotic spindles, and inappropriate chromosomal segregation, which can all 
contribute to malignant phenotypes.260,301  
 
Aurora A kinase in cancer 
Aurk A kinase has been shown to promote many processes significant in cancer 
formation and progression, and is upregulated in multiple cancer cell lines and 
malignancies including >50% of ovarian, colorectal, and ovarian tumors and 94% of 
invasive ductal breast adenocarcinomas.254,302-304 We recently reported Aurk A 
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upregulation and overexpression in ULMS.249,250 Aurk A overexpression and 
chromosomal amplification are characterized in many different tumor types. The 
protein is encoded on chromosomal region associated with frequent amplification in 
cancer.254,260,266,305,306 In addition to chromosomal amplification, Aurk A mRNA and 
protein expression is often upregulated in hepatocellular and ovarian carcinomas, 
colorectal cancer, neuroblastoma, breast cancers, and many other 
malignancies.251,307-310 Many of these reports also indicate that Aurk A protein 
expression levels correlate well with prognosis or survival and that it may be useful as 
a prognostic factor.251,307,309-311 
 
 Aurk A is implicated in numerous processes with known roles in cancer such as 
inactivation of tumor suppressor p53 and DNA repair molecule BRCA1, up-regulation 
of pro-cancer genes, and promoting cell survival and cellular motility/migration 
(described previously).255 Several functional studies have been performed to 
determine whether Aurk A overexpression alone is sufficient for malignant 
transformation; the results are inconclusive. While several groups have shown that 
overexpression of Aurk A kinase is sufficient to transform NIHT3T and rat fibroblast 
cell lines, several others demonstrate that Aurk A overexpression alone is not 
sufficient to induce malignant transformation.254,260,312 Forced overexpression of Aurk 
A helps DNA damaged cells bypass mitotic checkpoints, evade regulatory cell death 
mechanisms, and develop chemoresistance, all of which lead to genetic instability, a 
hallmark of cancer. 
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Targeting Aurk A kinase in cancer 
Given the potential usefulness of Aurora A inhibition in cancer therapy, several anti-
Aurk A drugs have emerged, have shown pre-clinical efficacy, and are currently 
undergoing further clinical investigation (Table 7). MLN8237 (Alisertib, Millennium 
Pharmaceuticals, Figure 6) is a second-generation small molecule Aurora A kinase 
inhibitor that blocks Aurk A kinase activity in vitro with concentrations as low as 1.2nM 
(enzyme assay).  While it is a specific Aurk A inhibitor, it can also weakly inhibit Aurk 
B kinase at or above 400nM concentrations.313-315 Nevertheless, MLN8237 exhibits a  
 
Table 7. Commercially developed Aurk A inhibitors. 
 
Inhibitor Name Additional Names Target(s)  
ZM447439 - Aurora A and B kinases 
VX-680 tozasertib Aurora A, B, and C kinases 
PHA-680632 - Aurora A, B, and C kinases 
PHA-739358 danusertib Aurora A, B, and C kinases 
MK-5180 - Aurora A kinase 
MLN 8054 - Aurora A kinase 
MLN8237 alisertib Aurora A kinase 
 
 
 
Figure 6. Structure of MLN8237. 
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200-fold selectivity for Aurk A over Aurk B or C in vitro; comprehensive studies 
indicate that no significant cross-reactivity occurs in a diverse panel of receptors, ion 
channels, and 205 kinases.315 Mechanistically, MLN8237 binds to the active site of 
the kinase domain in Aurk A, thereby preventing activation. This orally administered 
and rapidly available investigational drug is thought to promote mitotic spindle 
abnormality, trapping many cells in mitosis resulting in polyploidy and (ultimately) 
death via apoptotic pathways.314  
 
MLN8237 has been evaluated in a number of cell types. It was found most effective in 
leukemia and lymphoma cell lines, but also exhibited activity against Ewing’s sarcoma 
and neuroblastoma at >100nM doses. Rhabdomyosarcoma cell lines had IC50s in the 
100nM to 10uM range.316,317 Preliminary studies in mouse neuroblastoma xenografts 
as well as human lymphoma and leukemia indicate that MLN8237 effectively inhibits 
tumor growth at doses of 20mg/kg given twice daily for three weeks. To our 
knowledge, MLN8237 had not yet been tested in uterine leiomyosarcoma, 
leiomyosarcoma, or comprehensively in soft tissue sarcomas in vitro or in mouse 
models. 
 
MLN8237 been evaluated in a few clinical trials in cancer therapy to date. Phase I and 
II clinical trials with MLN8237 in pediatric solid tumors, leukemia, ovarian cancer, non-
Hodgkin’s lymphoma, peritoneal carcinoma, and hematological malignancies have 
shown marked improvement over standard treatments.313,318 Notably, a phase II 
clinical trial is currently underway to assess the efficacy of MLN8237 treat recurrent 
refractory solid tumors or leukemia in young patients. This study is enrolling patients 
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with sarcoma and is anticipated to be complete in February 2016. Although the results 
of the phase I clinical trial have not yet been published, a 2010 abstract from the 
annual American Society of Clinical Oncology (ASCO) meeting reveals preliminary 
study results; the most effective, toxicity-limiting dosing option is 80mg/m2/d to be 
given once per day for seven continuous days in a 28 day cycle. Dose limiting 
toxicities in this study included severe mood alteration, mucositis, nuetropenia-
thrombocytopenia, myelosuppression, and somnolence.319 
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Chapter 2: Materials and Methods 
 
 
Patients and clinical database. Medical records from more than 350 patients who 
were evaluated at The University of Texas MD Anderson Cancer Center (UTMDACC) 
for ULMS between January 1989 and April 2011 were accessed under the permission 
of an Institutional Review Board (IRB) approved protocol (Protocol #RCR05-0260). 
Patients included in the database were required to have documented history of 
uterine leiomyosarcoma. A clinical database was constructed using ClinicStation to 
incorporate many parameters including: 1) patient-related variables: date of birth, sex, 
race, age at admission, history of previous hysterectomy unrelated to ULMS 
diagnosis, and family history of sarcoma or other cancers; 2) medical history-related 
variables: first symptom associated with diagnosis of ULMS, age at initial diagnosis of 
ULMS, stage at diagnosis, number of recurrences prior to evaluation at MD Anderson, 
development of metastases prior to evaluation at MD Anderson; 3) tumor-associated 
variables: stage at presentation to UTMDACC, status at presentation to UTMDACC, 
tumor size, and number of mitoses per 10 high power fields; 4) treatment-related 
variables: neoadjuvant or adjuvant chemotherapy or radiation interventions, 
descriptions of surgical interventions, surgical margins obtained, and if lymph nodes 
were resected and found to contain malignant cells; and 5) outcome-related 
information: recurrences post-admission at UTMDACC, post-admission development 
of pulmonary and/or extra-pulmonary metastases and follow up information consisting 
of date of last follow up and status at that time. 
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Creation of tissue microarray (TMA). Under an IRB approved protocol at 
UTMDACC (Protocol #LAB04-0890), our clinical database was searched for patients 
for which formalin-fixed, paraffin-embedded (FFPE) tissue blocks were available. 
From our initial cohort of more than 350 patients, more than 200 could not be included 
on the TMA, mainly due to lack of tissue availability. All patients selected in our TMA 
cohort had sufficient follow up with the UTMDACC sarcoma center. Blocks were 
obtained for all cases that matched our criteria and the clinical diagnosis of ULMS 
was re-confirmed by UTMDACC pathologists (Alexander J. Lazar and Elizabeth G. 
Demicco, both soft tissue sarcoma experts) by further examination of H&E stained 
slides. The tissues were then organized, and control tissues were selected for 
inclusion on the TMA. H&E slides corresponding to each block were marked with a 
circle around the desired tumor area to indicate from where the punches were to be 
taken. An automated TMA apparatus (ATA-27, Beecher Instruments) was used to 
perform 0.6mm core punches in duplicate for each block. These punches were then 
formatted into a standard 4.5 x 2 x 1 cm recipient block to create ULMS TMA blocks 
A, B, C, and D as previously described.320 H&E stained slides of the cut TMA blocks 
were used to verify viable tumor within the punch sample area throughout the block. 
As previously described, ClinicStation was used to assemble an annotated clinical 
database corresponding to each sample that was used for correlative analysis. 
 
TMA immunohistochemistry and scoring criteria.  
Antibodies. Once constructed, the TMA was stained immunohistochemically for 
several potential biomarkers of interest. All primary antibodies and working 
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concentrations used for immunohistochemistry in this body of work are identified in 
Appendix Table A1.  
 
Immunohistochemical staining. Tissue microarray slides were placed in an oven at 
60°C overnight. Next, slides were de-waxed and rehydrated by a series of xylene and 
ethanol incubations. Antigen retrieval via microwave for 10-20min at 98ºC or steam 
cooker for 45min was carried out. Following endogenous blocking with H2O2 as 
previously described,320 samples were blocked with a 4% fish gelatin or 5% normal 
horse serum with 1% normal goat serum in PBS for 20min at room temperature (RT). 
The primary antibody was then applied overnight at 4°C in a humidity chamber. After 
several washes, secondary antibody was applied and incubated; a Mach 4 Universal 
HRP Polymer Detection Kit (BioCare Medical) or goat anti-rabbit/goat anti-mouse 
HRP (BioCare Medical) was used for detection. Briefly, excess 3,3-diaminobenzidine 
(DAB, Open Biosystems) was added to cover the tissues completely; and tissues 
were monitored via brightfield microscopy. When adequate DAB incubation length 
was reached, samples were washed in deionized water several times followed by 15-
20 second staining with Gill’s #3 hematoxylin (Sigma Aldrich). Slides were covered 
with Permount (Fisher Scientific, Inc) and glass cover slips; slides were allowed to dry 
horizontally before further examination. A BONDMAX automated 
immunohistochemistry apparatus and protocol was used to stain for some proteins. 
Specific protocols for each antibody are detailed in Appendix Table A2.  
 
Scoring criteria. Following staining for specified proteins; TMA slides were scored by 
independent observers (Kari Brewer Savannah, Alexander Lazar and Elizabeth 
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Demicco; the latter two are soft tissue sarcoma pathology experts). Care was taken to 
exclude samples of insufficient tumor quality or tissue from further analysis. TMA 
slides were scored for both intensity (0 = absent, 1= weak, 2= moderate, 3= strong) 
and for distribution (percentage of cells in each tissue sample staining positively for 
each protein, 0-100%). Distribution was scored as absent (<10% of cells per sample 
positive), low (10-49% of cells per sample positive) and high (≥50% cells per sample 
positive). Membranous staining for some proteins was also noted. For most markers, 
intensities of 0 or 1 (absent and weak) were grouped together and considered 
“absent-weak” intensity while intensities of 2 or 3 (moderate and strong) were 
combined as “moderate-strong” intensity for statistical analysis. Distribution 
expression levels were grouped as none (under 10% of cells positive), low (10-49% 
positive) and high (>50% positive). For most markers, only samples with >50% of 
cells staining positively were considered as “high” for statistical evaluation. For 
progesterone receptor, estrogen receptor, Ki67, and cyclin D1, only the percentage of 
cell nuclei per sample expressing the proteins was evaluated. For statistical 
calculations, all samples with >10% of cells per sample with positive expression were 
considered high expression. Rb intensity was scored as absent (score of 0) or strong 
(score of ≥1) for statistical analyses. Likewise, the percentage of cells expressing Rb 
per ULMS sample was scored as absent (<10% cells per sample positive) or high 
(>10% of cells positive). SMA, SMM, desmin, caldesmon, WT-1, c-KIT, nuclear β-
catenin, and membranous β-catenin were scored as absent (-), high (+) or weak/focal, 
which was counted as high (+) for statistical considerations. All other proteins were 
scored as per the described standard. 
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ULMS primary cell cultures. ULMS primary cell cultures were created by our 
laboratory directly from patient tumors under an IRB approved protocol and with 
informed consent from the patients (Protocol #LAB06-0581). Surgical specimens were 
received in ~20mL sterile PBS in a conical vial with approximately 5-30g of tumor. 
PBS was aspirated and the tumor was transferred to a glass petri dish. 10-20mL of 
DMEM media was added and the tumor was cut into 1mm portions using a sterile 
scalpel. Minced tumor was then transferred in DMEM to a 50mL Falcon spinner flask 
and the petri dish was rinsed 3 times with DMEM to collect any remaining tissue. 
Media was added to the flask to bring the total volume to 25mL and 2.5mL of 3% 
collagenase Type 1 (Sigma), 5.0mL of 0.02% DNAse I, Type II (Sigma), and 1.0mL of 
1.5mg/mL hyaluronidase (Sigma) were added. Concentrations of enzymes were 
adjusted to reflect initial tumor weight. Spinner flasks were placed on a Bell-Stir at 
speed 8 at 37°C for 2-4h or until tumor digestion occurred. The sample was then 
strained through a sterile mesh screen into a new 50mL tube and centrifuged at 
1500rpm at room RT for 5min. Undigested tissue was discarded. Following 
centrifugation, media was aspirated and PBS as added for a total volume of 40mL to 
wash the cell pellet. The sample was centrifuged a second time at 1500rpm at RT for 
10min and PBS was aspirated. The pellet was then resuspended in 20mL of PBS and 
histopaque tubes were set up for every 1mL of cell pellet. 10mL of 100% histopaque 
(Sigma) was added to each 50mL conical tube and 15mL of 75% histopaque in PBS 
was added carefully on top of the 100% histopaque. The cell suspension was added 
slowly to the top of the histopaque, taking care that the solutions were not mixed. 
Tubes were sealed and centrifuged at 1800rpm for 30min at 4°C. The first interface 
(tumor cells) was carefully pipetted out of the tube without disrupting the histopaque 
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layer or second interface (lymphocytes). 50mL of PBS was added to the extracted 
cells and the solution was centrifuged at 1800rpm at RT for 5min. PBS was aspirated 
and cells were resuspended in DMEM with high glucose, 10% FBS, and 1% 
antibiotics (penicillin/streptomycin), placed in a cell culture flask, and incubated at 
37°C. All tumor handling was done with sterile technique to prevent possible 
contamination.  
 
Short Tandem Repeat (STR).  DNA fingerprinting via sequencing of short tandem 
repeats (STR) was used to validate cell lines and the tumors from which they 
originated at increasing passages. DNA from cell strains/lines was obtained using a 
Qiagen Blood & Cell Culture DNA Maxi kit as per manufacturer’s recommendations. 
An AmpFISTR Identifier PCR Amplification kit (Applied Biosystems) was used to 
amplify tumor DNA for fingerprinting. The kit was used as directed by Applied 
Biosystems and results in amplification of the amelogenin gender determining marker 
and 15 tetranucleotide repeat loci using multiple primers. Cell strain fingerprints were 
compared with fingerprints of the original tumors when available; if not available, 
fingerprints were compared with those from the earliest available passage of cells. 
Cell line fingerprints were compared with known fingerprints given by the American 
Type Culture Collection (ATCC) or other published records. These markers/loci and 
methodology are consistent with worldwide database recommendations for tumor and 
cell identity validation.  
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p53 mutational analysis. p53 mutational analyses were conducted on cell 
strains/lines as previously described.321 Genomic DNA was extracted using a QUIamp 
DNA Mini Kit (Qiagen Sciences) as per kit instructions. A NanoDrop 
spectrophotometer was employed to evaluate the integrity and concentration of 
extracted DNA. Primers specifically designed to recognize and bind intronic 
sequences flaking exons five through nine of the p53 gene were obtained (Sigma 
Genosys).  Briefly, 100ng genomic DNA underwent polymerase chain reaction (PCR) 
amplification for exons 5-9 of the p53 gene in an Eppendorf Mastercycler Pro Thermal 
Cycler (Eppindorf AG). The PCR product was then sequenced via an Applied 
Biosystems 373 automated DNA sequencing instrument and sequence analysis was 
performed with Sequence Scanner (version 1.0, Applied Biosystems). 
 
GEIMSA.  500,000 cells were counted and suspended in 10mL of media. 10µg/mL of 
colcemid was added for a final concentration of 0.05µg/mL in media and incubated at 
37°C for 2h in a 15mL conical tube. The cells were then spun down at 1200rpm for 
5min and supernatant was aspirated. The pellet was washed once with 5mL of PBS 
and spun down again, discarding the supernatant. 1mL of 75mM potassium chloride 
was added to the cell pellet and incubated at RT for 30min to lyse the cells. Slides 
were washed with cold ethanol and chilled at -20°C for a minimum of 45min and fixing 
solution of methanol: glacial acetic acid (3:1) was prepared. The fixing solution was 
added to KCl/cell suspension for a final volume of 10mL and incubated for 10min at 
RT. Cells were then spun down at 1200rpm for 5min, supernatant was aspirated, the 
pellet was resuspended in 1mL of fixing solution, and 1-3 drops of cell suspension 
was dropped onto each cold slide. Slides were dried at 68°C for 2h and stained with 
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GIEMSA stain for 1-2h. Following several washes in deionized water to remove 
excess staining solution, slides were cover slipped and examined in immersion oil at 
100x. 
 
Cell culture. Human SKLMS1, Mes-Sa, and normal smooth muscle cells (NSMC) 
were obtained from the American Type Culture Collection (ATCC, SKLMS1 and Mes-
Sa) and ScienCell Research Laboratories (Carlesbad, CA, NSMC). Leiomyosarcoma 
cell strains Leio012, Leio016, Leio196, Leio285, Leio485, Leio505, and Leio987B 
were created in our laboratory. Cells were cultured in DMEM/F-12 50/50 with the 
exception of Mes-Sa and normal smooth muscle cells, which were cultured in 
McCoy’s 5A Modified Medium and Smooth Muscle Cell Medium, respectively. Media 
were supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. All 
media and supplements were purchased from Cell Gro, Inc. Short Tandem Repeat 
(STR) DNA fingerprint testing was performed on cell lines and strains every 10-15 
passages to confirm cell identity.  
 
Reagents for experimental procedures. Commercially available antibodies were 
employed during western blotting, immunohistochemistry, and immunofluorescence. 
Antibodies directed against desmin, pS6K, S6K, p4EBP1, 4EBP1, pAKT, AKT, PTEN, 
cyclin D1, and Aurora A kinase were purchased from Cell Signaling (Danvers, MA). 
Cleaved PARP was purchased from Abcam (Cambridge, MA) and p21, p53, vimentin, 
and β-actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). CD31 for immunofluorescence studies was purchased from BD Pharmagen (San 
Diego, CA) and Ki67 was obtained from Thermo/Lab Vision (Kalamazoo, MI). 
!! 60!
Additional details regarding antibodies, including working concentrations, are provided 
in Appendix Table A3. Goat anti-rabbit IgG and goat anti-mouse IgG antibodies 
conjugated to horseradish peroxidase (Santa Cruz Biotechnology) were used as 
secondary antibodies. The Dead End Fluorometric TUNEL Kit (Promega, Madison, 
WI) was employed and used as directed for terminal deoxyribonucleotide transferase-
mediated nick-end labeling (TUNEL).  
 
Rapamycin for in vitro studies was purchased as a powder and reconstituted in 
DMSO. A liquid, orally ingested formulation of rapamycin, Rapamune (Pfizer), was 
purchased from the UTMDACC pharmacy and used for in vivo experiments. 
Doxorubicin was purchased from (APP Pharmaceuticals), diluted with sterile water, 
aliquoted, and stored in an opaque container at -20ºC until use. MLN8237, an 
investigational Aurk A inhibitor, was kindly provided by Millennium Pharmaceuticals 
(Cambridge, MA). For animal studies, MLN8237 powder (95.94% pure) was 
suspended in an equivolume solution of MLN8237 dissolved in 20% 2-hydroxypropyl-
β-cyclodextrin in sterile water and a solution of 2% sodium bicarbonate in sterile water 
for final concentrations of 10% 2-hydroxypropyl-β-cyclodextrin and 1% sodium 
bicarbonate. The two solutions were prepared separately within 14 days of use and 
mixed together each morning for daily use. The 95.94% purity of MLN8237 in powder 
form was accounted for in animal calculations so that each mouse received 
30mg/kg/daily of active drug.  
 
Western blotting. Western blot analyses were used to evaluate levels of protein 
expression and phosphorylation and were conducted as previously described.187 
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Briefly, protein lysates were made following treatment and kept at 20ºC until use. A 
Bradford assay was performed to formulate a standard curve using bovine serum 
albumin (BSA) and to determine concentration of protein in lysate by fitting 
absorbance values to the BSA standard curve. Aliquots of 40µg protein were 
prepared with a final concentration of 40µg protein and 1x loading buffer in 10% β-
mercaptoethanol in 40µl total volume. The protein was loaded into 8, 10, or 12% bis-
acrylamide gels and 10µl of a protein molecular weight marker was added to the first 
well of each gel for protein molecular weight determination. Proteins were run at 
100volts for 90min or until desired separation of proteins occurred. Nitrocellulose 
membranes were cut to size and dipped in 100% methanol then soaked in transfer 
buffer before use. The transfer was run at 100volts for 60min and membranes were 
washed with deionized water thoroughly following transfer. All western blots were 
blocked in either 5% bovine serum albumin or milk in PBS-T for 1h and incubated 
overnight at 4ºC with 1:1000 primary antibody, except β-actin, which was incubated 
1:5000 for 45min at RT. Membranes were then washed 3 times for 10min with PBS-T 
and secondary antibody was applied for 1h at RT. Goat anti-rabbit IgG and goat anti-
mouse IgG antibodies conjugated to horseradish peroxidase (Santa Cruz 
Biotechnology, Inc) were used as secondary antibodies (1:3000).  Blots were then 
washed 3 times for 10min with PBS-T and developed in an x-ray apparatus using a 
Western Lightning ECL kit (Perkin-Elmer, Inc.). β-actin expression was used to ensure 
normalized protein levels in each sample. 
 
Cell growth analysis. Cell growth was measured via MTS assay using a CellTiter96 
Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega) as previously 
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described.185 Cells were plated in 96 well plates with 100µL of media per well. The 
following day, all media was replaced with 200µL of drug-containing media or media 
with DMSO as controls. Media was replaced as described every 48h for the duration 
of the experiment. Media alone or media containing the highest concentration(s) of 
drug(s) were added to empty wells containing no cells as controls at the time of the 
final media change. 20µL MTS (Sigma Aldrich) was added to each well and allowed to 
incubate at 37ºC for 4h. Following incubation, absorbances of each well were read 
using a Beckman absorbance detector (Beckman Coulter, Inc.) with a 490nm 
wavelength filter.  Absorbances of media alone or drug containing media in wells 
without cells was subtracted from control and drug treated wells, respectively. Drug 
treated wells were then normalized to non-treated controls for analysis of cell 
proliferation effects. Combination treatments were performed with 24h pre-treatment 
of rapamycin or MLN8237, followed by combination therapy for 72h, or co-treatment 
of rapamycin and MLN8237 for 96h. Drug concentrations required to inhibit cell 
growth by 50% (GI50) were determined by interpolation of dose-response curves. 
Averages of at least three wells in triplicate experiments were averaged to obtain final 
values.  
 
Clonogenic assays were employed to assess cell proliferation with both pre- and 
continuous- dosing treatments and were conducted as previously described.185 
Briefly, for pre-treatment, cells were plated in culture dishes at 80% confluency, 
allowed to attach, and treated for 24h. The following day, cells were trypsinized, 
counted, and 200 viable cells were re-plated in 6 well plates and allowed to normal 
medium. After 10 (Leio285, SKLMS1) or 14 (Mes-Sa) days, media was aspirated and 
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colonies were stained with a 5% glutaraldehyde and 0.1% crystal violet in 20% 
methanol for 2h at RT. Plates were then rinsed well with water and dried. Images 
were captured digitally and the number of large colonies in each well was counted. 
Alternatively, for continuous treatment, 200 viable cells per well were first plated and 
then treated with drugs at doses indicated, following the procedure described above. 
Drug/media was replenished for both pre- and continuous-treatments every 48h for 
the duration of the experiment. 
 
Cell cycle analysis. Determination of cell cycle progression was conducted as 
previously described.187 Following drug treatment for 48h, cells were trypsinized, 
pelleted at 1500rpm for 5min, and washed with PBS. After 2 washes, cells were 
resuspended in 70% ethanol in water and fixed at -20ºC overnight. Cells were spun 
down, washed twice with PBS, and resuspended in 5% propidium iodide (PI) solution 
with 10µg/mL RNAse. After 30min incubation on ice in the absence of light, cells were 
analyzed for DNA content using fluorescence-activated cell sorting (FACS) with an 
Epics XL-MCL flowcytometer (Beckman-Coulter, Miami, FL) and Multicycle software 
(Phoenix Flow Systems, San Diego, CA).  
 
FACS analysis for detection of apoptosis. FITC-conjugated Annexin V was used in 
conjunction with PI to assess levels of apoptotic cells through FACS analyses as 
previously described.187 Briefly, cells were plated at ~60 or 80% confluence (96h and 
48h treatments, respectively) and allowed to attach overnight. The following day, drug 
was added and replaced every 48h for the duration of treatment. Cells were then 
trypsinized, collected, and neutralized with fresh media. Care was taken to collect 
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dead and floating cells. Next, cells were pelleted by centrifugation at 1500rpm for 
5min and washed with PBS. After 2 washes, cells were resuspended in 100µL 1x 
binding buffer and PI and Annexin V-FITC were added as directed (Annexin V:FITC 
Apoptosis Detection Kit 1; BD Pharmagen). The cells were incubated for 30min on ice 
in the absence of light and an additional 200µL of binding buffer was added just 
before FACS analysis using an Epics XL-MCL flowcytometer (Beckman-Coulter, 
Miami, FL). Analyses were performed with System II software (Beckman-Coulter, 
Miami, FL).   
 
SiRNA knockdown. 2x105 cells/well were plated in 2mL of media with 10% FBS and 
no antibiotics in a 6 well plate and allowed to attach overnight. The following day, 
media was replaced and serum-free media (mock), non-targeting SiRNA with 20µL 
Extreme Gene transfection reagent in serum-free media, or Aurk A targeting SiRNA 
with 20µL of Extreme Gene transfection reagent in serum-free media were added at 
4µg/100µL to each well. SiRNA was incubated with the cells for 24h and replaced with 
FBS and antibiotic-supplemented media. Cells were harvested at 48h after removal of 
SiRNA, care was taken to preserve floating apoptotic cells for FACS analysis. Cells 
were also lysed for western blot confirmation of knockdown.  
 
Animal experiments. All animal procedures/care were approved by UTMDACC 
Institutional Animal Care and Usage Committee (Protocol #07-95-06336). Animals 
received humane care as per the Animal Welfare Act and the NIH "Guide for the Care 
and Use of Laboratory Animals." Animal models were utilized as previously 
described.322 Viable SKLMS1 cells were confirmed using trypan blue staining, and 
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2X106cells/0.1mL RPMI/mouse were used.  Cell suspensions were injected 
subcutaneously into the flank of 6-8 week old female hairless SCID mice (n= 7-8 per 
group) and growth was measured twice weekly; after establishment of palpable 
lesions (average diameter of ~4-5mm), mice were assigned to one of the following 
treatment groups: 1) vehicle control; 2) rapamycin (3.75 mg/kg/d, per gavage, 5 days 
per week); 3) MLN8237 (15mg/kg/bid, per gavage) or 4) combination of both agents. 
Rapamycin dose followed previously published studies323; MLN8237 dose was 
selected based on the company’s recommendation and previously published data 
demonstrating that the maximal tolerated dose of the compound in most mouse 
strains (continuous dosing for ~21 days) is approximately 20mg/kg/bid (i.e. a total of 
40mg/kg/d) and anti-tumor efficacy is observed with a total dose of 30mg/kg/d.315,324 
Of note, MLN8237 was administered alone on day one of treatment while rapamycin 
treatment was initiated on day two. Mice were followed for tumor size, well-being, and 
body weight, and sacrificed when control group tumors reached an average of 1.5cm 
in largest dimension (21 days of treatment). Tumors were resected, weighed, and 
frozen or fixed in formalin and paraffin-embedded for immunohistochemical studies.  
 
Immunohistochemistry and immunofluorescence for xenograft experiments. 
IHC and immunofluorescence studies were conducted as previously described.322,325 
Slides prepared from tumor xenografts were warmed for ~45min on a plate warmer at 
60°C. Next, they were de-waxed and re-hydrated through a series of xylene and 
ethanol incubations. Commercially available antibodies against phospho-S6 ribosomal 
protein (pS6RP, used as a surrogate for phosphorylated S6 Kinase; Ser235/236, 
#2211S, Cell Signaling, Danvers, MA; 1:200; 10mM sodium citrate buffer at pH6.0 
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with microwave retrieval for 10min at 98°C), phospho-4EBP1 (Thr70, #9455, Cell 
Signaling; 1:400; 10mM sodium citrate buffer at pH6.0 with microwave retrieval for 
10min at 98°C) were used for immunohistochemistry. Appropriate biotinylated 
secondary antibodies and horseradish peroxidase-labeled streptavadin (4 plus system 
Biocare Medical, Concord, CA) were used for immunostaining, with 3,3-
diaminobenzidine serving as chromagen. For xenograft tissues with primary 
antibodies made in mouse, fragment blocking was performed prior to administration of 
primary antibody. Briefly, 1:10 mouse IgG f(ab) was mixed suspended in normal 
house (1:10) and normal goat (1:10) serum in PBS, applied to the tissues, and 
incubated at 4°C overnight. The following day, tissues were washed well, reincubated 
with protein block for 10min, and primary antibody was added. 
 
Frozen sections were used for fluorescent CD31 and TUNEL detection. Frozen 
tissues were fixed with cold acetone and chloroform, washed in PBS, and blocked 
with 4% fish gelatin in PBS for 20min. Next, rat anti-mouse CD31 (BD Pharmagen, 
1:500) in 4% fish gelatin solution was added and incubated overnight at 4ºC. 
Secondary goat-anti-rat IgG antibody conjugated to Alexa Fluor 594 (Invitrogen) was 
incubated for 1h at RT under limited light exposure. Slides were then washed, stained 
with Hoechst dye (Molecular Probes; 1:10,000 in PBS) and cover slipped using 
fluorescent mounting medium. Terminal deoxyribonucleotide transferase-mediated 
nick-end labeling (TUNEL) experiments to evaluate levels of apoptosis via were 
performed on frozen tissues as directed by the Dead End Fluorometric TUNEL Kit 
purchased from Promega.  
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Ki67, TUNEL, and CD31 counts were calculated as the average number per high 
power field (200x) in five separate fields of two to three independent tumors from each 
group. The percentage of proliferating cells as indicated by Ki67 expression was 
calculated by dividing the number of Ki67 positive cells by the total number of nuclei 
stained by Gills #3 hematoxylin per field. The percentage of apoptotic cells was 
calculated by dividing the number of apoptotic cells by the total number of Hoescht-
stained nuclei present in each field.  
 
Statistical analysis. Spearman Rank Correlation was used to determine the 
correlation between biomarkers’ expression and disease status/tumor status. For 
markers scored as – or +, Fisher’s exact test was employed. Correlation between the 
different biomarkers was also evaluated using Spearman's correlation coefficient 
analyses; only one tissue sample per lesion was included for analysis. To evaluate 
the correlation of TMA biomarker expression and patient outcome (recurrence-free 
survival [RFS], metastasis-free survival [MFS], and disease specific survival [DSS]) 
each independent variable was examined separately in a univariable Cox proportional 
hazards model. Local recurrence was defined as pelvic, abdominal, or retroperitoneal 
recurrence where tumor did not infiltrate other organs. Metastases were characterized 
as tumor presence outside of the retroperitoneal, abdominal or pelvic regions such as 
lung or brain, and tumor infiltration into retroperitoneal/abdominal/pelvic organs such 
as kidney, bone, and liver. All tumor recurrence or metastases was confirmed via 
clinical/radiological evidence. All time intervals to recurrence, metastases, or death 
were defined as the interval of time between the diagnosis of the tumor with which the 
patient first presented to UTMDACC to the date when the recurrence/metastases 
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occurred or the patient died, respectively. Only local tumors were considered for 
outcome analysis; one tissue specimen from the earliest occurring tumor available 
was selected per patient. A p-value of p≤0.05 was set as the cutoff. All computations 
were performed using SAS for Windows (release 9.2; SAS Institute, Cary, NC).  
 
To score each gene expression profile of ULMS or normal myometrium for similarity 
to a predefined gene transcription “signature” of the PI3K/AKT/mTOR pathway, we 
derived a ''t score'' for the sample profile in relation to the signature patterns as 
previously described.326-328 In brief, the PI3K mRNA t score was defined as the two-
sided t statistic comparing the average of the PI3K-induced genes with that of the 
repressed genes within each tumor (after normalizing the log-transformed values to 
standard deviations from the median across samples). The mapping of transcripts or 
genes between the two array datasets was made on the Entrez Gene identifier; where 
multiple human array probe sets referenced the same gene, one probe set with the 
highest variation represented the gene.  
 
Cell culture-based assays were repeated at least twice; mean ± SD was calculated. 
Cell lines were examined separately. For outcomes that were measured at a single 
time point, two-sample t-tests were used to assess differences. To determine whether 
the cytotoxic interactions of rapamycin and MLN8237 in SKLMS1 cells were 
synergistic, additive, or antagonistic, drug effects were examined using the 
combination index (CI) method of Chou and Talalay.329 Briefly, the fraction affected 
(Fa) was calculated from cell viability assays, and CIs were generated using 
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CalcuSyn software (Biosoft, Cambridge, UK). Differences in xenograft growth in vivo 
were assessed using a two-tailed Student's t-test. Significance was set at p≤0.05.  
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Chapter 3: Identifying molecular deregulations in human ULMS  
 
ULMS tissue microarray. A large tissue microarray (TMA) was constructed to 
facilitate identification of molecular deregulations in ULMS in a streamlined and high-
throughput manner (Figure 7). Eight tumor samples were not considered for further 
evaluation after thorough examination of tissues and patient history revealed tumors 
may not be ULMS. In total, two hundred and forty three tumor blocks (representing 
208 lesions retrieved from 109 patients) containing sufficient viable tumor tissue 
adequate for analytic purposes were selected for TMA construction. These included 
18 primary lesions, 66 recurrent lesions, and 124 metastatic lesions. In addition, 
FFPE blocks of 10 healthy gastrointestinal smooth muscle specimens, 15 healthy 
myometrium samples, and 10 benign leiomyomas were identified as controls. ULMS 
patient clinical information including demographic, therapeutic, tumor, and clinical 
outcome variables were retrieved from institutional medical records and tabulated for 
correlative analyses. Blocks were organized and sent to the MD Anderson Pathology 
Core for physical construction of the TMA as previously described.320 The completed 
tissue microarray consisted of 4 blocks; 3 blocks were composed of 70 samples and 1 
was comprised of 76 samples. Tumor samples from each block are included in 
duplicate to ensure staining quality and consistency. There are also 5 blocks with 
large tumors included on each of the four master TMA blocks for quality control 
between TMA 
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Figure 7. Uterine Leiomyosarcoma tissue microarray. ULMS tissue microarray 
paraffin blocks and corresponding slides. Four blocks in total contain 243 tumor 
samples and represent 208 lesions from 109 patients. 
 
slides. Two-hundred and eight different lesions were identified on the TMA for 
inclusion in biomarker analyses; localized tumors from 57 independent patients were 
utilized for outcome analyses.  
 
Evaluation smooth muscle and gynecological differentiation markers.  
In many tumor types, loss of differentiation markers can confound already difficult 
diagnoses. Recurrent and metastatic ULMS diagnosis can be complicated in part due 
to their frequent variability in morphology. Potential loss of differentiation markers in 
ULMS could contribute significantly to difficulty with diagnosis and awareness of the 
frequency of loss of differentiation markers in ULMS could aid pathologists in 
diagnosis of more complicated ULMS cases. Towards this goal, we evaluated the 
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expression of several markers of both smooth muscle and gynecological 
differentiation in our large ULMS TMA.  
 
Smooth muscle differentiation markers 
Cells originating from smooth muscle stain positively for smooth muscle markers such 
as smooth muscle actin (SMA), smooth muscle myosin (SMM), desmin, and 
caldesmon (Figure 8A and Table 8A). SMA expression was observed diffusely in 
88% (n=182), focally in 7% (n=14) of ULMS samples; expression was not found in 6% 
(n=12) of ULMS specimens. Diffuse expression of SMM was found in 72% (n=146) of 
ULMS, focal expression was found in 7% (n=15) of ULMS and 21% (n=43) did not 
express SMM. Desmin expression was observed diffusely in 66% (n=135) of ULMS, 
focally in 21% (n=43) of ULMS and was not expressed in 14% (n=28) of ULMS 
samples. Lastly, diffuse expression of caldesmon was found in 70% (n=143), focal 
expression in 12% (n=24), and no expression in 19% (n=38) of ULMS samples on our 
TMA. No GI smooth muscle, myometrium, or leiomyoma controls exhibited loss of any 
smooth muscle differentiation markers (Appendix Table A4A). Three of the four 
muscle markers examined in this study were significantly lost in ULMS compared with 
controls (SMA, p=0.0823; SMM, p=0.0020; desmin, p=0.0130; caldesmon, p=0.0039).  
 
In our series, we found significant loss of smooth muscle differentiation markers; 31% 
of ULMS lost at least one of the four muscle markers, 18% lost at least 2, 9% lost 
expression of at least 3 markers, and 2% of confirmed ULMS lost expression of all 4 
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Figure 8. Differentiation markers in controls compared to ULMS. Photographic 
representations of A) smooth muscle differentiation markers and B) gynecological 
differentiation markers in ULMS versus controls. Loss of differentiation markers was 
observed for all markers in ULMS but not in controls.330 
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muscle markers examined. No normal smooth muscle controls or leiomyoma 
exhibited any loss in muscle marker expression. Loss of 2 or more muscle markers 
examined was found more frequently in ULMS; this difference was statistically 
significant (p=0.0046). A marked increase in loss of muscle markers was observed 
within tumor groups; recurrent and metastatic tumors had a loss of muscle markers 
nearly 3 fold higher than primary tumors and the only group exhibiting loss of all 4 
muscle markers were metastatic tumors (Supplementary Table S4B). 
 
Gynecological differentiation markers 
Next, we examined the expression of three gynecological differentiation markers in 
ULMS: Wilms Tumor 1 (WT-1), estrogen receptor (ER), and progesterone receptor 
(PR; Figure 8B, Table8B). These markers are high in tissues of gynecological origin 
thus, we wanted to examine whether they were largely retained or lost in ULMS.  GI 
smooth muscle was not used as a control for gynecological differentiation markers 
because it does not originate from gynecological tissues and therefore, is not 
expected to express differentiation markers specific to tissues of that origin. Nuclear 
WT-1 expression was found in 96% (n=23) of myometrium and leiomyoma controls 
compared with only 55% (n=111) of ULMS samples (p<0.0001; Table 8B). Further, 
WT-1 loss was found within ULMS tumor progression groups; more advanced tumors 
exhibited increased WT-1 loss (Appendix Table A4B). 
 
High levels of hormone receptors such as estrogen and progesterone receptors are 
found commonly in gynecologic tissues. Elevated levels of hormone receptors have 
also been suggested to drive gynecological tumors. To determine expression levels of 
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estrogen and progesterone receptors in ULMS, the TMA was utilized. We found a 
marked reduction of estrogen and progesterone receptors in ULMS compared with 
myometrium and leiomyoma controls (p<0.0001 and <0.0001, respectively; Table 
8B). Estrogen receptor expression was high in 32% (n=67), weak in 13% (n=26) and 
absent in 55% (n=114) of ULMS samples included on the TMA. Similarly, 
progesterone receptor was highly expressed in 45% (n=89), weakly expressed in 17% 
(n=33) and was not expressed in 39% (n=78) of ULMS tissues (Appendix Table 
A4B). An average of 38% (±35%) and 28% (±36%) of ULMS cells per sample 
exhibited positive staining for ER and PR, respectively (Appendix Table A4B).! For 
both receptors, marked loss of expression was observed in ULMS. 
 
Smooth muscle and gynecological differentiation marker’s correlations to 
outcome. 
 
Expression of smooth muscle and gynecological differentiation markers were 
examined for correlation with recurrent-free, metastasis-free, and disease specific 
survival. Loss of smooth muscle myosin and caldesmon were both significantly 
associated with recurrence-free survival (p=0.0073 [HR=0.28, 95% CI: 0.11-0.71] for 
both proteins). Loss of two or more of the four muscle markers we evaluated also 
correlated with RFS (p=0.0073 [HR=0.28, 95% CI: 0.11-0.71). We also found that 
reduced estrogen receptor expression correlated to longer recurrence-free survival 
(p=0.0432 [HR=0.99, 95% CI: 0.98-1.00]). No muscle or gynecological differentiation 
markers correlated significantly with metastasis-free or disease specific survival 
(Table 9). 
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Table 8. Smooth muscle and gynecological differentiation markers’ expressions 
in ULMS versus control. 
 
 
 Smooth muscle  Leiomyoma  ULMS  
          
Marker Total n= Loss  
Total 
n= Loss   
Total 
n= Loss P 
A. Smooth muscle differentiation markers     
SMA 25 0 (0%)  7 0 (0%)  208 12 (6%) 0.0823 
SMM 25 0 (0%)  8 0 (0%)  204 43 (21%) 0.0020 
Desmin 25 0 (0%)  7 0 (0%)  206 28 (14%) 0.0130 
Caldesmon 25 0 (0%) 8 0 (0%) 205 38 (18%) 0.0039 
Loss ≥50% 
markers 25 0 (0%) 
 7 0 (0%)  199 35 (18%) 0.0046 
B. Gynecological differentiation markers P* 
 Myometrium  Leiomyoma  ULMS  
Nuclear 
WT-1 14 1 (7%)  10 0 (0%)  202 91 (45%) <0.0001 
Marker Total n= high  
Total 
n= high  
Total 
n= high  
ER 15 
15 
(100%)  8 
6 
(75%)  207 
67 
(32%) 
<0.0001 
PR 14 
14 
(100%)  7 
5 
(71%)  200 
89 
(45%) 
<0.0001 
p compares all controls (GI smooth muscle, myometrium,  and leiomyoma) to 
ULMS for all smooth muscle differentiation markers 
p* compares controls (myometrium and leiomyoma only) to ULMS for all 
gynecological differentiation markers 
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Table 9. Differentiation markers’ correlations to outcome in ULMS. 
A. Biomarker intensity expression univariate correlation to recurrence-free 
(RFS) and metastasis-free (MFS) survival 
  RFS (univariable) MFS (univariable) 
Marker P 
Hazard Ratio 
(95% CI) P 
Hazard Ratio     
(95% CI) 
Loss of SMA 0.4318 - 0.9583 - 
Loss of SMM 0.0073 0.28 (0.11-0.71) 0.5454 - 
Loss of Desmin 0.6304 - 0.4833 - 
Loss of Caldesmon 0.0073 0.28 (0.11-0.71) 0.5454 - 
Loss of ≥ 50%  
muscle markers 0.0073 0.28 (0.11-0.71) 0.5454 - 
Loss of WT-1 0.9216 - 0.2544 - 
Loss of ER 0.0432 0.99 (0.98-1.00) 0.1460 - 
Loss of PR 0.0771 - 0.2820 - 
B. Biomarker intensity expression univariate and multivariate correlation to 
disease specific survival  
 DSS (univariable) 
Marker P Hazard Ratio (95% CI) 
Loss of SMA 0.1720 - 
Loss of SMM 0.0649 - 
Loss of Desmin 0.8608 - 
Loss of Caldesmon 0.0649 - 
Loss of ≥ 50% 
muscle markers 0.0649 - 
Loss of WT-1 0.8483 - 
Loss of ER 0.0839 - 
Loss of PR 0.6371 - !
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Evaluation of cancer-related biomarkers. 
An array of studies have presented clinical prognosticators for ULMS, however, most 
have not examined potential molecular biomarkers. To our knowledge, this study 
represents one of the largest clinical databases and undoubtedly provides the most 
comprehensive evaluation of potential markers in ULMS published to-date. We 
constructed a TMA to examine intensity expression profiles of several potentially 
critical proteins in ULMS compared to healthy smooth muscle and benign leiomyoma 
(Table 10). The percentages of cells expressing each protein at low, moderate, and 
high levels are given for controls and ULMS in Appendix Tables A5B and A6B, 
respectively; only differences in distribution correlating with outcome are noted in this 
text. Tumor status was also examined; primary, recurrent, and metastatic ULMS 
groups were compared to identify biomarkers that were differentially expressed 
(Table 11 and Appendix Table A6A). One sample per ULMS lesion within the TMA 
was utilized for biomarker analysis (n=208). Further, we examined biomarker 
correlation to outcomes (Table 12 intensity, Appendix Table A7 distribution). For 
outcomes, only one local lesion per patient was evaluated (n=57). 
 
Proliferation 
Ki67 and cyclin D1 were evaluated as markers of proliferation and found to have 
significantly increased expression compared to controls (Figure 9). About one quarter 
(n=50) of ULMS samples expressed no Ki67 while 63% (n=129) had low expression 
and 13% (n=13) had high expression of Ki67. Cyclin D1 was expressed in 25% of 
ULMS; 20% (n=41) had low expression and 5% (n=11) had high expression. An 
average of 22% (±18%) and 8% (±17%) of cells per ULMS sample expressed Ki67 
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and cyclin D1, respectively. Elevated cyclin D1, but not Ki67, expression was 
observed in leiomyoma compared with other controls (25% [n=2 of 10] and 8% [n=2 of 
25], respectively). In sum, both Ki67 and cyclin D1 expression were increased 
significantly in tumor versus controls (p<0.0001 and p=0.0099).  
 
Survival 
Next, markers of survival were evaluated (Figure 9). Bcl-2 expression was slightly 
reduced in ULMS samples compared with controls, but this difference was not 
significant (p=0.3556). All but one ULMS expressed Bcl-2: 34% (n=69) had weak 
expression, 47% (n=95) had moderate expression and 19% of ULMS samples had 
strong expression of Bcl-2. An average of 43% (±33%) of cells per ULMS sample 
expressed Bcl-2. Between controls, Bcl-2 expression was higher in myometrium and 
leiomyoma compared with GI smooth muscle (Appendix Table A5A). Survivin 
expression was assessed for both nuclear and cytoplasmic intensities; increased 
expression was observed in both locations, but only increased nuclear expression 
was significant in ULMS versus controls (p<0.0001). Both nuclear and cytoplasmic 
survivin expression was observed in all ULMS samples. Strong nuclear expression of 
survivin was observed in only one case of ULMS (0.5%); strong cytoplasmic 
expression was not observed. Further, 67% (n=135) and 30% (n=60) of ULMS 
moderately expressed cytoplasmic and nuclear survivin, respectively. Weak 
cytoplasmic expression was noted in 33% (n=66) and weak nuclear expression was 
observed in 70% (n=140) of ULMS. Averages of 69% (±18%) and 39% (±19%) cells  
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Figure 9. Markers of proliferation and survival. Photographic representation of 
markers of proliferation and markers of survival in ULMS compared with myometrium 
and leiomyoma controls.330  
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per ULMS sample were observed to express cytoplasmic and nuclear survivin, 
respectively.  
 
Invasion and angiogenesis 
Expressions of invasion-associated proteins MMP-2 and MMP-9 were investigated 
(Figure 10). MMP-2 expression was observed infrequently in ULMS; 94% (n=189) 
samples did not express MMP-2, 2% (n=5) had weak expression, 2% (n=4) had 
moderate expression, and only 1% (n=3) strongly expressed MMP-2. Conversely, all 
but one ULMS expressed MMP-9; 41% (n=83) had weak expression, 36% (n=72) had 
moderate expression, and 23% (n=46) had strong MMP-9 expression. While both 
MMP-2 and MMP-9 showed slightly increased expression in tumor versus normal 
tissues, the differences were not significant (p=0.4893 and p=0.2521, respectively). 
Averages of 5% (±19%) and 77% (±23%) of ULMS cells showed expression for MMP-
2 and MMP-9, respectively. Additionally, we evaluated the expression of vascular 
endothelial growth factor (VEGF), a critical and driving protein in angiogenesis 
(Figure 10). VEGF expression was noted in all but one ULMS sample. High 
expression was observed in 19% (n=39), moderate expression in 47% (n=95), and 
low expression in 34% (n=69) of ULMS examined. VEGF expression increased 
significantly in tumor versus controls (p=0.0287) with an average of 63% (±23%) of 
cells per ULMS sample staining positively.  
 
Oncoproteins and tumor suppressors 
Utilizing the TMA, expression levels of select tumor oncogenes and suppressors were 
also evaluated (Figure 11). MDM2, p53, and p16 levels all showed significantly  
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Figure 10. Markers of invasion and angiogenesis. Images of markers of invasion 
(MMP-2 and MMP-9) and angiogenesis (VEGF) in ULMS compared to controls. 
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Figure 11. Oncoprotein and tumor suppressor expression in myometrium, 
leiomyoma, and ULMS. Photographic representation of MDM2, p53, p16, and Rb 
expression in ULMS compared to myometrium and leiomyoma controls.330  
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increased expression in tumor compared with controls (p=0.0228, p=0.0018, and 
p<0.0001, respectively). MDM2 expression was absent from 88% (n=176) of ULMS 
while 3% (n=6) had weak expression, 14% (n=27) had moderate expression and 2% 
(n=4) had strong expression. Additionally, 43% of ULMS did not stain positively for 
p53 and 25% (n=52) stained weakly for p53. Moderate p53 expression was observed 
in 31% (n=64) and strong expression in one additional ULMS sample compared with 
no moderate or strong staining in controls. Rb expression was not found in 59% 
(n=117) of ULMS. Weak expression of Rb was detected in 14% (n=27) and strong 
expression was seen in 27% (n=53) of ULMS compared to none in controls. 
Expression of p16 was observed in nearly all ULMS samples. Weak expression was 
found in 14% (n=29), moderate expression in 31% (n=62) and strong expression in 
49% (n=98) of ULMS. Only 6% (n=13) of ULMS did not express p16 compared with 
more than half of all controls. An average of 2% (±10%) of ULMS cells per sample 
expressed MDM2 while 26% (±32%) expressed p53 and 66% (±32%) had positive 
expression for p16. Within controls, GI smooth muscle showed reduced expression of 
p53 compared to myometrium and leiomyoma (Appendix Table A5). Additionally, Rb 
expression decreased significantly (p=0.0239) in ULMS; an average of 10% (±20%) of 
ULMS cells in each sample expressed Rb. 
 
Signaling molecule β−catenin 
Given its potential implications in cancer cell signaling, we evaluated expression 
levels of β-catenin (Figure 12). Expression was noted in nearly all ULMS samples; 
34% (n=69) had low expression, 42% (n=85) had moderate expression, and 22% 
(n=45) had strong expression of cytoplasmic β-catenin.  Only 1% (n=3) of ULMS did 
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Figure 12. β-catenin expression in ULMS compared to controls. Photographic 
representation of β-catenin expression in ULMS. Notably, nuclear expression and 
membranous expression of β-catenin was also observed in ULMS.330 
 
not express cytoplasmic β-catenin and we found that expression was increased 
significantly in ULMS compared with controls (p<0.0001). It was expressed in an 
average of 62% (±27%) cells per ULMS sample. Interestingly, nuclear and 
membranous β-catenin expression were found in 7% (n=14) and 20% (n=41) of 
ULMS samples, respectively; nuclear or membranous expression was not found in 
any controls (p=0.0012 and 0.26, respectively; Appendix Table A5A)  
 
Biomarker correlations: tumor status and outcome 
Interestingly, expressions of several markers were significantly different between 
primary, recurrent, and metastatic lesions (Table 11). VEGF expression was 
significantly decreased in local (primary and recurrent) versus metastatic lesions 
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(p=0.0358). Conversely, MDM2 expression is significantly increased in local versus 
metastatic lesions (p=0.0148). p53 expression is significantly higher in advanced 
disease (recurrent and metastatic) as compared with primary ULMS (p=0.0074) and 
similarly, nuclear expression of β-catenin was found elevated in advanced ULMS 
compared with primary lesions (p=0.0012). Next, the correlation between expression 
levels of each biomarker and patient outcome was evaluated by univariable Cox 
proportions model (Table 12). In these analyses, only localized ULMS samples were 
included (n=57). Increased cytoplasmic and nuclear survivin correlated with shorter 
recurrence-free survival (p=0.0020 [HR=3.78, 95% CI: 1.63-8.81] and p=0.0144 
[HR=2.35, 95% CI:1.19-4.66], respectively). Enhanced nuclear distribution expression 
of survivin also correlated to decreased RFS (p=0.007 [HR=1.03, 95% CI:1.01-1.05]). 
Both nuclear and cytoplasmic β-catenin high intensity expression (p=0.0369 
[HR=1.58, 95% CI: 1.03-2.42] and p=0.0010 [HR=5.81], respectively) and high 
distribution expression (p=0.0045 [HR=1.02, 95% CI: 1.01-1.04) and p=0.0001 
[HR=5.81, 95% CI:2.03-16.60], respectively) were also associated with shorter RFS. 
Interestingly, high MMP-9 intensity expression correlated significantly with increased 
MFS (p=0.0251 [HR=0.57, 95% CI: 0.35-0.93]). Only high Bcl-2 intensity and 
distribution intensities correlated to longer DSS (p=0.0381 [HR=0.61, 95% CI: 0.38-
0.97] and p=0.0142 [HR=0.98, 95% CI: 0.97-1.00], respectively). Taken together, 
these data identify several biomarkers for ULMS although no significant biomarkers 
correlate well to DSS. Additionally, this work presents a number of potential 
therapeutic targets for further evaluation towards new therapies for ULMS in the 
clinical setting.  
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Table 10. Cancer-related biomarkers’ correlation to disease status. 
Spearman Rank Correlation with Disease Status 
 Smooth muscle Leiomyoma ULMS  
Marker 
Total n= 
 high 
expression 
(%)  
Total 
n= 
 high 
expression 
(%)  
Total 
n= 
 high 
expression 
(%)  P 
Proliferation               
Ki67 24 0 (0%) 6 0 (0%) 205 155 (76%) <0.0001 
Cyclin D1 25 0 (0%) 8 0 (0%) 207 52 (25%) 0.0099 
Marker 
Total n= 
moderate-
strong 
intensity 
(%) 
Total 
n= 
moderate-
strong 
intensity 
(%) 
Total 
n= 
moderate-
strong 
intensity 
(%)  
Survival               
Bcl-2 24 14 (58%) 8 3 (38%) 204 85 (42%) 0.3556 
Cyt. survivin 25 13 (52%) 8 5 (63%) 201 135 (67%) 0.1723 
Nuc. survivin 25 1 (4%) 8 0 (0%) 201 61 (30%) <0.0001 
Invasion               
MMP2 25 0 (0%) 8 0 (0%) 201 7 (3%) 0.4893 
MMP9 25 18 (72%) 8 4 (50%) 202 118 (58%) 0.2521 
Angiogenesis               
VEGF 25 15 (60%) 8 4 (50%) 204 134 (66%) 0.0287 
Oncoproteins and tumor suppressors         
MDM2 25 0 (0%) 5 0 (0%) 200 18 (9%) 0.0228 
p53 25 0 (0%) 7 0 (0%) 204 65 (32%) 0.0018 
p16 25 7 (28%) 7 3 (43%) 202 160 (79%) <0.0001 
Rb 24 19 (79%) 6 6 (100%) 197 80 (41%) 0.0239 
Signaling               
Cyt. β-catenin 25 0 (0%) 8 0 (0%) 202 130 (64%) <0.0001 
Nuc. β-catenin 25 0 (0%) 8 0 (0%) 203 14 (7%) 0.0012* 
Memb. β-
catenin 
25 0 (0%) 8 0 (0%) 203 41 (20%) 0.26* 
Total n= indicates the number of evaluable samples in each dataset 
@ is defined as having a score of 0 on a scale of 0-3 (defined in *) and indicates complete loss 
of protein expression 
*p values were calculated by chi-squared test, except where 50% of the cells had expected 
counts less than 5%, in which case Fisher's exact test was applied  
All p-values compared control (myometrium, GI smooth muscle, leiomyoma) versus ULMS; 
bolded values indicate statistical significance (p<0.05) 
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Table 11. Cancer-related biomarkers’ correlation to tumor status. 
Spearman Rank Correlation with Tumor Status 
                
 Primary ULMS Recurrent ULMS Metastatic ULMS  
Marker 
Total 
n= 
 high 
expression 
(%)  
Total 
n= 
 high 
expression 
(%)  
Total 
n= 
 high 
expression 
(%)  P 
Proliferation               
Ki67 18 9 (50%) 64 55 (86%) 123 91 (74%) 0.1210 
Cyclin D1 18 6 (34%) 65 18 (28%) 124 28 (23%) 0.0663 
Marker 
Total 
n= 
moderate-
strong 
intensity 
(%) 
Total 
n= 
moderate-
strong 
intensity (%) 
Total 
n= 
moderate-
strong 
intensity (%)  
Survival               
Bcl-2 18 10 (55%) 64 26 (41%) 122 49 (40%) 0.1991 
Cyt. survivin 18 7 (39%) 63 45 (71%) 120 83 (69%) 0.1033 
Nuc. survivin 18 2 (11%) 63 21 (34%) 120 38 (32%) 0.2089 
Invasion               
MMP2 18 0 (0%) 65 2 (3%) 118 5 (5%) 0.3892 
MMP9 18 11 (61%) 66 42 (64%) 118 65 (55%) 0.2324 
Angiogenesis               
VEGF 18 9 (50%) 65 36 (55%) 121 89 (74%) 0.0358 
Oncoproteins and tumor suppressors         
MDM2 18 2 (11%) 65 11 (17%) 117 5 (5%) 0.0148 
p53 17 5 (29%) 65 27 (42%) 122 22 (27%) <0.0001 
p16 18 10 (56%) 64 55 (86%) 120 95 (80%) 0.4723 
Rb 18 9 (50%) 62 24 (39%) 117 47 (40%) 0.2596 
Signaling               
Cyt. β-catenin 18 8 (44%) 64 43 (68%) 120 79 (66%) 0.1961 
Nuc. β-catenin 18 0 (0%) 64 11 (17%) 121 3 (2%) 0.0026* 
Memb. β-catenin 18 1 (6%) 64 13 (20%) 121 27 (22%) 0.36* 
                
Total n= indicates the number of evaluable samples in each dataset 
@ is defined as having a score of 0 on a scale of 0-3 (defined in *) and indicates complete loss of 
protein expression 
*p values were calculated by chi-squared test, except where 50% of the cells had expected 
counts less than 5%, in which case Fisher's exact test was applied  
All p-values compared control (myometrium, GI smooth muscle, leiomyoma) versus ULMS; 
bolded values indicate statistical significance (p<0.05) 
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Table 12. Expression of cancer biomarkers’ correlation to outcomes. 
A. Biomarker intensity expression univariate correlation to recurrence-free (RFS) 
and metastasis-free (MFS) survival 
  RFS (univariable) MFS (univariable) 
Marker P 
Hazard Ratio 
(95% CI) P 
Hazard Ratio     
(95% CI) 
Ki67 0.1909 - 0.2044 - 
Cyclin D1 0.5493 - 0.5559 - 
Bcl-2 0.4256 - 0.9340 - 
Cyt. survivin 0.0020 3.78 (1.63-8.81) 0.5778 - 
Nuc. survivin 0.0144 2.35 (1.19-4.66) 0.5060 - 
MMP2 0.9553   - 0.9925  -  
MMP9 0.1493  - 0.0251 0.57 (0.35-0.93)  
VEGF 0.1134 - 0.4774 - 
MDM2 0.6971 - 0.6054 - 
p53 0.1987 - 0.6027 - 
p16 0.8916 - 0.4812 - 
Rb 0.5758 - 0.8143 - 
Cyt. β-catenin 0.0369 1.58 (1.03-2.42) 0.2165 - 
Nuc. β-catenin 0.0010  5.81 (2.03-16.60)  0.6238 -  
Memb.  β-catenin 0.1519   0.5537   - 
B. Biomarker intensity expression univariate and multivariate correlation to 
disease specific survival 
  DSS (univariable) 
Marker P Hazard Ratio (95% CI) 
Ki67  0.1240 - 
Cyclin D1  0.4388 - 
Bcl-2  0.0381 0.61 (0.38-0.97) 
Cyt. survivin 0.5612 - 
Nuc. survivin 0.7355 - 
MMP2  0.8270  - 
MMP9   0.9404 - 
VEGF  0.8332 - 
MDM2  0.8361 - 
p53  0.2507 - 
p16  0.6224 - 
Rb  0.3709 - 
Cyt. β-catenin 0.3446 - 
Nuc. β-catenin  0.3173   - 
Memb.  β-catenin 0.5741 - 
Outcomes for all markers were calculated by Cox analysis. 
!
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Chapter 4: Evidence of Targetable Pathways in ULMS: The mTOR Pathway !
!
The AKT/mTOR pathway is highly activated in human ULMS 
Several studies have identified aberrant mTOR signaling in soft tissue sarcoma, 
including LMS107,187,331; however, to the best of our knowledge, it has not yet been 
determined if this pathway is activated in human ULMS specifically. Therefore, 
recently obtained gene expression profiles of 12 ULMS specimens (FIGO stage I) and 
10 healthy myometrium samples250 were compared bioinformatically to three 
previously reported different PI3K/AKT/mTOR-related gene expression signatures: 1) 
the CMap signature, which identified commonly deregulated genes using expression 
profiles generated from several different cell lines treated with PI3K inhibitors327; 2) 
the Saal profile, based on gene expression in breast cancers exhibiting PTEN loss 
(and thus exhibiting a highly active mTOR pathway)328; and 3) the Majumder gene set 
which examines gene regulation in mice over expressing AKT1.326 Each profiled 
ULMS or myometrium sample was scored for PI3K pathway activation based 
 
Figure 13. mTOR pathway is commonly activated in human ULMS. A 
PI3K/AKT/mTOR pathway is more active in ULMS, based on gene expression 
profiling data. Three previously described gene transcription signatures for the 
PI3K/AKT/mTOR pathway were applied to expression profiles of ULMS samples; 
each sample was scored for relative signature activity (heatmap is depicted: yellow = 
more active, blue = less active).249   
 
!! 91!
on pathway-specific transcriptional targets. For each signature evaluated, ULMS 
tumors had higher PI3K/AKT/mTOR pathway activation scores versus myometrium 
(p<0.01, each signature, two-sided t-test) (Figure 13), providing initial evidence of 
AKT/mTOR deregulation in ULMS.249   
 
mTOR pathway proteins are overexpressed in human ULMS.  
Next, we evaluated expression levels of the activated (phosphorylated) mTOR 
downstream effectors S6RP and 4EBP1 in a large human ULMS TMA. (Figure 14, 
Figure 17, Table 14A). Only samples representing different lesions were included in 
the final analysis (n=208). All ULMS specimens expressed pS6RP: low levels were 
observed in 28.5% (n=55), moderate expression was noted in 48.5% (n=97), and high 
expression was found in 24% (n=48). An average of 60.7% (±20) of tumor cells per 
sample exhibited positive pS6RP staining. While pS6RP expression was observed in 
all controls, staining intensity was found to be significantly lower (p<0.0001). No 
differences in the expression of this marker were identified between normal 
myometrium and leiomyoma. p4EBP1 was scored for both cytoplasmic and nuclear 
expression intensity. All ULMS samples expressed cytoplasmic p4EBP1: low levels 
were observed in 22% (n=43), moderate expression was noted in 59% (n=114), and 
high expression was found in 19% (n=36). An average of 72.5% (±14.4) of tumor cells 
per sample exhibited positive cytoplasmic p4EBP1 staining. Similarly, nuclear 
p4EBP1 expression was found in all ULMS samples: low levels were observed in 39% 
(n=75), moderate expression was noted in 45% (n=87), and high expression was 
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Figure 14. The mTOR pathway is commonly activated in human ULMS. 
Representative photographs of ULMS tissue microarray pS6RP, p4EBP1, and pAKT 
immunostaining (original images were captured at 20x (circles) or 400x magnification 
(squares) depicting differences in expression between tumor and normal smooth 
muscle. Staining for PTEN is also shown and includes an example of PTEN 
expression loss as compared to positive staining – the latter was observed in most 
evaluable samples.249  
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found in 16% (n=30). An average of 70.8% (±13.7) of tumor cells per sample 
exhibited positive nuclear p4EBP1 staining. All controls exhibited cytoplasmic and 
nuclear p4EBP1 staining, albeit at markedly lower levels compared to ULMS 
(p=0.0011 and p=0.0001, respectively; Appendix Table A8B).  
 
Expression of pAKT, the major upstream regulator of mTOR, was next evaluated 
(Figure 14, Figure 17, and Table 14A). All ULMS exhibited pAKT expression at 
varying degrees: low levels were observed in 41% (n=76), moderate in 47% (n=87), 
and high in 12% (n=23; Appendix Table A9A). An average of 66.4% (±20.4) of tumor 
cells per sample exhibited positive pAKT staining. In contrast, all control samples 
exhibited only low levels of pAKT expression (p<0.0001; Appendix Table A8A). Loss 
of the PTEN tumor suppressor was suggested as a potential common molecular LMS 
deregulation, contributing to mTOR activation.98 Interestingly, immunohistochemical 
analysis identified loss of PTEN expression in only 7% of ULMS samples (n=15); 9% 
of controls (two normal smooth muscle and one leiomyoma) exhibited no PTEN 
expression. Distribution scores for each marker in controls and ULMS are given in 
Appendix Table A8B and Appendix Table A9B, respectively. 
 
Next, we evaluated the association of biomarker expression to tumor status (primary, 
recurrent, or metastatic; Table 15A). pS6RP expression levels were identified in 
recurrent and metastatic ULMS samples compared to primary lesions (p=0.0259). 
pS6RP, cyoplasmic and nuclear p4EBP1 expression levels also associated 
significantly with recurrent and metastatic lesions compared to primary ULMS when a 
simple Fisher’s Test was applied (p=0.0005, p=0.05, and p=0.0088, respectively). 
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Further, Spearman Rank Correlation test was used to examine correlations between 
biomarkers. We found that pS6RP, cytoplasmic and nuclear p4EBP1, and pAKT 
expression all statistically correlated with one another but none significantly correlated 
with PTEN expression status (Table13). No difference between pAKT expression 
levels was noted between primary, recurrent, and/or metastatic ULMS specimens 
(Table 15A). Taken together, these data indicate that the mTOR pathway is highly 
activated in ULMS, but that the driver of this activation is not loss of the PTEN tumor 
suppressor per se, so there must be due to other contributing mechanisms.  
 
Table 13. Correlation between biomarkers by Spearman’s Rank test.249  
  pS6RP cyt. p4EBP1 
nuc. 
p4EBP1 pAKT PTEN 
pS6RP   
r=2.13 
p=0.002 
(n=186) 
r=0.193 
p=0.004 
(n=186) 
r=0.145 
p=0.027 
(n=180) 
r=0.056 
p=0.217 
(n=197) 
cyt. 
p4EBP1 
r=0.213 
p=0.002 
(n=186) 
  
r=0.416 
p<0.001 
(n=193) 
r=0.247 
p<0.001 
(n=185) 
r=0.053 
p=0.236 
(n=189) 
nuc. 
p4EBP1 
r=0.193 
p=0.004 
(n=186) 
r=0.416 
(p<0.001, 
n=193) 
  
r=0.216 
p=0.002 
(n=185) 
r=0.036 
p=0.310 
(n=189) 
pAKT 
r=0.145 
p=0.026 
(n=180) 
r=0.247 
p<0.001 
(n=185) 
r=0.216 
p=0.002 
(n=185) 
  
r=0.099 
p=0.091 
(n=183) 
PTEN 
r=0.056 
p=0.217 
(n=197) 
r=0.053 
p=0.236 
(n=189) 
r=0.036 
p=0.310 
(n=189) 
r=0.099 
p=0.091 
(n=183) 
  
total n= indicates the number of evaluable samples in each dataset 
bolded values indicate statistical significance (p<0.05) 
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Outcome analysis 
A univariable Cox model was utilized to determine whether the expression intensity 
and distribution (i.e., % positive cells) of any of the mTOR-related biomarkers was 
associated with clinical outcome; only localized ULMS specimens were included 
(n=57; Table 16). Only distribution of nuclear p4EBP1 correlated with any outcome 
factors; high distribution expression of nuclear p4EBP1 correlated with DSS 
(p=0.0494 [HR=1.03, 95% CI: 1.00-1.06]; Appendix Table A10). None of the mTOR-
related biomarkers correlated with RFS or MFS.  
 
Taken together, these data demonstrate mTOR deregulation as commonly occurring 
in human ULMS; their expression however, does not correlate well with outcome, 
indicating that mTOR pathway-related markers may serve as good biomarkers, but 
may not be viable prognostic markers. Further evaluation is needed to determine 
whether mTOR is a good potential ULMS therapeutic target. Identified mTOR 
overexpression provides rationale for further examination of factors promoting mTOR 
pathway deregulation. 
 
Tyrosine kinase Receptors may potentially contribute to deregulation of the 
mTOR pathway  
 
The mTOR pathway is activated by a large family of receptor tyrosine kinases (RTKs) 
that internalize cellular signals from extracellular molecules such as vascular 
endothelial growth factor (VEGF) and platelet derived growth factors α and β (PDGF-
α and PDGF-β). To explore molecular deregulations contributing to mTOR 
deregulation, a number of signaling molecules, including seven tyrosine kinase 
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receptors and two RTK ligands were evaluated for enhanced expression that may 
lend to pro-tumorigenic phenotypes. 
 
EGFR and IGFR 
First, expressions of epidermal growth factor receptor (EGFR) and insulin growth 
factor receptor 1 (IGF-1R) were evaluated (Table 14B, Figure 15). EGFR expression 
was present in over two-thirds of ULMS; 44% (n=88) had weak expression, 30% 
(n=60) had moderate expression, and 6% (n=12) had strong expression of EGFR 
(Appendix Table A9B). Weak IGF-1R expression was observed in 32% (n=64) of 
ULMS while moderate and strong expression was found in 14% (n=27) and 2% (n=4), 
respectively. IGF-1R expression was absent in only 52% (n=104) of ULMS compared  
 
Figure 15. EGFR and IGF-1R receptor tyrosine kinase expression in ULMS and 
controls. Images of EGFR and IGF-1R expression in myometrium, leiomyoma, and 
ULMS samples. A marked increase is found in ULMS compared to controls.330 
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to more than three-quarters of controls. EGFR and IGF-1R expressions were both 
increased in tumor versus controls, but only IGF-1R elevated expression was found to 
be significant (p=0.2239 and p=0.0003, respectively). The average of cells with 
positive expression per ULMS sample were EGFR - 73% (±14%) and IGF-1R - 23% 
(±32%; Appendix Figure A9B). Expression and distribution between controls is given 
in Appendix Figure A8B). 
 
PDGF-α and -β receptors and ligands  
Expression levels of platelet derived growth factor receptors alpha and beta (PDGFR-
α and PDGFR-β) and their respective ligands (PDGF-α and PDGF-β) were examined 
(Figure 16, Table 14B). PDGFR-α expression was strong in 42% (n=83), weak in 
50% (n=100) and absent in 9% (n=18) of ULMS (Appendix Table A9B). 
Furthermore, PDGF-α was strongly expressed in 8% (n=17), weakly expressed in 
64% (n=129) and not expressed in 28% (n=57) of ULMS. PDGFR-α expression 
significantly increased while PDGF-α ligand expression was significantly reduced in 
ULMS compared with controls (p<0.0001 and p<0.0001) with averages of 43% 
(±27%) and 23% (±25%) cells per ULMS sample with positive expression, 
respectively. Conversely, PDGFR-β and PDGF-β expression was strong in only 1% 
(n=1 and n=2, respectively) of ULMS samples; moderate expression was noted in 
21% (n=42) for PDGFR-β and 27% (n=54) for PDGF-β of samples. PDGFR-β was 
only weakly expressed in 74% (n=145) and was not expressed in 4% (n=8) of ULMS. 
Similarly, PDGF-β was weakly expressed in 72% (n=146) and absent in one ULMS 
sample. PDGFR-β and PDGF-β expression levels were both significantly increased in 
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Figure 16. Expression of PDGF family receptors and ligands in ULMS compared 
to controls. Photographic representation of PDGF receptors –α and –β show 
increased expression in ULMS compared to myometrium and leiomyoma controls. 
Further, PDGF-α ligand expression decreases in ULMS while PDGF–β ligand 
expression is enhanced.330 
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ULMS compared with controls (p<0.0001 and p=0009) and had positive expression in 
57% (±24%) and 57% (±24), respectively. Expression and distribution of controls is 
given in Appendix Figure A8B. 
 
c-KIT, MET and AXL 
Expression levels of c-KIT, MET, and AXL were also evaluated (Table 14B, Figure 
17). c-KIT expression was not common in ULMS; 98% (n=202) of all ULMS samples 
had no expression. Further, only 2% (n=5) of ULMS had weak c-KIT expression and 
no samples had strong expression (Appendix Figure A8B). Similarly, all controls 
were negative for c-KIT expression; there was no significant difference between 
ULMS and controls (p=0.46). c-KIT expression was absent in most samples and was 
therefore scored as present or absent; an average percentage of cells expressing c-
KIT could not be calculated. MET was expressed in all ULMS; 7% (n=14) had strong 
expression, 57% (n=117) had moderate expression, and 36% (n=73) weakly 
expressed MET (Appendix Table A9B). All controls also expressed MET and there 
was no significant difference between tumor and controls (p=0.40). The average 
number of ULMS cells per sample expressing MET was 85% (±9%). Expression of 
AXL was strong in 20% (n=40), weak in 58% (n=113) and absent in 22% (n=43) of 
ULMS; no controls had high expression. AXL expression increased significantly in 
ULMS versus controls (p=0.0168) and the average number of cells per ULMS sample 
positively expressing AXL was 40% (±33%).  
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Figure 17. c-KIT, MET, and AXL expression in ULMS compared to controls. 
Photographic representation of receptor tyrosine kinases c-KIT, MET, and AXL in 
ULMS indicate that c-KIT is not highly expressed in ULMS or controls. MET and AXL 
expressions are elevated in ULMS compared to controls.330 
 
Biomarker correlation to tumor status 
Several tyrosine kinase receptors and one ligand were differentially expressed 
depending on tumor status (Table 15B) Expression of EGFR and IGF-1R was 
significantly increased in advanced versus primary lesions (p=0.0009 and p=0.0349) 
while PDGF-α expression decreased in metastatic versus local disease (p=0.0238) 
and AXL expression was significantly elevated in advanced compared with primary 
ULMS (p=0.048).  
 
Outcome analysis 
RTK receptor and ligand intensities were correlated with patient outcome to identify 
molecular prognosticators and potential therapeutic targets. Only intensity expression 
of PDGF-β correlated to recurrence-free survival (p=0.0193 [HR=2.12, 95% CI: 1.13-
3.99]; Table 16A). PDGF-β intensity and distribution expressions also correlated to 
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metastasis-free survival (p=0.0439 [HR=0.30, 95% CI: 0.09-0.97] and p=0.0215 
[HR=0.98, 95% CI: 0.97-1.00], respectively). c-KIT intensity expression was the only 
mTOR pathway component identified to correlated to enhanced disease specific 
survival (p=0.0284 [HR=5.28, 95% CI: 1.19-23.35]), however, few c-KIT positive 
ULMS were identified and this correlation likely does not reflect true correlation. Of 
note, PDGFR-β and PDGF-β distribution expressions correlated with DSS (p=0.0394 
[HR=1.02, 95% CI: 1.00-1.04] and p=0.0284 [HR=5.28, 95% CI: 1.19-23.35], 
respectively; Appendix Table A10). 
 
Although enhanced activation of several RTKs we observed (including IGF-1R, 
PDGFR-β, and AXL) might contribute to ULMS mTOR pathway activation, they do not 
appear to be promising prognosticators. No single receptor is likely to be the solo or 
even primary contributor; however, hyperactivation of several receptors in concert 
may underline the observed elevated activity of the mTOR pathway. It is logical to 
focus therapeutic efforts on downstream loci where RTK signals converge in the 
mTOR pathway, given that no single receptor is the likely cause of pathway activation.  
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Figure 18. Heat map representation of mTOR activation in biomarkers. Heat map 
representation of mTOR activation in associated biomarker expression levels in each 
of the TMA spots for which all markers were available for A) mTOR pathway 
componentry. The mTOR pathway is highly active in ULMS compared to controls. Of 
note, PTEN levels were entered as negative (“lost”) in blue and as positive 
(“expressed”) in yellow; PTEN loss was not commonly observed in ULMS. B) 
differential expression of tyrosine kinase receptors/ligands in ULMS compared with 
controls.249,330  
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Table 14. Biomarker correlation to disease status for mTOR pathway 
componentry and tyrosine kinase receptors/ligands. 
 
  
 Control  Tumor   
 Smooth Muscle  Leiomyoma  ULMS   
Marker 
Total 
n= 
Moderate-
Strong 
Intensity 
(%)   
Total 
n= 
Moderate - 
Strong 
Intensity 
(%)   
Total 
n= 
Moderate 
- Strong 
Intensity 
(%)    
p  
A. mTor pathway componentry               
pS6RP 25 7 (28%)  8 2 (25%)  200 145 (73%) <0.0001 
cyt. 
p4EBP1 23 10 (43%)  7 2 (29%)  193 150 (78%) <0.0001 
nuc. 
p4EBP1 24 5 (22%)  7 3 (43%)  192 117 (61%) 0.0001 
pAKT 25 0 (0%)  7 0 (0%)  187 110 (59%) <0.0001 
PTEN 
Loss@ 25 2 (8%)   8 1 (13%)   203 15 (7%)   0.3670 
B. Tyrosine kinase receptors/ligands              
EGFR 25 3 (12%)  8 2 (25%)  199 72 (36%)  0.2239 
IGF-1R 25 0 (0%)  6 0 (0%)  199 31 (16%)  0.0003 
PDGFR-α 25 0 (0%)  8 0 (0%)  201 83 (41%)  <0.0001 
PDGFR-β 25 0 (0%)  8 0 (0%)  196 43 (22%)  <0.0001 
PDGF-α 25 10 (40%)  8 0 (0%)  203 17 (8%)  <0.0001 
PDGF-β 25 2 (8%)  8 0 (0%)  203 56 (28%)  0.0009 
c-KIT 25 0 (0%)  8 0 (0%)  207 5 (2%)  0.46* 
MET 25 14 (56%)  8 6 (79%)  204 131 (64%) 0.4013 
AXL 25 0 (0%)   8 0 (0%)   196 40 (20%)   0.0168 
Total n= indicates the number of evaluable samples in each dataset 
@ is defined as having a score of 0 on a scale of 0-3 (defined in *) and indicates complete 
loss of protein expression 
*p values were calculated by Fisher’s exact test  
All p-values compared control (myometrium, GI smooth muscle, leiomyoma) versus ULMS; 
bolded values indicate statistical significance (p<0.05) 
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Table 15. Biomarker correlation to tumor status for mTOR pathway 
componentry and tyrosine kinase receptors/ligands. 
 
    
 Primary ULMS  Recurrent ULMS  Metastatic ULMS   
Marker 
Total 
n= 
Moderate-
Strong 
Intensity 
(%)   
Total 
n= 
Moderate - 
Strong 
Intensity 
(%)   
Total 
n= 
Moderate - 
Strong 
Intensity 
(%)   
P   
A. mTor pathway componentry               
pS6RP 18 6 (33%)  61 47 (76%)  120 92 (77%)  0.0259b 
cyt. 
p4EBP1 16 9 (56%)  59 50 (85%)  118 91 (77%)  0.1762b 
nuc. 
p4EBP1 16 4 (25%)  59 39 (66%)  118 74 (63%)  0.3032b 
pAKT 16 9 (56%)  58 35 (60%)  113 66 (58%)  0.3878b 
PTEN 
Loss@ 18 1 (6%)   64 4 (6%)   121 10 (8%)   0.91a* 
B. Tyrosine kinase receptors/ligands      
EGFR 17 2 (12%)  65 23 (36%)  117 47 (40%)  0.0009b 
IGF-1R 18 2 (11%)  64 14 (22%)  117 15 (13%)  0.0349b 
PDGFR-α 18 2 (11%)  63 57 (90%)  120 24 (20%)  0.1165b 
PDGFR-β 18 2 (11%)  65 8 (12%)  120 7 (6%)  0.0926a 
PDGF-α 18 3 (17%)  61 10 (16%)  117 30 (26%)  0.0238a 
PDGF-β 18 4 (22%)  64 19 (30%)  121 33 (27%)  0.4659b 
c-KIT 18 0 (0%)  65 3 (5%)  124 2 (2%)  0.46b* 
MET 17 11 (65%)  64 46 (72%)  123 74 (60%)  0.1238a 
AXL 18 2 (11%)  61 8 (13%)  117 30 (26%)  0.048a 
Total n= indicates the number of evaluable samples in each dataset 
@ is defined as having a score of 0 on a scale of 0-3  and indicates complete loss of protein 
expression 
a compares local (primary and recurrent) to metastatic lesions 
b compares primary to advanced (recurrent and metastatic) lesions 
*p values were calculated by chi-squared test, except where 50% of the cells had expected 
counts less than 5%, in which case Fisher's exact test was applied  
All p-values compared control (myometrium, GI smooth muscle, leiomyoma) versus ULMS; 
bolded values indicate statistical significance (p<0.05) 
!!!!
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Table 16. Biomarker correlation to outcome. 
A. Biomarker intensity expression univariate correlation to recurrence-free 
(RFS) and metastasis-free (MFS) survival 
  
RFS (univariable) MFS (univariable) 
Marker P 
Hazard Ratio 
(95% CI) P 
Hazard Ratio     
(95% CI) 
pS6RP 0.1871 - 0.1381 - 
cyt. p4EBP1 0.0733 - 0.1122 - 
nuc. p4EBP1 0.0567 - 0.8343 - 
pAKT 0.5227 - 0.5592 - 
PTEN  0.9087    0.9308    
EGFR  0.5005 - 0.8481 - 
IGF-1R  0.0791 - 0.7211 - 
PDGFR-α 0.1153 - 0.4692 - 
PDGF-α 0.7117 - 0.1136 - 
PDGFR-β 0.1124 - 0.5837 - 
PDGF-β 0.0193 2.12 (1.13-3.99) 0.0439 0.30 (0.09-0.97) 
c-KIT 0.9570     0.1340   
MET 0.6183 - 0.1913 - 
AXL 0.1220 - 0.8066 - 
B. Biomarker intensity expression univariate and multivariate correlation 
to disease specific survival  
 DDS (univariable)  
Marker P Hazard Ratio (95% CI)   
pS6RP 0.1759 -   
cyt. p4EBP1 0.0856 -   
nuc. p4EBP1 0.0750 -   
pAKT 0.9899 -   
PTEN  0.7488     
EGFR  0.6093 -   
IGF-1R  0.6697 -   
PDGFR-α 0.0786 -   
PDGF-α 0.1671 -   
PDGFR-β 0.1889 -   
PDGF-β 0.4958 -   
c-KIT 0.0284  5.28 (1.19-23.35)    
MET 0.1237 -   
AXL 0.8277 -   
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Chapter 5. Creation and Development of Critical Bioresources!
!
One of the most significant obstacles hindering sarcoma research is the remarkable 
lack of commercially available bioresources. Currently, only one uterine sarcoma and 
two leiomyosarcoma cell lines are commercially available through the American Type 
Culture Collection (ATCC); only one is thought to actually represent human uterine 
leiomyosarcoma. Due to this profound lack of bioresources, we deemed it necessary 
to create our own. Towards this goal, we worked in close collaboration with the MD 
Anderson Cancer Center Tissue Bank and Surgery Department to consent patients 
pre-operatively. Through these mechanisms, we have secured multiple human 
specimens of leiomyosarcoma for scientific research. Tissues were transported to the 
laboratory from surgery, cells were disaggregated, and primary cell strains were 
created and grown as previously described.332 To date, we have created >15 Uterine 
LMS cell strains and several additional extra-uterine LMS strains, expanding on 
available bioresources and furthering our scientific studies. Table 14 shows the novel 
ULMS and select LMS cell strains that we have created; bolded strains indentify 
strains that were used in this body of this work.!
!
Prior to experimental use, all cell strains/cell lines were characterized and confirmed 
as LMS or ULMS. First, cell growth and proliferation via MTS assay were examined 
(Figure 19). Photographs of Leio285 cells at 24, 48, 72, and 96hr demonstrate high 
proliferation rates for this cell line with a doubling rate of about 24hr (Figure 18).!
!
!
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Table 17.  Novel LMS and ULMS cell strains created by our lab at the UTMDACC 
Sarcoma Research Center from primary patient tumors. !
Name Age Race Diagnosis Tumor Site 
Leio016 71 Caucasian Uterine LMS Retroperitoneal Recurrence 
Leio096 56 Caucasian Uterine LMS Lung Metastases 
Leio196 61 Caucasian Uterine LMS Bladder Recurrence 
Leio278 58 Caucasian Uterine LMS Ureter Recurrence 
Leio285 59 Caucasian Uterine LMS Lung Metastases 
Leio2987 53 Caucasian Uterine LMS Pelvic Recurrence 
Leio303 46 Caucasian Uterine LMS Mesentery Recurrence 
Leio360 46 Caucasian Uterine LMS Pelvic Recurrence 
Leio485 54 Caucasian Uterine LMS Pelvic Recurrence 
Leio505 60 Caucasian Uterine LMS Lung Metastases 
Leio594 61 
African 
American 
Uterine LMS Retroperitoneal Recurrence 
Leio661 71 Caucasian Uterine LMS Pelvic Recurrence 
Leio780 48 Caucasian Uterine LMS Lung Metastases 
Leio938 77 Caucasian Uterine LMS Pelvic Recurrence 
Leio012 42 
African 
American 
Retroperitoneal 
LMS 
Retroperitoneal Recurrence 
Leio987B 50 Hispanic 
Abdominal 
LMS 
Lung Metastases 
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Figure 19. Primary cell cultures were characterized for in vitro growth and 
proliferation ability. MTS proliferation assays showed doubling times of 24 to 48 h for 
LMS cell strains (Leio285, Leio505, and Leio987B) and B) microscope images of 
Leio285 cells at 24, 48, 72, and 96 h confirmed doubling times of 24-48 h. Newly 
created cell strains are comprehensively characterized for C) karyotype assessment 
via GIEMSA (the complex karyotype of Leio177 is shown), D) clonogenic ability 
(Leio285 shown), and E) WB expression of vimentin and desmin to validate strains as 
LMS/ULMS. F) Short tandem repeats (STR) are acquired for all ULMS cell strains and 
cells are tested against the original tumor every 5-10 passages to ensure quality.!
!
!
!
!
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Next, the karyotypes of each cell strain/line were evaluated using GIEMSA and clone-
forming ability was evaluated via clonogenic assays (Figure 18, Leio177). As an 
example, GIEMSA results using Leio177 are presented and show a complex 
karyotype; the figure also confirms that Leio285 has clone-forming ability. Additionally, 
immunoblotting was performed to ensure that all cells express vimentin, a marker of 
all mesenchymal cells, and desmin, a marker of muscle differentiation. Cells that did 
not express both markers could not be confirmed as LMS/ULMS and were not used in 
further studies. For example, Figure 7 showed vimentin and desmin WB in several cell 
strains. According to our standards, Leio285, Leio505, and Leio987B were considered 
viable LMS/ULMS cell strains while Leio097 and Leio465 were not confirmed and 
were not used further. Sequencing for p53 was also performed on select cell 
strains/cell lines (data not shown) to examine gene mutations in exons 5-9 of the 
gene. No mutations were found within this region for Leio285 or Mes-Sa, so these 
cells were deemed “wild type”. Notably, two mutations were found at codons 245 and 
247 of exon 7 in SKLMS1. These alterations were in accordance with known SKLMS1 
mutations.333 Short tandem repeat (STR) fingerprinting was used to validate cell strain 
integrity. Cell strain profiles were matched to the DNA profile of the solid tumor from 
which they were created for validation purposes (Figure 18, Leio987B). Fingerprints 
for commercially available cell lines were verified against known fingerprints. Of note, 
many primary ULMS cell strains start to show reduced proliferation and lose several 
of their morphological features, including spindle shape, at passages of 30 and 
higher. For this reason, all experiments were performed with cells in passages 5-15 to 
ensure that results are accurate and consistent.!
!
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To date, we have not successfully developed novel xenograft tumor mouse models for 
many of our LMS/ULMS cell strains. While we have experimented with several ULMS 
xenografts using our primary cell strains, none yielded reproducible in vivo growth. 
However, we have developed successful xenograft models of commercially available 
cells SKLMS1 and Mes-Sa for therapeutic experiments. The SKLMS1 xenograft 
model employed in this dissertation is further discussed in the materials and methods 
section. In total, we have created several xenograft-based mouse models for in vivo 
studies in ULMS. Cell strain/line and xenograft studies remain ongoing and 
development of additional resources is forthcoming.!
!!
 
 !!!!!!!!!!!!!!!!!!!!!
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Chapter 6: Targeting ULMS mTOR deregulation in vitro!
Utilizing our ULMS focused TMA, we demonstrated that the mTOR pathway was 
hyperactivated in these malignancies, correlating with disease status, tumor status, 
and patient outcome. From the following studies, we hypothesized that the mTOR 
pathway might be a viable therapeutic target in ULMS and designed a series of in 
vitro and murine-based experiments. !
!
The mTOR pathway is overexpressed in ULMS cells 
First, we evaluated if cultured human ULMS cells recapitulated clinical findings by 
overexpressing activated mTOR downstream effectors (pS6K and p4EBP1). Cells 
tested included SKLMS1, Mes-Sa, and four cell strains recently isolated by our 
laboratory from primary patient cultures. SKLMS1 is well-characterized LMS cell line 
of gynecological origin (ATCC), the ULMS cell strains were isolated and characterized 
as described above in materials and methods. Mes-Sa, a commercially available 
(ATCC), poorly differentiated uterine sarcoma cell line was also included; is unclear 
whether this cell line represents a ULMS or an alternative uterine sarcoma subtype, 
but it was included as a relevant positive control (we previously demonstrated that 
Mes-Sa had loss of PTEN expression.187 Lastly, normal smooth muscle cell primary 
cultures (NSMC) were used as controls (Figure 20). Western blots (WBs) showed 
increased pS6K and p4EBP1 expression in tumor cells versus control (Figure 20); 
increased levels of pAKT were observed in tumor cells (Figure 20). Excluding Mes-
Sa, none of the ULMS cell strains exhibited loss of PTEN expression (Figure 20). 
Together, these data are in concordance with data obtained 
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Figure 20. mTOR pathway is commonly activated in ULMS cells. Western blot 
analyses demonstrate increased phosphorylation of the mTOR downstream effectors 
S6K and 4EBP1, and the mTor upstream regulator, AKT, in protein extracts of human 
ULMS cell strains/lines as compared to expression observed in normal smooth 
muscle cells (NSMC). Only Mes-Sa cells exhibited loss of PTEN expression.249  
 
from our TMA and confirm that (similar to the observations in human specimens) 
activation of the mTOR axis is observed in ULMS cells growing in culture, rendering 
this a relevant model to test the effects of mTOR blockade.  
 
mTOR blockade inhibits ULMS growth in vitro and in vivo 
Rapamycin was utilized to examine effects mTORC1 inhibition on ULMS cell growth. 
Tumor cells were treated with incremental drug doses for 4h; decreased 
phosphorylation of S6K and 4EBP1 were detected in all ULMS cells; even at doses as 
low as 0.1nM (Figure 21). Functionally, a dose-dependent reduction in tumor cell 
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growth in response to rapamycin (0.01-50nM/96h) was observed in all cell 
lines/strains examined with GI50 levels of ~ 1nM (Figure 22A). Notably, NSMC were 
not significantly affected by rapamycin treatment.  
 
 
Figure 21. The mTOR pathway is inhibited with rapamycin. Rapamycin (0.1-
50nM/4h) blocks the activation of the mTOR downstream targets S6K and 4EBP1 
(WB analyses).249  
 
Additionally, mTORC1 blockade inhibited colony formation capacities of ULMS cells; 
rapamycin pre-treatment (24h) significantly reduced the number of large colonies by 
40-50% (p=0.0007, 0.0005, and 0.03 for SKLMS1, Leio285, and Mes-Sa, 
respectively); when administered continuously, rapamycin almost abrogated colony 
formation (p<0.0001, <0.0001 and =0.002 for SKLMS1, Leio285, and Mes-Sa, 
respectively; Figure 22B). Rapamycin has been suggested to promote G1 arrest and 
play a cytostatic rather than cytotoxic role in tumor growth inhibition 
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 Figure 22. mTOR blockade using rapamycin inhibits cell growth. A) MTS  
assays demonstrating a rapamycin-induced (96h) dose-dependent decrease in ULMS 
cell growth. In addition, B) rapamycin (both as pre- and continuous treatments) 
inhibits the colony formation capacity of ULMS cells. [Graphs represent the average of 
at least 2 repeated experiments ± SD; * denotes statistically significant 
effects(p<0.05)].249 
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Figure 23. mTOR blockade using rapamycin induces G1 cell cycle arrest.  A) 
Rapamycin treatment (1nM/48h) results in a G1 cell cycle arrest in ULMS cells. B) WB 
analyses demonstrate decrease in cyclin D1 and increased p21 expression in treated 
cells, independent of p53 mutational status. Increased p21 protein expression was 
found in cells harboring wild-type p53. C) No significant increase in apoptosis was 
noted by PI/Annexin V FACS analysis following rapamycin treatment (1nM/96h). 
[Graphs represent the average of at least two repeated experiments ± SD; * denotes 
statistically significant effects (p<0.05)].249 
 
Therefore, the effects of rapamycin on cell cycle progression and apoptosis were 
evaluated. Rapamycin treatment (1nM/48h) induced substantial G1 cell cycle arrest 
(p=0.02, 0.01, and 0.03 in SKLMS1, Leio285, and Mes-Sa, respectively; Figure 23A). 
This effect could partly be secondary to the observed decrease in cyclin D1 
expression and increased p21 expression in treated cells (Figure 23B). Interestingly, 
we found that G1 cell cycle arrest occurred independently of p53 mutational status.  In 
both wild-type p53 cell strains/lines (Leio285 and Mes-Sa), an increase in p53 protein 
expression was observed; increase was also found in p53 mutated cells (SKLMS1). In 
all cells, increased levels of p21 were observed independent of enhanced p53 
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expression or mutational status (Figure 23B). Notably, increased sub-G1 fractions 
were not noted in response to rapamycin as per PI staining FACS analysis (Figure 
23A). Furthermore, Annexin-V/PI staining FACS analysis, conducted after 96h 
rapamycin treatment, failed to demonstrate significant apoptosis (Figure 23C).   
 
Based on the above findings, we next sought to evaluate whether rapamycin effects 
could also be observed in vivo. Although ULMS primary cultures can be utilized for 
experimental studies in vitro, none of the cell strains available to us consistently grow 
in vivo. In contrast, SKLMS1 cells reproducibly grow as xenografts when injected into 
immunocompromised mice; therefore, this experimental model was selected for 
therapeutic experiments. Rapamycin (or vehicle control) treatment was initiated after 
tumor establishment (~4-5mm in largest dimension). Mice in both groups were 
followed for tumor size and toxicity; treatment was terminated when tumors in the 
control group reached an average of 1.5cm in largest dimension. Treatment with 
rapamycin resulted in tumor growth delay compared to vehicle-treated tumors (Figure 
24A). Average tumor volumes recorded at termination of the study were control 
group: 1361mm3±354 vs. rapamycin group: 895mm3±449 (p=0.0519; Figure 24A). 
While trending towards statistical significance, these data revealed that rapamycin 
exerted only marginal, cytostatic effects on ULMS growth. Similarly, a decrease in 
tumor weight was noted (control = 1.97g±1.11 vs. 1.1g±0.72) although it did not reach 
statistical significance (p=0.11; Figure 24B). To confirm that rapamycin inhibits 
mTORC1 activity in vivo, formalin-fixed, paraffin-embedded tumor sections from mice 
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Figure 24. Rapamycin treatment delays the growth of ULMS xenografts. A) 
Treatment with rapamycin resulted in SKLMS1 xenograft tumor growth delay 
compared to control vehicle-treated tumors. Rapamycin treatment induced a decrease 
trending towards statistical significance (p=0.0519) in tumor volume at termination of 
the study. B) A decrease in tumor weight was also noted, although it did not reach 
statistical significance (p=0.11): C) Immunohistochemical (IHC) staining confirmed 
decreased p4EBP1 and pS6RP expression in rapamycin treated tumors. Rapamycin 
treated tumors exhibited decreased proliferation (measured by Ki67), increased 
apoptosis (measured via TUNEL), and decreased (although not statistically 
significant) CD31 positivity (original images were captured at 400x magnification). [* 
denotes statistically significant effects (p<0.05)].249  
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of both study arms were immunohistochemically evaluated. Decreased p4EBP1 and 
pS6RP expression was observed in rapamycin-treated tumor samples (Figure 24C). 
Of note, a significant (p=0.001) decrease in the number of Ki67 expressing tumor 
cells was observed in rapamycin related samples (Figure 24C). A relatively small but 
significant increase in TUNEL expression was noted with rapamycin treatment 
(p=0.005; Figure 24C). Finally, a reduction in CD31 positive blood vessels was found 
in rapamycin treated tumors (9.5±0.99) compared to controls (12.4±4.5), although this 
reduction did not reach statistical significance (p=0.2). Taken together, observations 
made in this preclinical model recapitulate effects noted in human clinical studies, 
supporting identification of additional ULMS molecular aberrations therapeutically 
targetable in combination with mTOR.  
 
Rapamycin in combination with doxorubicin offers little therapeutic advantage. 
Patients with recurrent or metastatic ULMS often have tumors that cannot be wholly 
resected surgically, necessitating chemotherapy as first-line treatment. We examined 
if the addition of a commonly used ULMS chemotherapeutic agent (doxorubicin) to 
rapamycin treatment was therapeutically beneficial. Uterine sarcoma cells (Mes-Sa) 
and a doxorubicin-resistant Mes-Sa strain (Mes- Sa D5X) were employed for these 
studies. Mes-Sa cells responded moderately to low dose doxorubicin with a GI50 of 
about 0.5uM whereas growth of doxorubicin resistant Mes-Sa D5X cells was not 
significantly affected by chemotherapy (Figure 25A). Rapamycin (0.5nM) and 
doxorubicin (150nM) in low-dose combination (48h) significantly reduced cell growth 
(Figure 25B). Additionally, an MTS assay  (48h) was performed to examine anti-
proliferative effects; in combination, rapamycin and doxorubicin were not synergistic; 
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Figure 25. Rapamycin and doxorubicin combined treatment yielded additive 
anti-ULMS effects. A) MTS proliferation assay was employed to determine growth 
inhibition effects of rapamycin in sensitive (Mes-Sa) and resistant (Mes-Sa D5X). B) 
Combination therapy with low dose rapamycin and doxorubicin does not yield 
significantly beneficial results over single agent doxorubicin and C) rapamycin and 
doxorubicin do work synergistically in ULMS. [* denotes statistical significance 
(p<0.05, compared to control)]. 
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effects were likely additive (Figure 25C). Taken together, these data do not support 
the use of rapamycin in combination with conventional chemotherapies in the 
treatment of ULMS; molecular-based therapies may present with improved response 
when combined with rapamycin as anti-ULMS therapies and such therapies should 
therefore be evaluated.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Chapter 7: Aurora A kinase deregulation in ULMS and inhibition via MLN8237 
 
In the current era of molecularly targeted therapies, personalized agents hold the 
promise of increased efficacy and decreased toxicity compared to conventional 
chemotherapy. To identify novel, molecularly based targets for ULMS therapy, we 
entered into collaboration with Dr. Matthew L. Anderson, an investigator from Baylor 
College of Medicine. Together, we validated Aurora A kinase as a viable therapeutic 
target and carried out several studies that examined the effects of Aurk A inhibition in 
ULMS. 
 
Aurk A is upregulated/overexpressed in human ULMS tissues and cells 
In collaboration, an Illumina Gene Chip Array of 12 ULMS specimens (FIGO stage 1) 
and 10 healthy myometrium samples (Figure 26A) was used to compile genome-wide 
transcriptional profiles of more than 75 ULMS patients to compare gene expression of 
nearly 50,000 genes.250 From this dataset, we identified several differentially 
expressed genes in human ULMS versus healthy myometrium and leiomyoma. Of the 
overexpressed genes, more than half were known to be integrally involved with 
centrosome and spindle assembly, and functioned during mitosis. Notably, Aurora A 
and B kinases were identified as upregulated by 7.9-fold (p<10-11) and 3.5-fold (p<10-
6), respectively. Using semi-quantitative PCR (Figure 26B) and western blotting 
(Figure 26C), we validated that Aurk A is overexpressed in human ULMS tissues.250 
Next, we confirmed via western blotting that Aurk A kinase is overexpressed in a large 
panel of ULMS 
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Figure 26. Aurk A kinase is upregulated and overexpressed in human ULMS. A) 
A gene array conducted with Dr. Matthew Anderson (Baylor College of Medicine) 
reveals several genes differentially expressed in healthy myometrium, leiomyoma, 
and FIGO stage I ULMS. Genes identified included Aurk A and Aurk B kinases. B) 
Aurk A mRNA was upregulated in human ULMS by about 15-fold and C) Aurk A was 
overexpressed in human ULMS compared with leiomyoma controls. Taken together, 
these data advocate a role for Aurk A kinase in ULMS.250  
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Figure 27. Aurk A kinase is highly expressed in human ULMS and knock down 
induces apoptosis. A) WB analysis demonstrated increased Aurk A protein 
expression in a panel of ULMS cell strains/lines compared to normal smooth muscle 
cells (NSMC). B) Aurk A was readily knocked down using an SiRNA approach and C) 
knockdown induced significant apoptosis compared with mock and non-targeting 
controls.250  
 
cell strains/lines (Figure 27A) as compared to a smooth muscle control (NSMC). To 
examine if Aurk A may be a viable target, an SiRNA approach was used (knock down 
confirmed in Figure 27B). Knock down induced significant apoptosis (32% compared 
with 9.1% and 8.9% for mock- and non-targeting SiRNA-treated cells, respectively 
(Figure 27C). Taken together with preliminary conclusions from the gene array, our 
results suggest that Aurk A may be a relevant target to pair with mTOR inhibition for 
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improved ULMS therapy. and suggest that it may be a viable target for anti-ULMS 
therapies.  
 
The Aurora A kinase inhibitor, MLN8237, inhibits ULMS cell growth and induces 
G2/M cell cycle arrest and apoptosis 
Next, we aimed to evaluate the effects of Aurk A inhibition in ULMS to validate it as a 
promising co-target for combination therapy with rapamycin. Towards this aim, we 
acquired a novel, investigational, orally bioavailable, and selective Aurk-A inhibitor, 
MLN8237 (Millennium Pharmaceuticals), and first examined its anti-tumor effects in 
our in vitro ULMS model. MTS assays demonstrated marked MLN8237 dose-
dependent (0-100nM/96h) ULMS cell growth inhibition; estimated GI50 levels of ~ 
75nM were observed in several cell lines evaluated (Figure 28A). Notably, a large 
number of spherical, floating cells were observed with MLN8237 treatment, 
suggesting that the drug may induce apoptosis. Furthermore, MLN8237 abrogated 
ULMS colony formation capacity: 24h pre-treatment with MLN8237 resulted in 
markedly reduced numbers of colonies (p=0.003, 0.01, and 0.0004 for SKLMS1, 
Leio285, and Mes-Sa, respectively); under continuous treatment almost no colonies 
were observed (p=0.0002, =0.0002, and <0.0001 for SKLM1, Leio285, and Mes-Sa, 
respectively; Figure 28B). Next, the effects of MLN8237 on cell cycle progression 
were evaluated. MLN8237 treatment (75nM/48h) resulted in a marked G2/M cell cycle 
arrest (p=0.009, =0.03, and <0.0001 for SKLMS1, Leio285, and Mes-Sa, respectively; 
Figure 29A); significant increase in sub-G1 fraction was noted, indicating probable 
apoptosis (p=0.03, 0.04, and 0.04 for SKLMS1, Leio285, and Mes-Sa, respectively).  
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Figure 28. The Aurk A inhibitor, MLN8237, inhibits cell growth in ULMS.     A) 
MTS assays demonstrated marked MLN8237 dose-dependent (0-500nM/96h) ULMS 
cell growth inhibition. B) MLN8237 (both as pre- and continuous-treatment) abrogated 
the colony formation capacity of ULMS cells). [Graphs are the average of at least two 
independent studies; * denotes statistically significant effects (p<0.05)].249  
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 Figure 29.  The Aurk A inhibitor, MLN8237, induced G2/M cell cycle arrest and 
apoptosis. A) MLN8237 treatment (75nM/48h) resulted in a G2/M cell cycle arrest in 
ULMS cells. Furthermore, increased sub-G1 fraction was observed; B) an increase 
(~2-4 fold) in apoptosis was observed in MLN8237 treated cells compared to vehicle 
treated controls (Annexin-V/PI staining FACS analysis). C) WB analyses further 
demonstrated increased cleaved PARP in response to treatment. [Graphs represent 
the average of at least two repeated experiments ± SD; * denotes statistically 
significant effects (p<0.05)].249 
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To determine the impact of MLN8237 on ULMS apoptotic cell death, Annexin-V/PI 
staining FACS analyses were conducted (Figure 29B) following 96h of treatment. A 
significant increase (~2-4 fold) in apoptosis was observed in MLN8237 treated cells 
compared to vehicle treated controls (p=0.02, =0.002, and <0.0001, respectively for 
SKLMS1, Leio285, and Mes-Sa). A shorter treatment of 48h also showed substantial 
apoptotic activity (data not shown). Increased cleaved PARP was noticed after 48h of 
treatment, providing further evidence of MLN8237-induced apoptosis (Figure 29C). 
Together, these data confirm Aurk-A as a candidate anti-ULMS therapeutic target and 
demonstrate potential efficacy of MLN8237, suggesting that Aurk A and mTOR dual 
blockade in ULMS may yield improved therapeutic response over mTOR inhibition 
alone. !!!!!!!!!!!!!!!!!!!!!!!!!
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Chapter 8. Dual targeting of mTOR and Aurk A in ULMS  
 
Combining rapamycin and MLN8237 results in superior (synergistic) anti-ULMS 
effects  
 
Based on previous results, we sought to evaluate the usefulness of mTOR and Aurk A 
dual blockade in the treatment of ULMS. First, we determined ULMS growth effects of 
combined rapamycin and MLN8237. MTS assays of treated SKLMS1 cells were 
conducted to determine the combination index (CI), enabling assessment of potential 
interactions between these drugs (Figure 30A). Several scheduling regimens were 
tested: 1) simultaneous co-administration of rapamycin (increasing doses; 0-1nM) and 
MLN8237 (increasing doses; 0-100nM) for 96h; 2) 24h pre-treatment with rapamycin 
followed by co-treatment with MLN8237 for 72 hours; 3) 24h MLN8237 pre-treatment 
followed by 72hr co-treatment with rapamycin. Interestingly, while the first two 
regimens failed to demonstrate synergism between the drugs (for some doses 
antagonistic responses were even observed; CI>1.1), isobologram analyses revealed 
that growth-inhibitory effects of the drug combination were strongly synergistic when 
administered as per the third schedule (CI<0.9; Figure 30A). Similarly to our multi-
dose synergy experiment in SKLMS1, we confirmed that MLN8237 and rapamycin 
worked in synergy using two other ULMS cell lines/strains with single, low-dose 
treatments assessed via MTS assay (as per the above schedule). In doses below the 
GI50 for both rapamycin and MLN8237, reductions in cell proliferation by >50% in 
Leio285 and Mes-Sa were observed in the combination group compared to control 
(p<0.0001 for Leio285; p=0.0006 for Mes-Sa) and in either agent alone (p<0.02, 
Figure 30A). Similarly, combination therapy induced a superior inhibitory effect on 
colony formation compared to either agent alone (Figure 30B) and combination  
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Figure 30. Combined mTOR and Aurk A targeting results in superior and 
synergistic ULMS effects in vitro. A) MTS assays were conducted using increasing 
doses of both rapamycin and MLN8237, three different scheduling regimens were 
used: 1. simultaneous co-administration of rapamycin (increasing doses; 0-1nM) and 
MLN8237 (increasing doses; 0-100nM) for 96h (upper graph). 2. 24h pre-treatment 
with rapamycin followed by co-treatment with MLN8237 for 72h (middle graph) and 3. 
24h MLN8237 pre-treatment followed by 72h co-treatment with rapamycin (bottom 
graph). B) Fraction affected and isobologram analyses revealed that growth-inhibitor 
effects of the drug combination were strongly synergistic when administered per the 
third schedule (CI<0.9). C) Fraction affected and combination indices are given for all 
dosing schedules and confirm that the pre-treatment with MLN8237 schedule is 
synergistic; alternative schedules examined are not.249  
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Figure 31. Dual inhibition of mTOR and Aurk A yields superior and synergistic 
anti-ULMS effects in vitro.  A) Superior anti-growth effects are observed in Leio285 
and Mes-Sa cells in response to dual mTOR/Aurk A inhibition (administered in low 
doses as per the aforementioned schedule) compared to either agent alone. B) 
Furthermore, combination therapy induces a superior inhibitory effect on colony 
formation compared to either agent alone and C) the superior effects of combination 
therapy are not due to an increase in apoptosis compared to levels induced by 
MLN8237 alone. [Graphs represent an average of at least three repeated experiments 
±SD; * denotes statistically significant effects (p<0.05)].249  
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therapy did not increase levels of apoptosis compared to MLN8237 treatment alone 
(36.7% and 36.0%, respectively; Figure 31C). 
 
Dual blockade of mTOR and Aurk A kinase in ULMS is effective in vivo.  
Lastly, to determine whether the effects noted in vitro could be recapitulated in vivo, a 
four-armed therapeutic study was conducted comparing the effect of combination 
treatment to each drug alone or vehicle control. Of note, in accord with in vitro 
findings, mice were treated with MLN8237 and rapamycin sequentially. No major side 
effects or discomforts were noted; average mouse weights at the termination of the 
study were: control – 24.9g±0.7, rapamycin – 24.3g±2, MLN8237 – 23.6g±2.2, and 
combination – 22.9g±2.3. MLN8237 as a single agent inhibited SKLMS1 xenograft 
growth compared to control (average tumor volumes at study termination were 
MLN8237 - 765mm3±429 and control - 1361mm3±354, p=0.012; Figure 32A). Most 
importantly, combination therapy resulted in significant growth abrogation compared 
to rapamycin, MLN8237, or control alone; average of combination treatment tumor 
volumes at study termination was 227mm3±185 (p=0.0016, =0.0047, and <0.0001, 
respectively; (Figure 32B). Average tumor weights recorded at termination of the 
study were control group: 2.0g±1.1; rapamycin group: 1.1g±0.72; MLN8237 group: 
1.2g±0.99; and combination group: 0.15g±0.13 (Figure 32C). In summary, dual 
inhibition of mTOR and Aurk A kinase in ULMS using rapamycin and MLN8237 
resulted in superior and synergist effects compared to either therapy alone. H&E 
staining confirmed spindle shaped leiomyosarcoma cells with a large number of 
mitosis present (Figure 33). Interestingly, large circular cells with high mitotic counts 
were observed in the MLN8237 and co-treated tumors. Tumors treated with MLN8237  
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Figure 32. Combined mTOR and Aurk A targeting results in superior anti-ULMS 
effects in vivo. A) The impact of combined therapy was assessed in vivo using 
SKLMS1 xenografts growing in hairless SCID mice. MLN8237 as a single agent 
significantly inhibited tumor growth as compared to control. Most importantly, 
combination therapy resulted in significant growth abrogation as compared to 
rapamycin, MLN8237, or vehicle. B) Tumors are visibly smaller in mice treated with 
combination therapy than in any other group. C) Combination treated mice exhibited 
the most significant decrease in tumor weight as compared to all other therapeutic 
arms.249  
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Figure 33. Dual mTOR and Aurk A inhibition in ULMS in vivo yielded markedly 
improved anti-ULMS effects. A) IHC analyses demonstrated decreased Ki67 
positive staining cells in all treatment groups, the most pronounced was in 
combination treatment tumors. An increase in TUNEL positive cells was noted in all 
treated tumors. Moreover, combination treated tumors exhibited the greatest 
decrease in CD31 positivity. [All graphs represent an average of at least two repeated 
experiments; * denotes statistically significant effects (p<0.05)].249  
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were more solid with a rubbery texture upon resection whereas tumors treated with 
rapamycin or vehicle had a very soft, mushy texture. IHC analysis demonstrated 
significantly decreased Ki67 positive staining cells in all treatment groups compared to 
control (p<0.002), most pronounced were combination treated tumors. An increase in 
TUNEL positive cells was noted in all treated tumors. Moreover, combination treated 
tumors exhibited the greatest decrease in CD31 positivity (Figure 33).  Based on 
these results, we hypothesized that MLN8237 may be exerting an anti-angiogenic 
effect on our tumors. To examine if MLN8237 induced apoptosis of blood vessel cells, 
co-immunofluorescence studies were conducted on resected tumors staining for 
TUNEL and CD-31. No co-localization was observed (data not shown). Taken 
together, these data suggest that mTOR blockade in combination with Aurora A 
kinase inhibition results in significant anti-ULMS effects in vitro and in vivo, a finding of 
potential clinical utility.  
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Chapter 10: Discussion 
Clinical and translational relevance 
ULMS, though relatively uncommon, is a devastating disease accounting for more 
than 25% of uterine cancer-related deaths. More than 50-80% of ULMS patients will 
face recurrent disease and only 8-28% of women with advanced disease will survive 
five years. Caregivers, patients, and their families are confronted with a comparative 
lack of robust prognostic markers or efficacious therapeutic strategies. Significant 
improvement in ULMS treatment mandates enhanced knowledge of the molecular 
forces driving ULMS, an objective hampered by the global lack of vital bioresources 
such as clinical databases, human tissue repositories, cell lines, and animal models. 
This body of work seeks to bridge this large research gap by utilizing the remarkable 
bioresources available at The University of Texas MD Anderson Cancer Center.  
 
Our work represents one of the largest cohort (>100 patients) and arguably, the most 
comprehensive molecular expression studies in ULMS to date. Many markers that we 
examined were differentially express in ULMS compared to controls and could be 
used as potential biomarkers and most importantly, therapeutic targets. We observed 
pronounced loss of both smooth muscle and gynecological differentiation markers as 
well as deregulation of many molecules important in cancer such as Bcl-2, VEGF, and 
several tumor suppressors/oncoproteins. Further, our observations on expression 
profiles of several less recognized molecules such as survivin, AXL, and nuclear and 
membranous β-catenin, suggest potentially novel roles for proteins in ULMS and 
cancer. Unfortunately, few prognostic markers were identified. 
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In addition to the clinical and translational relevance of this project, there are also 
basic and pre-clinical science applications with the potential to facilitate increased 
clinical/translationally relevant work in the future. As mentioned, ULMS research is 
significantly hampered by the lack of clinical databases, human tissue studies, cell 
lines, and animal models essential to contemporary molecular oncology research. 
Ongoing efforts to consent patients for the development of vital ULMS cell lines will 
help to generate critical bioresources for continued ULMS research. Securing such 
requisite ULMS investigative tools is a significant part of this proposal; achieving this 
goal will have positive impacts extending considerably beyond the laboratory.  
 
Towards identifying deregulated molecules for use in developing novel therapies for 
ULMS, we detected significant upregulation in both mTOR and Aurk A kinase. Using 
rapamycin (mTOR inhibitor) and MLN8237 (Aurk A inhibitor), we targeted both 
molecules in a dual blockade therapeutic approach. Our studies demonstrate that 
dual inhibition of mTOR and Aurk A kinase via rapamycin and MLN8237 yields 
remarkable synergistic anti-ULMS effects in vitro and in murine studies. In our work 
we provide pre-clinical evidence to support clinical investigation into dual inhibition of 
mTOR and Aurk A. We believe that combining these therapies in the clinic could 
prove to be of great benefit in the treatment of ULMS. Furthermore, the results of 
these studies can easily and directly translate into clinical investigations with the hope 
of positively impacting our ability to preserve the lives of patients burdened by this 
disease. 
 
!! 139!
 
In summary, enhanced knowledge of the clinical presentation, patient and tumor 
variables, therapeutic response, and outcome of a large cohorts of patients, coupled 
with the establishment of a large, clinically annotated microarray enabled the 
assessment of molecular marker expression, will help scientists and physicians 
secure new insights into drug design and targeting as well as clinical care. 
Furthermore, the development of in vitro and in vivo ULMS models markedly 
enhances the ability to investigate the efficacy of novel therapies. More importantly, 
this research may provide physicians with new clinically relevant insights that can 
translate directly to improved patient care via evidence-based treatment regimens. By 
identifying and validating molecularly based, translationally relevant therapies and 
providing a rationale to translate these into clinical trials, this study hopes to facilitate 
progress in ULMS treatment and outcomes.  
 
Tissue microarray 
A significant limitation to therapeutic advancement in ULMS is the lack of 
comprehensive research. Few published studies report data derived from cohorts of 
>100 patients; most are small reports of 5-30 patient cohorts and virtually all of these 
examine five or fewer molecular markers. To our knowledge, the tissue microarray 
study represented here comprises one of the largest and most comprehensively 
examined ULMS series to date utilizing 109 patients and nearly 250 tumor samples. 
Notably, only 21 primary ULMS samples are included in this TMA compared with 
more than 100 metastatic cases. One explanation for this discrepancy is that MD 
Anderson Cancer Center is a tertiary cancer care facility and as such, is more likely to 
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treat advanced cancers. Additionally, many women with ULMS undergo surgery at 
primary care centers for conditions presumed benign, such as a symptomatic uterine 
leiomyoma (uterine fibroids).30 These lesions are benign and can be identified in 
approximately two-thirds of women; as such, snap frozen tissues are not necessarily 
preserved or retrievable for study at a tertiary center.25,30 Regardless, the composition 
of tumors in this TMA slightly favors advanced stage ULMS; given that stage at 
diagnosis correlates directly with survival, our TMA can be a good tool to examine 
molecular deregulations contributing to tumorigenesis and identify molecular 
prognosticators, especially in aggressive and lethal late stage tumors. 
 
Smooth muscle differentiation markers 
Pathologic diagnosis of ULMS, especially abdominal/pelvic recurrences and distant 
metastases, is sometimes confounded by variability in tumor cell morphology and 
growth patterns. Loss of smooth muscle and gynecological-specific markers in 
advanced or dedifferentiated tumors can also be deceiving, rendering definitive 
diagnosis difficult. Potential loss of differentiation markers in ULMS could contribute 
significantly to difficulty with diagnosis, and awareness of the frequency of loss of 
differentiation markers in ULMS could aid pathologists in the diagnosis of more 
complicated ULMS cases. We examined the ULMS samples in our TMA for evidence 
of smooth muscle marker loss and found loss of at least one smooth muscle marker in 
more than one-third of our ULMS; only 2% of ULMS tissues lost all of the four smooth 
muscle markers examined. Loss of each of the smooth muscle markers was 
significant in tumor versus controls and correlated to decrease recurrence-free 
survival. In general, tumors with aggressive histologies were more likely to lose 
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muscle markers, stressing the importance of additional diagnostic tools for accurate 
diagnosis.  
 
Gynecological differentiation markers 
In addition to loss of smooth muscle differentiation markers, ULMS exhibited marked 
loss of gynecological markers WT-1, estrogen receptor, and progesterone receptor. 
ULMS arise from the uterine smooth muscle layer and are thus a gynecological 
malignancy. Coosemans et al. reported that many uterine sarcomas express WT-1 
and found in a 38 tissue series that 76% of ULMS had WT-1 expression. Our results 
in a much larger cohort of ULMS suggest that WT-1 is not as frequently expressed 
and is only found in about 55% of ULMS. Uterine tissues highly express many 
hormone receptors, underscoring the possibility that ULMS could be hormonally 
regulated and therefore, targeted via hormone-based therapies.334,335 Indeed, several 
groups have studied hormone receptor expression in ULMS and leiomyoma. Leitao et 
al. reported marked decrease in hormone receptors in ULMS compared to 
leiomyoma; estrogen receptor expression was reduced from 78% in leiomyoma to 
only 40% in leiomyosarcoma. Similarly, progesterone receptor levels were reduced 
from 88% in leiomyoma to 38% in leiomyosarcoma; both findings were statistically 
significant. Progesterone receptor expression also predicted lower risk of recurrence 
in ULMS.335 Several studies, including ours, confirm these results in LMS and 
ULMS.60,334,336,337 In our studies, estrogen receptor was significantly decreased from 
100% in healthy myometrium to 75% in leiomyoma. A further decrease was seen in 
ULMS, where estrogen receptor was reduced more than two-fold from 100% 
myometrium to only 45% in ULMS. Similarly, expression of progesterone receptor 
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decreased by about 30% in leiomyoma and by about 70% in ULMS versus 
myometrium.  
 
The loss of hormone receptors such as PR and ER may have significant biological 
effects and likely contributes to tumorigenesis. For example, a breast cancer study 
found that loss of PR correlated to overexpression of HER2, a kinase receptor that 
activates cell growth signaling and can function in tumorigenesis.338 Similarly, loss of 
ER can have profound biological effects, such as epigenetic silencing, on downstream 
targets, including PR, cathepsin D, cyclin D1, and c-myc and in breast cancer, loss of 
ER is associated with malignant progression.339-341 Notably, a study in breast cancer 
concluded that tumors originally ER negative will recur as ER negative tumors, but 
that tumors originally ER positive can loose ER expression; loss of ER significantly 
predicted poor response to further endocrine-based therapy, making the tumors 
harder to treat and therefore, more deadly.342 
 
In general, few correlations have been identified between estrogen/progesterone 
receptor expression and survival in ULMS. In one study, neither receptor was 
associated with risk of recurrence334 and in another, the expression of progesterone, 
but not estrogen, suggested a risk of recurrence.335 A third study suggested that 
elevated estrogen and progesterone receptor expressions positively impacted 
survival.343 Our findings indicate that estrogen receptor, but not progesterone 
correlated with longer recurrence-free survival, but that neither receptor was 
predictive of better disease-specific survival. The implications of these findings may 
have implications in the management of ULMS patients.  
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Most women with ULMS undergo dual hysterectomy/oophorectomy and may 
therefore be candidates for hormone-based therapy (e.g. estrogen replacement). 
Several studies have shown that hormone replacement therapy, especially estrogen-
based therapies, can fuel tumor development and re-growth in breast cancer.344 Our 
examination of estrogen and progesterone receptor expression in ULMS concludes 
that expression of either receptor is markedly reduced in ULMS compared with 
leiomyoma or myometrium, suggesting that hormone therapy may not be a viable 
option in ULMS. These results are in agreement with several independent 
studies.334,335 Even if the clinical benefit of hormone replacement therapy were 
substantial in ULMS patients, the risk: benefit ratio must be carefully considered. 
Taken together, these findings suggest that ULMS is not likely driven appreciably 
driven by estrogen or progesterone. Interestingly, drugs targeting hormone receptors 
(e.g. tamoxifen and medroxyprogesterone acetate) slightly increase the likelihood of 
developing uterine sarcoma and ULMS.344,345 The use of hormone replacement 
therapy following hysterectomy/oophorectomy in women with ULMS remains 
controversial; until further evidence provides definitive conclusions, it is prudent to err 
on the side of caution when using hormone replacement therapies. 
 
Cancer-related biomarkers 
In order to understand the traditional cancer biology governing tumorigenesis in 
ULMS, expression of several proteins identified as deregulated in cancer were 
examined. Therapeutic exploitation of molecular factors underlying tumorigenesis 
(e.g., invasion-facilitating matrix metalloproteinases in highly metastatic or VEGF in 
!! 144!
highly vascular tumors) has had mixed therapeutic results.346-349 A better 
understanding of the basic cancer biology in ULMS will further development of 
therapeutic interventions.  
 
Proliferation 
Ki67 is a nuclear protein found throughout the cell cycle except in G0 that likely 
functions in ribosomal RNA transcription and is a marker of cellular proliferation. The 
precise function of Ki67 in the cell cycle remains unclear.350 Several studies in a 
variety of cancers have shown high Ki67 expression correlated with aggressive tumor 
phenotypes and less favorable outcomes.351-353 In rapidly proliferating ULMS cells 
compared to slower growing, regulated normal tissues, and logic dictates that Ki67 
would be highly expressed. Several studies support this logic, including our 
own.337,354-356  
 
Cyclin D1, a cyclin family protein that regulates cell cycle transition from G1 to S 
phases, has previously been examined as a marker of proliferation.339,357,358 Cyclin D1 
serves as a co-factor for many transcriptional factors; it binds CDK4/6 to activate the 
complex that phosphorylates the retinoblastoma (Rb) tumor suppressor protein. Rb 
hyperphosphorylation triggers the release of Rb-sequestered E2F and leads to 
transcription of genes required for transition into S phase; cyclin D1 also functions as 
a transcriptional cofactor.359 Overexpression of cyclin D1 has been identified in 
several human tumors and Sherr et al. hypothesize that cyclin D1 overexpression 
promotes cell proliferation and differentiation via by facilitating a quicker G1/S 
transition.360 Our studies and the studies of others agree that although cyclin D1 can 
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serve as a marker of proliferation, it is not a strong prognostic marker in many human 
cancers, including ULMS.360-362  
 
Survival 
Tumor cells often have dysregulations that promote cell survival and allow bypass of 
biological cell-death signals when signaling, cell division, or DNA integrity surveillance 
mechanisms go awry. Apoptosis, a programmed cell death mechanism, is triggered 
by a number of intrinsic and extrinsic initiators such as TNF-α or mitochondrial 
dysregulation-mediated cytochrome c release.363 In healthy cells, a tightly regulated 
balance between pro-apoptotic and anti-apoptotic proteins directs cell fate; however, 
overexpression of anti-apoptotic molecules in many types of cancers shifts the 
equilibrium to favor cell survival.363  
 
Bcl-2 is a prominent member of an anti-apoptotic family of proteins that play critical 
homeostatic roles in apoptosis. Bcl-2 prevents cytochrome c release induced by pro-
apoptotic proteins (i.e. Bad, Bax, and Bok) from the mitochondria, thereby inhibiting 
apoptosis and counteracting pro-death signaling.364 To thwart pro-death signals and 
promote cell survival despite dysfunction, many tumors upregulate Bcl-2 expression. 
In fact, Bcl-2 is upregulated in several tumor types including cancers of the prostate, 
bladder, lung, and breast and also in leukemia.365-369 High expression of Bcl-2 is 
observed in some sarcomas (e.g. synovial sarcoma) but not in others (e.g. 
MPNST).370 Our study found that myometrium and leiomyoma controls had higher 
Bcl-2 high intensity and distribution expressions than ULMS; less than half of ULMS 
expressed the pro-survival molecule. These findings in a large (>200 sample) cohort 
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confirm Zhai et al. reports of Bcl-2 expression in only 43% ULMS and substantially 
higher expression in leiomyoma within a small cohort study.337 Although it is a pro-
survival molecule and therefore might be expected to aid tumors, we found that high 
intensity and distribution Bcl-2 expression correlated with improved disease-specific 
survival. While this is in contrast to Brambilla et al.371 and Kim et al.372, our findings 
are supported by several independent groups who also found that Bcl-2 expression 
correlates with a more favorable outcome.337,365,373-378 The potential mechanisms to 
shed light on why Bcl-2 expression is associated with improved survival are 
unclear,377 however, Bcl-2 has several functions other than anti-apoptotic activity by 
binding with and neutralizing pro-apoptotic family members such as Bax. Bcl-2 has 
been found to play a protective role in oxidative stress, binds beclin-1 to block beclin-1 
induced autophagy and cell death, and can modulate calcium levels.379-381 In 
colorectal cancer, loss of Bcl-2 was linked to metastatic progression.379 It is possible 
that Bcl-2, through mechanisms yet to be elucidated, can also prevent tumors from 
metastatic progression, thereby improving survival. 
 
Survivin is a pro-life molecule that plays a major role in the pro- versus anti-apoptotic 
molecular balance that regulates apoptosis. As a member of the IAP (inhibitor of 
apoptosis) family, survivin binds to effector caspases to prevent propagation of pro-
death signals that would mechanistically commit the cell to apoptosis; it can be 
regulated by β-catenin activation and WNT signaling. Most importantly, survivin is 
differentially expressed in tumor, but not terminally differentiated, healthy cells, 
making it an attractive potential biomarker and therapeutic target. While role(s) for 
overexpressed survivin in malignancies that are unrelated to anti-apoptotic regulation 
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have not yet been elucidated, localization to mitotic spindle poles during G2/M 
suggests an additional function in mitotic regulation. Overexpression of survivin was 
previously documented in sarcoma,382 but to our knowledge, has not yet been 
reported in ULMS. Our findings conclude survivin expression in both nuclear and 
cytoplasmic compartments is elevated in ULMS compared with controls; increase in 
nuclear, but not cytoplasmic, expression was significant. Intensity expression of both 
nuclear and cytoplasmic survivin were predictive of shorter recurrence free survival 
and nuclear distribution expression also correlated to shorter RFS. In non-small cell 
lung cancer, nuclear expression predicted longer recurrence-free and overall 
survival.383 It also correlated to poorer prognosis in glioblastoma;384 cytoplasmic 
expression did not correlate with survival in the same study.384 However, survivin was 
expressed significantly in uterine cervical squamous cell carcinoma compared with 
controls, but was not predictive of outcome.385 In breast cancer, the expression of 
surviving predicted early recurrence.386 Our study found neither cytoplasmic nor 
nuclear survivin expression to correlate with disease-specific survival. These findings 
indicate that nuclear survivin expression may be utilized as a biomarker and 
prognostic factor, and may be targeted for therapy to reduce the risk of recurrence in 
ULMS. 
 
Invasion 
Many factors are responsible for a tumor’s ability to invade and ultimately, 
metastasize. Fidler et al. describes the steps necessary to facilitate tumor invasion 
and metastasis.387 One critical step of this process is tumor extravasation, which 
requires degradation of extracellular matrix adjacent to the tumor. Matrix 
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metalloproteinases are a part of a family of zinc-dependent endopeptidases that 
facilitate breakdown of the tumor matrix and surrounding stroma. Several matrix 
metalloproteinases are responsible for breakdown of extracellular matrix (including 
MMP2 and MMP9). In this study, no significant increase in MMP2 expression was 
identified and any observed MMP2 expression in ULMS was rare. These findings 
contrast with most published reports in ULMS which indicate that around 50% of 
ULMS express MMP2.104 Inhibition of MMP9 in a rat sarcoma model inhibited tumor 
metastasis, indicating that MMP9 may be critical for tumor progression.388 In our 
ULMS TMA, we did not observe significantly increased MMP9 expression and 
therefore, cannot support the previous study. Since there are many proteins that can 
function similarly in the MMP family, it is also feasible that other MMP family members 
play more predominant roles to facilitate invasion and metastasis in ULMS. 
Nevertheless, the effects of MMP2 and MMP9 are likely minor in ULMS. 
 
Angiogenesis 
Angiogenesis is an essential part of tumor proliferation and progression. Blood 
vessels deliver molecular oxygen and critical nutrients via the bloodstream to rapidly 
dividing tumor cells and remove waste to keep the tumor microenvironment conducive 
for tumor growth. Vascular endothelial growth factor (VEGF) is a critical molecule 
responsible for endothelial cell migration, a critical step in vasculogenesis and 
angiogenesis.389 VEGF binds to and activates VEGF receptors, thereby initiating 
formation and remodeling of blood vessels within the tumor microenvironment.265 Our 
studies suggested that VEGF is overexpressed in human ULMS; significantly elevated 
levels were also identified in tumor progression groups. Together, these data 
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demonstrate that VEGF is important in ULMS and may represent a therapeutic target 
to halt disease progression. Elevated VEGF expression has been previously noted 
and inhibitors of VEGF and its receptor examined in many tumor models including 
Ewing’s sarcoma, angiosarcoma, and leiomyosarcoma.134,390,391 While largely 
ineffective in most cancers, VEGF receptor inhibitors in leiomyosarcoma have shown 
therapeutic benefit and prolonged disease stabilization.134 The role of VEGF, VEGFR, 
and endothelial cells in ULMS is unique because in this mesenchymal cell model, 
endothelial cells are critical and the two must work together to facilitate tumor growth.! 
 
Tumor suppressors and oncoproteins 
Expression and function of several tumor suppressors and oncoproteins can directly 
contribute to tumorigenesis. The p53 tumor suppressor is perhaps one of the most 
widely studied and frequently mutated proteins in cancer.392 The protein has many 
cellular functions including DNA damage repair, regulation of cell proliferation via p21, 
and transcription of many pro-survival molecules.393 It is regarded as the “Guardian of 
the Genome” for its widely diverse functions and effects. When stable, p53 forms a 
tetramer, translocates into the nucleus, and acts as a transcription factor to induce 
transcription of many pro-apoptotic genes such as Bax, Apaf-1, and PUMA as well as 
growth arrest-inducing p21 and Gadd45. It also transcribes MDM-2 as part of a self-
regulating negative feedback mechanism.393 A loss of function mutation in p53 results 
in accumulation of the protein within in the nucleus. We report a statistically significant 
accumulation of p53 in more than 30% of ULMS, suggesting that p53 mutation in 
ULMS is common. Further, p53 mutation is more prevalent in advanced ULMS 
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compared with primary disease and may partially contribute to accelerated 
tumorigenesis and aggressiveness in advanced lesions.  
 
As a critical molecule for cellular equilibrium and homeostasis, p53 is closely 
regulated by MDM-2, an oncoprotein that functions as an E3 ubiquitin ligase and 
ubiquitinates p53, resulting in degradation of the protein. High levels of MDM2 
correlate with low levels of stable and transcriptionally functional p53, resulting in a 
shift in equilibrium favoring cell survival.393 Several studies in de-differentiated 
liposarcoma have established overexpressed MDM2 and in cases of retroperitoneal 
sarcomas, MDM2 overexpression may sometimes be utilized to help distinguish 
between ULMS and LPS.332 We and others report significant MDM2 overexpression in 
ULMS.394,395 Interestingly, ovexpression in our series is found predominantly in local 
lesions and is significantly lower in metastatic ULMS.  
 
p16 is a cyclin-dependent kinase inhibitor and tumor suppressor that negatively 
regulates cell cycle progression. Functional p16 sequesters CDK4, preventing CDK4-
mediated phosphorylation of Rb and subsequent pro-growth downstream effects.  We 
and several others observed diffuse and strong p16 expression in ULMS compared 
with leiomyoma or myometrium.396-401 While it is unclear why a tumor suppressor 
would be consistently overexpressed in ULMS compared to benign leiomyoma, Atkins 
et al. suggest that overexpression could be the result of gene mutation or loss of 
protein functionality.397 Although at least one small cohort study found that elevated 
and diffuse p16 expression correlated statistically with poor clinical course, we did not 
find any significant association between p16 expression and outcome. Notably, 
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several studies, including ours, agree that healthy myometrium minimally express p16 
while some leiomyomas express p16 weakly and focally suggesting that gain of p16 
expression may be an important molecular event in tumor progression.396,397,399 Taken 
together, these data suggest that p16 could be used as a molecular biomarker to aid 
in the discrimination of ULMS from leiomyoma in cases of complex or atypical cases.  
 
The retinoblastoma protein (Rb) is a widely recognized tumor suppressor frequently 
mutated or lost in cancers. Phosphorylated Rb protein is a gatekeeper of the cell cycle 
and regulates G1 progression to S phase, halting the cycle in G1 if damaged DNA is 
present. When Rb is lost or has a nonfunctional mutation, tumor cells with frequently 
altered and damaged DNA is able to progress through G1 into S phase and continue 
cellular replication. Notably, women with hereditary Rb syndromes that are 
characterized by loss of Rb have a higher risk for developing ULMS.402 We examined 
Rb expression in a large ULMS cohort and concluded that expression is significantly 
reduced in tumor versus controls and therefore, it can serve as a biomarker for ULMS. 
Taken together, we found deregulations in p53, MDM2, p16, and Rb are relatively 
common in ULMS and likely contribute to tumorigenesis. We found that all tumor 
oncoproteins examined were overexpressed compared with controls and the single 
tumor suppressor we examined, Rb, was significantly reduced compared with 
controls. Notably, the tumor suppressors and oncoproteins we examined interact with 
one another and in concert, can control the cell’s fate via regulatory mechanisms; 
their expressions likely rely on regulation by each other.  
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Signaling: β-catenin 
β-catenin is a central signaling molecule that initiates the WNT pathway and is critical 
in wound healing and cell proliferation.403 Further, dysregulation of WNT pathway 
through β-catenin has been shown to promote mTOR activation and propagate pro-
life signals. Accumulation of β−catenin in the cytoplasm can be a result of mutation in 
the CTNNB1 gene (this gene encodes for β-catenin protein) and results in nuclear 
translocation and transcriptional activation of many pro-growth and pro-survival 
genes.404 Additionally, a cre-recombinase driven mouse model featuring constitutively 
activated β-catenin within the uterine mesenchyme resulted in the development of 
uterine sarcomas and activation of the mTOR pathway in mice.405 Given these 
implications and that cancer has been described as both a hyper-proliferative disorder 
and a “wound that over heals,”406 we examined β-catenin expression in human ULMS. 
Several investigators have found cytoplasmic β-catenin overexpression in more than 
half of LMS and ULMS.407,408 Our results identified significant β-catenin 
overexpression in 64% of ULMS and agree well with existing reports.408 Further, we 
found high cytoplasmic β-catenin to be statistically correlated to recurrence-free 
survival in ULMS.  
 
Nuclear β-catenin has been observed in many cancers,409,410 however, several small 
studies have failed to observe nuclear expression in LMS/ULMS.411,412 Our data 
disagree with these previously published reports in ULMS and suggest that nuclear β-
catenin is in fact overexpressed in a small number (~7%) of ULMS cases. Although 
the percentage of ULMS expressing nuclear β-catenin was small, the difference 
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between ULMS and control expression was significant. Recently, Kildal et al. reported 
that 23% of ULMS (n=231) expressed nuclear β-catenin and that high expression 
correlated with lower 5-year survival.408 Although expression is much more prevalent 
than in our study, we did find that nuclear β-catenin correlated with RFS and together, 
our findings agree that nuclear β-catenin is expressed in ULMS and could potentially 
serve as a molecular biomarker or therapeutic target.408 Notably, our study also found 
nuclear β-catenin correlated with tumor status; higher levels of nuclear expression 
were found in recurrent and metastatic lesion than in primary ULMS, suggesting a role 
for nuclear β-catenin in advanced ULMS.  
 
Membranous β-catenin expression has been observed in many epithelial-derived 
cancers;413,414 however, studies in sarcoma have largely failed to demonstrate 
appreciable membranous β-catenin expression.411,412,415-417 In epithelial cells, 
membranous β-catenin functions in the cadherin-cadherin cellular adhesion process; 
loss of membranous β-catenin associated with greater tumor invasiveness and worse 
outcome.418-422 Klidal et al. were the first to demonstrate membranous β-catenin in 
uterine sarcoma and concluded that expression was limited only to ULMS (25% 
ULMS expressed membranous β-catenin); endometrial stromal sarcoma, 
carcinosarcoma, and healthy myometrium controls did not express membranous β-
catenin.408 Further, they reported that elevated membranous β-catenin correlated to 
poor survival.408 Using our TMA, we found 20% of ULMS stained positively for 
membranous β-catenin compared with none of the controls. Our data agree well with 
findings from Kildal et al.; however, we did not observe a significant association of 
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membranous β-catenin to tumor status or outcome. Together, these data conclude 
that membranous β-catenin is differentially expressed in ULMS over other uterine 
sarcomas and suggest a potential role in ULMS development and progression. The 
underlying cause of membranous β-catenin and its functional significance remains 
unclear, however, a ULMS-specific role is likely.  
 
mTOR associated proteins 
The mTOR pathway is a major cell growth-signaling pathway in sarcoma. mTOR is 
center in the signaling cascades and contributes to cell survival, growth, migration, 
and cell cycle progression via regulation of mRNA translation.114 Enhanced mTOR 
signaling, serving as a convergence point for multiple upstream molecular 
deregulations, is commonly observed in many malignancies, making this axis an 
attractive anti-cancer therapeutic target.109 Recent data suggest a role for this 
pathway in LMS.107,196,423,424 In 2007, Hernandez et al. proposed that elevated 
activation of the mTOR pathway was critical in the development of leiomyosarcoma.98 
Using GEM mouse models, researchers conditionally knocked out PTEN, causing 
rapid development of leiomyosarcoma.98 Recently, Setsu et al. suggested that the 
AKT/mTOR pathway Is highly activated in soft tissue leiomyosarcomas and 
upregulation of this pathway was significantly associated with shorter survival.107 
Studies here extend these observations to ULMS, a particularly devastating LMS 
subset, demonstrating increased ULMS mTOR activation.  
 
To provide rationale for further studies, we queried a ULMS gene array that compared 
ULMS to normal myometrium and leiomyoma.250 We compared gene signatures in 
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ULMS to three known signatures associated with PI3K/AKT/mTOR pathway 
hyperactivation. The CMap signature was based on “The Connectivity Map” dataset 
and mapped expression profiles of several different cell lines treated with PI3K 
inhibitors to identify genes with reduced expression following treatment.327 The 
second gene set used for comparison was the Saal profile, which mapped gene 
expression in breast cancers with characterized PTEN loss (and therefore, highly 
activated mTOR pathways).328 The third and final gene expression model that we 
used was the Majumder gene set examining gene regulation in mice with 
overexpressed AKT1.326 Together, the three gene expression profiles were used to 
characterize a set of genes associated with PI3K/AKT/mTOR pathway activation. The 
PI3K/AKT/mTOR pathway was highly active in ULMS compared with myometrium. 
These results confirm that on the level of RNA expression, there is marked 
enrichment of PI3K/AKT/mTOR pathway gene activations, suggesting that the mTOR 
pathway is overexpressed and may be a viable therapeutic target. Towards that end, 
we have evaluated expression of several proteins in this pathway to identify possible 
biomarkers, prognosticators, and therapeutic targets. 
 
The functions and significance of p4EBP1, pS6RP, and pAKT are reviewed in the in 
the introduction to this work. In our study, enhanced mTOR signaling occurred with 
disease progression; activation of mTOR downstream effector 4EBP1 correlated with 
poor prognosis in localized ULMS patients, making it a potential ULMS molecular 
prognosticator. While this is the first report to examine mTOR pathway levels in 
ULMS, findings agree well with elevated levels of activated mTOR pathway proteins 
and correlation to poor prognosis found in a recent LMS study. 107 Activated 4EPB1, 
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S6RP (used as a surrogate for S6K), and AKT statistically correlated with one another 
and in tumors versus controls, suggesting they are viable biomarkers in ULMS. 
However, only nuclear distribution expression of p4EBP1 correlated with outcome.  
 
PTEN 
Loss of PTEN was previously implicated in driving tumorigenesis through elevating 
mTOR pathway activity in a transgenic LMS mouse model.98 Furthermore, the gene 
encoding PTEN is located on chromosome 10q23 in a region that is frequently lost in 
LMS and in other STS.184,425-429 Although PTEN loss can mTOR pathway activation, 
Rivera et al. show that loss may not be predictive of response to mTOR inhibitors 
temsirolimus or ridaforolimus240 and studies suggest that PTEN loss may not be 
associated significantly with clinical outcome in some cancers, including LMS.107,236  
We found that loss of PTEN expression occurred in only 7% of the ULMS samples in 
our study. This is in accord with previous reports demonstrating a low PTEN mutation 
rate (~5%) in ULMS.430 Notably, two smooth muscle controls and one leiomyoma 
exhibited loss of PTEN. All control tissues on our TMA were acquired from patients 
upon tumor resection and PTEN loss in control tissues is likely contributed to the fact 
that they were taken from areas near a malignant lesion and therefore, may show 
some signs of tumorigenicity. In contrast to epithelioid sarcomas, where 88% of 
samples had identified PTEN reduction or loss and PTEN loss was a major 
contributing factor to AKT/mTOR pathway activation, our study and those of others 
have shown that PTEN loss is not frequent in ULMS and therefore, is not a prominent 
mechanism underlying mTOR activation.99,184,238,431,432 However, there may be a small 
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subset of patients with highly active mTOR signaling resulting, at least in part, from 
PTEN loss. 
 
Receptor tyrosine kinases 
mTOR activation can also be due to multiple upstream molecular derangements 
acquired throughout the tumorigenic process.150 Among possible derangements, over-
expression and activation of tyrosine kinase receptors (RTKs) can contribute to 
mTOR activation. As part of a complex signaling network, the mTOR pathway is 
activated by a number of receptor tyrosine kinases at the cell surface that internalize 
mitogenic signals. Overexpression or activation of RTKs has been identified in many 
sarcomas.332,433-435 While knowledge is limited, several studies suggest that RTKs 
such as PDGF-α and IGF-1R are over-expressed in ULMS.436,437 In this study, we 
sought to identify RTKs that were overexpressed and potentially contributing to mTOR 
activation by evaluating their expression levels in human ULMS. 
 
The epidermal growth factor (EGFR, Her-1, Erb-B1) is a class I RTK that regulates 
mitosis and can be over-expressed in cancer.184 Relatively few studies have 
examined EGFR expression in uterine sarcoma or uterine leiomyosarcoma, but our 
studies supports existing reports that EGFR is not differentially expressed in ULMS 
and leiomyoma; it is not likely a contributing force to mTOR activation.438 No 
significant genetic amplifications or alterations have been noted.439 Notably, 
overexpression of nuclear EGFR in breast cancer cells resulted in EGF accumulation 
in the nucleus; nuclear accumulation led to EGF-mediated induction of Aurk A 
expression via cofactor STAT5.440 While an interesting observation, we did not find 
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overexpression of EGFR in ULMS and therefore, it is not likely responsible for the 
marked upregulation of Aurk A that we observed.  
 
Next, we evaluated the insulin growth factor receptor 1 (IGF-1R), an RTK that has 
previously been reported to be overexpressed in ULMS.436 The IGF-1R plays roles in 
enhancement of cellular proliferation, and differentiation.389 Cell growth inhibition 
resulted when IGF-1R was not present within the cell.441 Enhanced expression of IGF-
1R has been observed in many cell lines and human cancers including breast, 
colonic, cervical, and prostatic cancers.442-448 One group documented the 
overexpression of IGF-1R in ULMS436 and several publications indicate that it may be 
a viable therapeutic target for sarcomas.109,134,449 Our study concluded that IGF-1R is 
overexpressed significantly in ULMS versus leiomyoma and myometrium controls and 
suggests a potential role for IGF-1R as a therapeutic target; it likely contributes to 
mTOR activation in ULMS. Notably, IGF-1R expression did not correlate to outcome. 
 
The PDGF family of RTKs represent a diverse family of receptors that hetero- or 
homodimerize to activate and transmit pro-growth signals intracellularly.450-453 The 
effects of PDGF on the uterus and leiomyomas was reviewed by Ciarmela et al.454 
When fully activated, PDGFR-α and -β are known to trigger downstream activation of 
the PI3K/AKT/mTOR pathway. As such, we evaluated the expressions of PDGFR-α, 
PDGFR-β, and the PDGF-α and –β ligands that bind to and activate the receptors. 
Our studies concluded that PDGFR-α expression is significantly higher in smooth 
muscle controls than in ULMS; less than half of ULMS had moderate-high level 
expression. Further, PDGFR-β expression was found to be moderate- high in almost 
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one-quarter of ULMS compared with no controls. While existing literature on PDGF 
receptor and ligand expression in ULMS is sparse, our results agree well with existing 
reports.406,437,455 Notably, we found PDGFR-β distribution expression to correlate 
significantly to DSS. Adams et al., examined a small subset of human ULMS tissues 
for PDGF-α mutation; no mutations were detected.437 Given the effectiveness of 
imatinib mesylate, a dual c-KIT and PDGFR inhibitor, several groups have suggested 
its use in ULMS.220,456 Clinical trials with imatinib mesylate in ULMS have been largely 
disappointing and failed to yield significantly improved results.220 Examining 
expression of RTKs is crucial to understanding PI3K/AKT/mTOR activation in ULMS; 
however, evaluation of ligand expression may also provide useful insight. We 
investigated expressions of PDGF-α and PDGF-β ligands and found PDGF-β was 
significantly overexpressed compared with controls. Conversely, PDGF-α expression 
was significantly reduced in ULMS. PDGF-β intensity expression correlated to both 
recurrence-free and metastasis-free survival while PDGF-α expression predicted only 
shorter MFS. PDGF-mediated activation of PDGFRs may contribute to marked 
hyperactivation of the mTOR pathway in ULMS, however, it is unlikely the 
predominant or even a major contributor. 
  
c-KIT (CD117) is a receptor tyrosine kinase activated by the stem cell factor (SCF) 
ligand; it propagates pro-survival and pro-growth signals via PI3K/AKT/mTOR 
signaling.457 Deregulation of c-KIT in at least one other STS subtype tumors is well 
established and has been molecularly targeted with c-KIT inhibitor imatinib with 
excellent therapeutic benefit. Some reports suggest that c-KIT is overexpressed in 
ULMS.458,459 However, we and several others did not observe c-KIT expression in 
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ULMS, suggesting that c-KIT would not be a viable therapeutic target.460-462 This 
hypothesis is supported by in vitro work by Merimsky et al. where the use of imatinib 
for c-KIT inhibition in ULMS cells was examined; inhibition of c-KIT had no effect on 
cell growth.220  
 
MET is a unique RTK activated by hepatocyte growth factor (HGF). The receptor can 
activate the PI3K/AKT/mTOR pathway in two ways: 1) MET can directly activate PI3K, 
and 2) MET can activate the Ras oncoprotein, stimulating activation of the AKT 
pathway through an intersecting cell growth regulation pathway. Deregulation of MET 
in sarcoma and in LMS, has been identified;332,463,464  amplification of MET gene copy 
number is also observed in LMS.89 We found no statistical difference in MET 
expression between tumor and controls. Although Gao et al. showed that a MET 
inhibitor effectively inhibit the growth of SKLMS1 and SKLMS1 xenografts.465 MET is 
not differentially expressed in tumor versus normal tissue controls and therefore, MET 
inhibition likely does not represent a viable therapeutic option in human ULMS.  
 
The final tyrosine kinase receptor that we examined is a TAMM family receptor named 
AXL.466 Activated by Gas6 ligand, AXL signals through the mTOR pathway via PI3K, 
is shown to be overexpressed in cancer, and is thought to contribute to 
tumorigenesis.467 However, relatively fewer studies have focused on AXL. 
Interestingly, AXL knock out mice are viable and do not have show significant 
phenotypic consequences, indicating that if AXL function is critical in tumorigenesis, 
its functions may be redundant with other receptor(s). Further, if any two of the three 
known family receptors (AXL, Tyro 3, and Mer) are knocked out, mice are still viable 
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and fertile. Triple knockdown results in viable but unfertile males who produce no 
viable sperm.468 Our studies suggested that AXL expression was significantly 
elevated in ULMS compared with normal controls and further, that AXL expression 
rises significantly with tumor progression. To the best of our knowledge, this study is 
the first to date to evaluate AXL expression in ULMS or LMS. Interestingly, Yang et al. 
provided evidence of a c-KIT to AXL “switch” in GIST where resistant tumors show 
downregulated c-KIT accompanied by upregulation of AXL.469 A c-KIT to AXL switch 
would be an interesting explanation of observed ineffectiveness of c-KIT inhibitors in 
ULMS. Notably, our studies shown overexpression of AXL and very minimal 
expression of c-KIT in ULMS. Perhaps there is a correlation between low c-KIT and 
high AXL expression due to a “c-KIT to AXL switch.” If the switch is reversible, 
inhibition of AXL may lead to enhanced c-KIT expression, which could be potentially 
targeted with imatinib or other c-KIT inhibitors.  
 
A marked deregulation in tyrosine kinase receptors has been shown in other 
sarcomas.332,434,435 We found deregulation in several RTKs in human ULMS that quite 
likely have functional significance and might explain AKT/mTOR pathway activation in 
ULMS. However, we did not examine the activated (phosphorylated) levels of each 
receptor, but rather the receptor expression as a whole. In several studies, it is 
apparent that overexpression does not necessarily lead to high activation and 
hyperactivation is not necessarily a result of enhanced expression.470 Regardless of 
the cause of mTOR upregulation in ULMS, mTOR downstream targets pS6RP and 
p4EBP1 are highly activated and overexpressed in ULMS, providing a rationale for 
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further studies in vitro and in vivo to examine the potential therapeutic benefits of 
targeting mTOR in ULMS.  
 
mTOR pathway and inhibition via rapamycin in ULMS cell strains/lines 
Few, if any, studies have examined mTOR pathway activation in ULMS in vitro. 
Elevated mTOR activity was found in one LMS cell line (SKLMS1) in two independent 
studies.268,471 Here, we demonstrated high AKT/mTOR pathway activity in a large 
panel of ULMS cell lines and strains. We also showed that mTOR activation 
contributes to ULMS cell growth and cell cycle progression; rapamycin arresting cells 
in G1 without inducing apoptosis.135 These results agree with nearly all other 
published reports on the effects of rapamycin in vitro against cancer.209,472-475 While 
Huang et al. report that G1 arrest is dependent on p53 status, we and others observe 
G1 arrest and accompanying effects in ULMS cells independent of p53 mutational 
status.476 The latter finding is of clinical relevance given that p53 mutations occur in 
human ULMS92 and that p53 mutation can contribute to conventional 
chemotherapeutic resistance.477  
 
Several reports show that rapamycin and its analogs have only modest effects in 
human STS, despite marked upregulation of the mTOR pathway in several STS, 
LMS, and ULMS.107,209,210,473,478-481  Our results from murine xenograft models agree 
well with human clinical studies and demonstrate that despite excellent in vitro 
sensitivity, rapamycin is not a sufficient monotherapy in vivo for the treatment of 
ULMS.  
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While encouraging, these data also demonstrate the limitation of single agent mTOR 
inhibitors as treatment for ULMS, resulting in cytostatic effects that might not be 
sufficient to improve patient outcomes, reminiscent of mTOR blockade-based trials in 
other human solid tumors and in LMS.238,482 Identifying additional targets for inhibition 
in combination with mTOR is thus urgently needed, a strategy currently being 
evaluated in conjunction with radiotherapy- conventional chemotherapy-, and 
molecular-based therapies in the context of several malignancies.483 Murphy et al. 
report that inhibition of mTOR sensitizes STS and blood vessels to radiotherapy.484 
Since the mTOR pathway is upregulated in ULMS, low-dose rapamycin treatment 
may be a therapeutic benefit in combination with radiotherapy. Each modality alone 
has shown minimal effects on cell growth, but together, they are proposed to act 
synergistically and may be of patient benefit.484  
 
Following promising results of a case study of gemcitabine and rapamycin in LMS, 
Merimsky et al. carried out several in vitro experiments to evaluate the efficacy of the 
combined therapy in LMS and ULMS.220 In this study, combination therapy did not 
show significant therapeutic benefit compared with gemcitabine alone.220 Imatinib in 
combination with rapamycin was also examined and found to have no effects on LMS 
or ULMS alone or in combination with rapamycin, presumably because we and others 
have found that its c-KIT target is not expressed in ULMS.219 Towards evaluating 
mTOR blockade in combination with conventional chemotherapies, we utilized 
doxorubicin and rapamycin in combination therapy in vitro against ULMS. Our results 
did not yield synergistic anti-growth effects and were similar to previously noted 
outcomes achieved with combination gemcitabine and rapamycin,220 suggesting that 
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standard conventional first-line chemotherapies (gemcitabine or doxorubicin) do not 
yield superior results when combined with mTOR blockade. In this new era of 
personalized medicine, mTOR inhibition combined with molecularly based therapies 
should be further examined. 
 
Recently we have identified that ULMS overexpress gene products regulating 
centrosome structure and function, highlighting a role for Aurk A as a novel ULMS 
therapeutic target. In our recent study a Gene Chip Array was used to gather 
genome-wide transcriptional profiles for more than 75 ULMS patients, comparing 
mRNA expression of nearly 50,000 genes to profiles acquired from leiomyoma and 
health myometrium.250 Several genes were identified as up- or down-regulated in 
ULMS; many of the genes up-regulated were centrosome-related proteins including 
Aurk A (7.9-fold up-regulation).250 Few studies have examined Aurk A expression or 
function in sarcoma317,485,486 and to the best of our knowledge, this and our previous 
study were the only to validate Aurk A overexpression in LMS or ULMS. Additionally, 
SiRNA knockdown induced marked apoptosis in our studies, indicating functional 
importance for Aurk A in cell survival.250 Next, we validated that Aurk A is upregulated 
and overexpressed in ULMS. In vitro, we found that ULMS cells are sensitive to 
MLN8237 at doses similar to those previously reported,324 observing significant 
treatment-induced growth inhibition, G2/M arrest, and a 2- to 4- fold increase in 
apoptosis compared with vehicle treated cells.315 Interestingly, several potential non-
kinase functions for Aurk A have recently emerged.255 MLN8237 is thought to inhibit 
only functions related to kinase activity and therefore, may not completely inhibit Aurk 
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A functions. Altogether, our studies, backed by literature, suggest that Aurk A kinase 
is a viable therapeutic target.  
 
We hypothesized that since Aurk A inhibition via MLN8237 only killed about 25-50% 
of ULMS cells in vitro, a combined therapy approach with mTOR may yield superior 
effects. Additionally, dual therapy approaches often require lower doses of drug, 
resulting in lower clinical toxicity and side effects and enhanced quality of life for the 
patient while on therapeutic interventions. Aware that a critical next step in utilizing 
mTOR inhibition for ULMS treatment mandates developing effective drug 
combinations and taking into account our finding that Aurk-A might be a novel ULMS 
therapeutic target, we evaluated dual mTOR and Aurk-A blockade in our preclinical 
models. To the best of our knowledge this therapeutic combination has not been 
previously reported.  
 
Timing of drug administration in combination therapies is an important consideration. 
Several reports conclude that drug administration timing significantly affects the 
outcome of the drug combination.10 For example, doxorubicin and TRAIL combination 
therapy yields superior results in STS, but only when doxorubicin is administered first, 
suggesting that it may sensitize cells to the secondary treatment.10 Notably, Wang et 
al. found that dual inhibition induced an elevated level of apoptosis compared to either 
compound alone or the sum of the two compounds.10 Merimsky et al. touch on the 
subject in 2004, stating:  
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“The use of such combinations requires smart planning and choice of drugs to 
be combined, their proper dosing as well as correct sequence and schedule of 
application. This is of crucial importance to enable synergism rather than 
antagonism between combined drugs.”219  
 
In the study Merimsky referred to, he combined rapamycin and gemcitabine therapies 
for the treatment of metastatic LMS. By combining a traditional chemotherapeutic 
agent, gemcitabine, and a cell signaling inhibitor, rapamycin, cancer cells were 
selectively targeted at 2 different phases (G1 phase – rapamycin, S phase – 
gemcitabine).219  
 
We evaluated three timing combinations in our synergy study: co-treatment, 
rapamycin pre-treatment, and MLN8237 pre-treatment. Our data demonstrate that 
MLN8237 synergizes with rapamycin to induce superior in vitro Notably, synergism 
was found only when MLN8237 was administered prior to rapamycin treatment, 
highlighting the importance of scheduling sequences in development of therapeutic 
combination regimens. While it is unclear if pre-treatment with MLN8237 sensitized 
ULMS cells to rapamycin therapy, it was logical to first administer a cytotoxic agent to 
arrest cells in G2/M and kill as many tumor cells as possible. Interestingly, enhanced 
apoptosis was not observed in combination therapy groups compared to MLN8237 
groups. The cells able to evade apoptosis via MLN8237 were then trapped in G1 by 
rapamycin and experienced cytostatic growth inhibition effects. These results likely 
reflect the differential impact of these compounds on cell cycle progression, although 
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the exact mechanisms underlying the observed anti-tumor effects remain to be 
determined.  
 
A pronounced synergistic effect is observed when ULMS are pre-treated with 
MLN8237 then co-treated with MLN8237 and rapamycin, suggesting a potential link 
between Aurk A and mTOR. Interestingly, Saeki et. al published a potential model for 
Aurk A-mediated malignant transformation.487 In this model, they predicted that Aurk 
A overexpression alone was not sufficient for tumorigenesis, but coupled with cellular 
effectors or mTOR pathway activation, could contribute greatly to full transformation. 
This predicted model is the presents a potential link between mTOR and Aurk A.487 
Wang et. al show induction of mTOR activation in a transgenic mouse model featuring 
an Aurk A transgene leading to overexpression of Aurk A kinase.488 Although the 
group could not recapitulate these effects in cultured cells, they concluded that 
marked activation of the mTOR pathway was induced by Aurk A kinase 
overexpression.488 They concluded that the activation may be a long-term effect and 
therefore, not observed in shorter cell-based experiments.488 Aurk A kinase has 
demonstrated nuclear localization and functions within the nucleus during mitosis, 
however, cytoplasmic localization of Aurk A has also been observed irrespective of 
cell cycle in many cancers. The cytoplasmic function of Aurk A remains unclear, but 
as a Ser/Thr kinase, it is possible that Aurk A may phosphorylate AKT, TSC2, or other 
mTOR-associated proteins, thereby activating the pathway and promoting cell growth. 
In this hypothesis, targeting Aurk A first would not only result in apoptosis, but also in 
a reduction of mTOR activity. This decline in mTOR activity, coupled with suppression 
from combination MLN8237 and rapamycin treatment could explain the synergistic 
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effects that are observed with this unique dosing schedule. Studies examining the 
recognition and activation sites of Aurk A and AKT/mTor pathway components as well 
as binding and functional studies would be required to confirm this hypothesis.  
 
In vivo, combination therapy produced stabilization of disease in 100% of mice in that 
treatment group (n=8) for the duration of the 3-week treatment. Additional studies are 
necessary to see if complete or partial response can be achieved with an extended 
therapeutic treatment window. Also, further studies are necessary to define the 
duration of disease stabilization resulting from dual inhibition of mTOR and Aurk A 
kinase in ULMS. We found that MLN8237 treatment resulted in polyploidy in many 
cells, which agree well with published reports using Aurk A inhibitors in cancer.315 
Also, we found a marked reduction in CD31 expression indicative of angiogenic 
inhibition with MLN8237 and in combination treatment. To evaluate whether MLN8237 
induced apoptosis in blood vessels, a co-immunofluorescence study for CD31 and 
TUNEL in xenograft tissues from all treatment groups was performed (data not 
shown). We did not observe any co-localization, indicating that MLN8237 likely does 
not have direct anti-angiogenic properties. Further, we believe that the significant size 
reduction in MLN8237-treated and co-treated tumors may be the culprit for fewer 
blood vessels, as smaller tumors do not require extensive vasculature networks 
compared with larger tumors. Combination therapy in vivo resulted in synergistic, anti-
ULMS effects compared to either agent alone (although MLN8237 was given at a 
dose lower than the maximal tolerated dose (MTD).489 
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Our studies demonstrate that dual inhibition of mTOR and Aurk A kinase via 
rapamycin and MLN8237 yields remarkable synergistic anti-ULMS effects in vitro and 
in murine studies. Additionally, several recent clinical trials with rapalogs and case 
studies with Aurk A inhibitors suggest that neither compound is therapeutically 
sufficient in humans. However, both drugs are fairly well tolerated at clinically relevant 
doses. In our work we provide pre-clinical evidence to support clinical investigation 
into dual inhibition of mTOR and Aurk A. We believe that combining these therapies in 
the clinic could prove to be of great benefit in the treatment of ULMS.  
 
In summary, ULMS is a dismal disease and few women will survive more than 5 years 
after diagnosis. The aim of this work was to provide a better understanding of the 
deregulations promoting tumorigenesis in ULMS so that more efficacious therapies 
can be designed and tested clinically. Our findings suggest that deregulations leading 
to enhanced mTOR signaling and Aurk A overexpression play important roles in 
ULMS tumorigenicity. Dual blockade of mTOR and Aurk A in ULMS worked 
synergistically to abrogate cell proliferation in vivo and in vitro. Our results provide 
supporting justification for clinical trials to evaluate combined mTOR and Aurk-A 
inhibitors to enhance the anti-ULMS effects observed with either inhibitor alone.  
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Chapter 11: Future Directions 
 
While we examined several possible causes of deregulation in the mTOR pathway, it 
is complex system and several other proteins may contribute to mTOR pathway 
activation. More than 20 families of receptor tyrosine kinases have been discovered. 
In our study, we examined seven major tyrosine kinase receptors that have previously 
been indicated in cancer. However, we did not investigate all receptors and it is 
possible that deregulation of these receptors may play into the significant 
hyperactivation of the mTOR pathway. For example, kinase receptor ROR2 was 
recently found to be overexpressed in LMS and functioned to enhance tumor 
invasiveness; knockdown of ROR2 in LMS resulted in tumor mass decline. A number 
of additional molecules could be responsible for driving tumorigenesis in ULMS 
including RTKs such as ROR2, signaling kinases such as MAPK, tumor suppressors 
such as BRCA1, and tumor oncoproteins such as Ras. A further evaluation of such 
proteins may yield additional biomarkers, prognosticators, and therapeutic targets. 
 
Mutations in or silencing of upstream effectors may also contribute to mTOR 
activation. For example, activating mutations in AKT, PI3K, and Ras have been 
identified in cancer.107,490 Recently, Setsu et al. examined PI3KCA and AKT1 gene 
mutations in LMS to determine if mutation, at least in part, could contribute to high 
activity of mTOR pathway activity they observed. No mutations were observed at 
hotspots of either gene. This study suggests that gene mutations in PI3KCA and 
AKT1 are not common in LMS and are not responsible for increased activity of the 
mTOR pathway.107 Several other mutations could contribute to mTOR activity 
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including those in PTEN, TSC1/2, Rheb, mTOR, or RTKs and should be investigated 
further.  
 
MicroRNAs (miRNAs) have recently emerged as regulatory mechanisms for several 
critical cancer-related proteins.491 Very few studies have been conducted to identify 
functional and critical miRNAs in uterine leiomyosarcoma. In a recent study by Nuovo 
et al., MiR-221 was identified in 87% of ULMS (13/18), compared with no leiomyomas 
and was proposed as a means to differentiate between the two lesions.492 Although 
few miRNA studies have been conducted in ULMS, additional studies may be 
warranted to identify a novel level of regulation in the disease. Further, miRNAs from 
the tumor microenvironment may also play roles in tumorigenesis and should be 
examined in ULMS.493-495 
 
Our studies examined smooth muscle and gynecological differentiation markers. In 
addition to those reported in this dissertation, several additional diagnostic markers 
such as CD10, S-100 protein, and vimentin were evaluated. Tumors were also 
stratified into subtypes and evaluated for correlation to outcomes. An extra-uterine 
LMS tissue microarray was constructed and is currently being stained and scored for 
several markers for comparison to ULMS expression profiles. These data comprise a 
histology/diagnostic-based manuscript that is currently being drafted. 
 
In our studies, we examined several cancer-related biomarkers and biomarkers 
relating to the mTOR pathway. These studies are presented and discussed in the 
body of this work. However, we also examined several other potential biomarkers with 
!! 172!
evidence of importance in sarcoma and ULMS. For example, histone deacetylases 
(HDACs) are a class of proteins that deacetylate lysine residues on histones, thereby 
unraveling DNA and making it more accessible to transcriptional proteins. They are 
also thought to have non-histone targets and have distinct cellular locations, some 
being exclusively nuclear, some exclusively cytoplasmic, some membrane-
associated, and a few HDACs are seen in both the nucleus and the cytoplasm. Many 
HDAC functions not related to their deacetylase activity have not yet been elucidated, 
but HDAC 8 was found to be overexpressed in leiomyosarcoma compared with 
normal controls. We have several ongoing studies in our lab involving HDAC inhibition 
in cancer and preliminary data shows that HDACs may be important in ULMS. We 
found that several HDACs were overexpressed significantly in ULMS compared to 
smooth muscle controls including HDAC2 (cytoplasmic and nuclear intensities), 
HDAC 3 (cytoplasmic and nuclear intensity), HDAC 6 (cytoplasmic intensity), HDAC 8 
(cytoplasmic and nuclear intensities), and HDAC 10 (cytoplasmic intensity). 
Additionally, expression of several HDACs were found to correlate to survival. We are 
currently investigating the role of HDACs in sarcoma and will be further pursing these 
findings. 
 
Finally, we have completed construction and analysis on our large ULMS database, 
which includes more than three hundred identified ULMS patients from UTMDACC, 
regardless of tissue availability (this database includes patients on the ULMS TMA). In 
these patients, we have examined our database for several clinicopathologic 
parameters (i.e. stage, size, mitotic count, surgical margins, age, race, etc.) and 
correlated them to recurrence-free, metastasis-free, and disease specific survival. 
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Together with the cancer-related biomarkers reported in this work, we are finalizing a 
comprehensive manuscript for submission to report these data. This work will 
represent one of the largest cohort clinical database reports coupled with arguably the 
most comprehensive molecular study of ULMS to date. !
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Appendix Table A1. Antibodies used for immunohistochemistry. 
Name of Marker Company City, State Catalog # Antibody Origin Clone 
Smooth muscle/gynecological differentiation markers 
SMA Sigma St. Louis, MO A2547 Mouse monoclonal 1A4 
SMM Dako Carpinteria, CA IR066 Mouse monoclonal SMMS-1 
Desmin Sigma St. Louis, MO M0760 Mouse monoclonal D33 
Caldesmon Dako Carpinteria, CA M3557 Mouse monoclonal h-CD 
WT-1 Dako Carpinteria, CA M3561 Mouse monoclonal 6F-H2 
Estrogen Receptor Novocastra Buffalo Grove, IL NCL-ER-6F11 Mouse monoclonal 6F11 
Progesterone Receptor Dako Carpinteria, CA M3568 Mouse monoclonal PgR 1294 
Cancer-related markers         
Ki-67 Dako Carpinteria, CA M7240 Mouse monoclonal MIB-1 
Cyclin D1 Labvision Freemont, CA RM-9104-S Rabbit monoclonal SP4 
Bcl-2 Biogenex San Ramon , CA AM287 Mouse monoclonal 100 
Survivin Abcam Cambridge, MA Ab469 Rabbit polyclonal - 
MMP2 Chemicon Billerica, MA AB807 Rabbit polyclonal - 
MMP9 Chemicon Billerica, MA AB13458 Rabbit polyclonal - 
MDM2 Calbiochem Rockland, MA OP46 Mouse monoclonal 1F2 
VEGF Santa Cruz Biotechnology Santa Cruz, CA sc-152 Rabbit polyclonal A20 / SC-152 
p53 Dako Carpinteria, CA M7001 Mouse monoclonal D0-7 
p16 MTM Laboratories Heidleberg, Germany 9517 Mouse monoclonal E6H4 
Rb BD Biosciences San Jose, CA 554136 Mouse monoclonal G3-245 
β-catenin BD Biosciences San Jose, CA 610154 Mouse monoclonal 14 
mTor pathway components 
pS6RP (Ser235/236) Cell Signaling Danvers, MA 2211 Rabbit polyclonal - 
p4EBP1 (Thr70) Cell Signaling Danvers, MA 9455 Rabbit polyclonal - 
pAKT (Ser473) Cell Signaling Danvers, MA 9271 Rabbit polyclonal - 
PTEN Dako Carpinteria, CA M3627 Mouse monoclonal 6H2.1 
Tyrosine kinase receptors/ligands 
EGFR Zymed Carlsbad, CA 08-4205 Mouse monoclonal 31G7 
IGF-1R Ventana Tucson, AZ 790-4346 Rabbit monoclonal G11 
PDGFR-α Santa Cruz Biotechnology Santa Cruz, CA sc-338 Rabbit polyclonal C-20 
PDGFR−β Santa Cruz Biotechnology Santa Cruz, CA sc-339 Rabbit polyclonal P-20 
PDGF−α Santa Cruz Biotechnology Santa Cruz, CA sc-128 Rabbit polyclonal N-30 
PDGF−β Santa Cruz Biotechnology Santa Cruz, CA sc-7878 Rabbit polyclonal H-55 
C-kit (CD117) Dako Carpinteria, CA A4502 Rabbit polyclonal CD117 
MET Santa Cruz Biotechnology Santa Cruz, CA SC-10 Rabbit polyclonal C12 
AXL Cell Signaling Danvers, MA 4566 Rabbit monoclonal C44G1 
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Appendix Table A2. Protocols for immuohistochemistry experiments. 
Name of Marker Dilution Blocking Agent(s) HIER method HIER buffer 
Smooth muscle/gynecological differentiation markers 
SMA 1:80,000 Antibody diluent buffer (Ventana) no antigen retrieval  no antigen retrieval  
SMM 1:200 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 30min Citrate buffer, pH6.0 
Desmin 1:200 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 20min Citrate buffer, pH6.0 
Caldesmon  1:50 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 30min Citrate buffer, pH6.0 
WT-1 1:40 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 15min Tris-EDTA buffer, pH8.0 
Estrogen Receptor 1:35 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 30min Citrate buffer, pH6.0 
Progesterone Receptor 1:200 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 20min Citrate buffer, pH6.0 
Cancer-related markers       
Ki-67 1:100 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 25min Citrate buffer, pH6.0 
Cyclin D1 1:20 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 35min TRIS-HCl, pH9.0 
Bcl-2 1:20 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 25min Citrate buffer, pH6.0 
Survivin 1:500 5% horse serum & 1% goat serum Steam Cooker for 40min Citrate buffer, pH6.0 
MMP2 1:500 5% horse serum & 1% goat serum no antigen retrieval  No antigen  
MMP9 1:1000 5% horse serum & 1% goat serum no antigen retrieval  No antigen retrieval  
VEGF 1:50 Antibody diluent buffer (Ventana) Dako Auto Stainer, 45min Citrate buffer, pH6.0 
MDM2 1:20 Antibody diluent buffer (Diagnostic Biosystems) Pressure cooker, 45 min Citrate buffer, pH6.0 
p53 1:100 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 5 min Citrate buffer, pH6.0 
p16 1:2 Antibody diluent buffer (Diagnostic Biosystems) Pressure cooker, 45 min Citrate buffer, pH6.0 
Rb 1:100 Antibody diluent buffer (Diagnostic Biosystems) Pressure cooker, 45 min Citrate buffer, pH6.0 
β−catenin 1:400 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 20min TRIS-HCl, pH9.0 
mTor pathway components 
pS6RP (Ser235/236) 1:200 5% horse serum & 1% goat serum Microwave, 10min, 98ºC 10mM Sodium citrate, pH6.0 
p4EBP1 (Thr70) 1:400 5% horse serum & 1% goat serum Microwave, 10min, 98ºC 10mM Sodium citrate, pH6.0 
pAKT (Ser473) 1:50 5% horse serum & 1% goat serum Microwave, 10min, 98C Borg decloaker, pH9.0 
PTEN 1:100 Antibody diluent buffer (Ventana) BOND MAX 20min, 100C TRIS-HCl, pH9.0 
Tyrosine kinase receptors/ligands 
EGFR 1:200 Antibody diluent buffer (Ventana) no antigen retrieval  pre-tx P24 enzyme, 1 min 
IGF-1R 1:2 pre-diluted  Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 5min Citrate buffer, pH6.0 
PDGFR-α 1:50 Antibody diluent buffer (Ventana) BOND MAX, 45min Citrate buffer, pH6.0 
PDGFR−β 1:50 Antibody diluent buffer (Ventana) BOND MAX, 45min Citrate buffer, pH6.0 
PDGF−α 1:50 Antibody diluent buffer (Ventana) BOND MAX, 45 min Citrate buffer, pH6.0 
PDGF−β 1:10 Antibody diluent buffer (Ventana) Steam Cooker for 45 min Tris/EDTA, pH8.0 
C-kit (CD117) 1:100 Antibody diluent buffer (Ventana) BOND MAX, 100ºC, 15min Citrate buffer, pH6.0 
MET 1:100 5% horse serum & 1% goat serum Steam Cooker for 45 min DIVA decloaker, pH6.0 
AXL 1:100 5% horse serum & 1% goat serum Steam Cooker for 40min Borg decloaker, pH8.0 
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Appendix Table A3. Antibodies used for western blotting (WB). 
Protein Antibody Origin Clone Dilution Company City, State Catalog # 
Blocking 
buffer Incubation 
pS6K (Thr389) Mouse monoclonal 1A5 1:1000 Cell Signaling Danvers, MA 9206 5% non-fat milk overnight, 4ºC 
S6K Rabbit monoclonal 49D7 1:1000 Cell Signaling Danvers, MA 2708 5% non-fat milk overnight, 4ºC 
p4EBP1 (Thr70) Rabbit polyclonal - 1:1000 Cell Signaling Danvers, MA 9455 5% BSA overnight, 4ºC 
4EBP1 Rabbit polyclonal - 1:1000 Cell Signaling Danvers, MA 9452 5% BSA overnight, 4ºC 
pAKT (Ser473) Rabbit monoclonal 193H12 1:1000 Cell Signaling Danvers, MA 4058 5% BSA overnight, 4ºC 
AKT Rabbit polyclonal - 1:1000 Cell Signaling Danvers, MA 9272 5% BSA overnight, 4ºC 
PTEN Rabbit monoclonal 138G6 1:1000 Cell Signaling Danvers, MA 9559 5% BSA overnight, 4ºC 
Cyclin D1 Mouse monoclonal DSC6 1:1000 Cell Signaling Danvers, MA 2926 5% non-fat milk overnight, 4ºC 
p21 Rabbit polyclonal C-19 1:1000 
Santa Cruz 
Biotechnology Santa Cruz, CA Sc-397 5% BSA overnight, 4ºC 
p53 Mouse monoclonal DO-1 1:1000 
Santa Cruz 
Biotechnology Santa Cruz, CA sc-126 5% non-fat milk overnight, 4ºC 
Aurora A Rabbit polyclonal - 1:1000 Cell Signaling Danvers, MA 3902 5% non-fat milk overnight, 4ºC 
Cleaved PARP Rabbit polyclonal - 1:1000 Abcam Cambridge, MA ab2322 5% BSA overnight, 4ºC 
β-actin (HRP 
conjugate) 
Mouse 
monoclonal C4 1:3000 
Santa Cruz 
Biotechnology Santa Cruz, CA sc-47778 Same as 1º Ab 45min, RT 
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Appendix Table A4. Differentiation marker expression in controls and ULMS. 
A. Differentiation markers in controls                 
 GI Smooth Muscle  Myometrium   Leiomyoma 
Marker Total n= negative focal diffuse   
Total 
n= negative  focal diffuse   
Total 
n= negative focal diffuse 
Smooth muscle differentiation markers                     
SMA 10 0 (0%) 0 (0%) 10 (100%)  15 0 (0%) 0 (0%) 15 (100%)  7 0 (0%) 0 (0%) 7 (100%) 
SMM 10 0 (0%) 0 (0%) 10 (100%)  15 0 (0%) 0 (0%) 15 (100%)  8 0 (0%) 1 (12%) 7 (88%) 
Desmin 10 0 (0%) 0 (0%) 10 (100%)  15 0 (0%) 0 (0%) 15 (100%)  7 0 (0%) 0 (0%) 7 (100%) 
Caldesmon 10 0 (0%) 0 (0%) 10 (100%)  15 0 (0%) 0 (0%) 15 (100%)  8 0 (0%) 0 (0%) 8 (100%) 
Gynecological differentiation markers             
Nuclear WT-1 8 8 (100%) 0 (0%) 0 (0%)  14 1 (7%) 0 (0%) 13 (93%)  10 0 (0%) 0 (0%) 10 (100%) 
Marker Total n= absent low high   
Total 
n= absent low high   
Total 
n= absent low high 
ER 10 6 (60%) 0 (0%) 4 (40%)  15 0 (0%) 0 (0%) 15 (100%)  8 2 (25%) 0 (0%) 6 (75%) 
PR 10 1 (10%) 3 (30%) 6 (60%)   14 0 (0%) 0 (0%) 14 (100%)   7 0 (0%) 2 (29%) 5 (71%) 
B. Differentiation markers in ULMS                  
 Primary  Recurrent  Metastatic 
Marker Total n= negative focal diffuse   
Total 
n= negative  focal diffuse   
Total 
n= negative focal diffuse 
Smooth muscle differentiation markers                     
SMA 18 2 (11%) 0 (0%) 16 (89%)  66 0 (0%) 3 (5%) 63 (95%)  124 10 (8%) 11 (9%) 103 (83%) 
SMM 18 1 (6%) 2 (11%) 15 (83%)  65 17 (26%) 4 (6%) 44 (68%)  121 25 (21%) 9 (7%) 87 (72%) 
Desmin 18 0 (0%) 15 (89%) 2 (11%)  65 16 (25%) 5 (7%) 44 (68%)  123 12 (10%) 22 (18%) 89 (72%) 
Caldesmon 18 2 (11%) 1 (6%) 15 (83%)  65 13 (20%) 9 (14%) 43 (66%)  122 23 (19%) 14 (11%) 85 (70%) 
Gynecological differentiation markers             
Nuclear WT-1 18 5 (28%) 0 (0%) 13 (72%)  63 24 (38%) 0 (0%) 39 (62%)  121 62 (51%) 0 (0%) 59 (49%) 
Marker Total n= absent low high  
Total 
n= absent low high  
Total 
n= absent low high 
ER 18 10 (56%) 0 (0%) 8 (44%)  65 37 (57%) 8 (12%) 20 (31%)  124 67 (54%) 18 (15%) 39 (31%) 
PR 18 7 (39%) 3 (17%) 8 (44%)   65 29 (45%) 5 (8%) 31 (48%)   117 42 (36%) 25 (21%) 50 (43%) 
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Appendix Table A5. Expression and distribution of cancer-related markers in controls. 
 GI Smooth Muscle  Myometrium  Leiomyoma 
A. Intensity                                 
Marker Total n= absent weak moderate strong   
Total 
n= absent weak 
modera
te strong   
Total 
n= absent weak 
modera
te strong 
Survival                       
Bcl-2  10 
6 
(60%) 
1 
(10%) 
3 
 (30%) 
0  
(0%)  14 
0  
(0%) 
3  
(21%) 
8  
(57%) 3 (21%)  8 
2 
(25%) 
3 
(38%) 
3 
(38%) 
0  
(0%) 
Cyt. 
survivin  10 
0  
(0%) 
5 
(50%) 
4 
 (40%) 
1 
 (10%)  15 
0 
 (0%) 
7  
(47%) 
8 
 (53%) 
0  
(0%)  8 
0  
(0%) 
3 
(38%) 
4 
(50%) 
1  
(13%) 
Nuc. 
survivin  10 
1 
(10%) 
8 
(80%) 
1 
 (10%) 
0 
 (0%)   15 
0 
 (0%) 
15 
(100%) 
0 
 (0%) 
0 
 (0%)   8 
1 
(13%) 
7 
(88%) 
0  
(0%) 
0 
 (0%) 
Invasion                       
MMP-2 10 
10 
(100%) 
0 
(0%) 
0 
 (0%) 
0  
(0%)  15 
14 
(93%) 
1  
(7%) 
0 
 (0%) 
0 
 (0%)  8 
7 
(88%) 
1 
(13%) 
0 
 (0%) 
0 
 (0%) 
MMP-9 10 
0  
(0%) 
4 
(40%) 
6 
 (60%) 
0 
 (0%)   15 
0 
 (0%) 3 (20%) 
12  
(80%) 
0 
 (0%)   8 
0  
(0%) 
4 
(50%) 
4 
(50%) 
0 
 (0%) 
Angiogenesis                           
VEGF 10 
0  
(0%) 
4 
(40%) 
6 
 (60%) 
0 
 (0%)   15 
0  
(0%) 6 (40%) 
9 
 (60%) 
0 
 (0%)   8 
 0  
(0%) 
4 
(50%) 
4 
(50%) 
0 
 (0%) 
Oncoproteins and tumor suppressors                   
MDM2 10 
10 
(100%) 
0 
(0%) 
0 
 (0%) 
0 
 (0%)  15 
15 
(100%) 
0 
 (0%) 
0 
 (0%) 
0 
 (0%)  5 
5 
(100%) 
0  
(0%) 
0 
 (0%) 
0 
 (0%) 
p53 10 
9 
(90%) 
1 
(10%) 
0 
 (0%) 
0 
 (0%)  15 
7 
(47%) 8 (53%) 
0 
 (0%) 
0 
 (0%)  7 
3 
(43%) 
4 
(57%) 
0 
 (0%) 
0 
 (0%) 
p16 10 
6 
(60%) 
1 
(10%) 
1 
 (10%) 
2 
 (20%)  15 
11 
(73%) 
0  
(0%) 
2  
(13%) 2 (13%)  7 
3 
(43%) 
1 
(14%) 
1 
(14%) 
2  
(29%) 
Rb 
10 2  (20% 
8 
(80%) - 
0 
 (0%)  14 
3 
(21%) 
11 
(79%) - 
0 
 (0%)  6 
0  
(0%) 
6 
(100%) - 
0 
 (0%) 
Signaling                                   
Cyt. β-
catenin 
10 9 (40%) 
6 
(60%) 
0  
(0%) 
0 
 (0%)   15 
2 
(13%) 
13 
(87%) 
0 
 (0%) 0 (0%)   8 
4 
(50%0 
4 
(50%) 
0 
 (0%) 
0 
 (0%) 
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B. Distribution   GI Smooth Muscle        Myometrium                    Leiomyoma   
Marker Total n= absent low high 
Average    
(+/- SD) 
  Total n= absent low high 
Average    
(+/- SD) 
  Total n= absent low high 
Average   
(+/- SD) 
Proliferation                      
Ki67 10 
10 
(100%) 
0  
(0%) 
0  
(0%) 
0%   
(+/- 0)  14 
14 
(100%) 
0  
(0%) 
0 
 (0%) 
0%    
(+/- 0)  6 
6 
(100%) 
0  
(0%) 
0 
(0%) 
0%    
(+/- 0) 
Cyclin D1 10 
9 
(90%) 
1 
(10%) 
0  
(0%) 
2%   
(+/-) 6)   15 
14 
(93%) 
1  
(7%) 
0 
 (0%) 
2%    
(+/-3)    8 
6 
(75%) 
2 
(25%) 
0 
 (0%) 
6%    
(+/- 12) 
survival                     
Bcl-2  10 
6 
(60%) 
1 
(10%) 
3  
(30%) 
23% 
(+/-31)  14 
0  
(0%) 
1  
(7%) 
13 
(93%) 
60%  
(+/-12)   8 
2 
(25%) 
2 
(25%) 
4  
(50%) 
41%   
(+/-28) 
Cyt. survivin  10 
0  
(0%) 
2 
(20%) 
8  
(80%) 
59% 
(+/-23)  15 
0  
(0%) 
1  
(7%) 
14 
(93%) 
67%  
(+/-13)   8 
0 
 (0%) 
3 
(38%) 
5 
 (63%) 
55%  
(+/-24) 
Nuc. survivin  10 
2 
(20%) 
4 
(40%) 
4  
(40%) 
30% 
(+/-22)   15 
0  
(0%) 
8  
(53%) 
7 
 (47%) 
41%  
(+/-15)    8 
2 
(25%) 
5 
(63%) 
1  
(13%) 
27%  
(+/-18) 
Invasion                     
MMP-2 10 
10 
(100%) 
0  
(0%) 
0  
(0%) 
0%   
(+/-0)  15 
14 
(93%) 
0  
(0%) 
1  
(7%) 
6%    
(+/-23)   8 
7 
(88%) 
0  
(0%) 
1 
 (13%) 
11%  
(+/-32) 
MMP-9 10 
0  
(0%) 
0  
(0%) 
10 
(100%) 
90% 
(+/-0)   15 
0  
(0%) 
4  
(27%) 
11 
(73%) 
71%  
(+/-28)    8 
0  
(0%) 
1 
(13%) 
7  
(88%) 
83%  
(+/-18) 
Angiogenesis                            
VEGF 10 
0  
(0%) 
3 
(30%) 
7 
 (70%) 
51% 
(+/-19)   15 
0  
(0%) 
6  
(40%) 
9  
(60%) 
53%   
(+/-16)    8 
0 
 (0%) 
3 
(38%) 
5  
(63%) 
55%  
(+/-21) 
Oncoproteins and tumor suppressors                  
MDM2 10 
10 
(100%) 
0  
(0%) 
0  
(0%) 
0%   
(+/-0)  15 
15 
(100%) 
0 
 (0%) 
0 
 (0%) 
0%    
(+/-0)   5 
5 
(100%) 
0 
(0%) 
0 
 (0%) 
0%    
(+/-0) 
p53 10 
9 
(90%) 
1 
(10%) 
0  
(0%) 
2%   
(+/-6)  15 
13 
(87%) 
2  
(13%) 
0  
(0%) 
3%    
(+/-4)   7 
6 
(86%) 
1 
(14%) 
0  
(0%) 
4%    
(+/-4) 
p16 10 
9 
(90%) 
1 
(10%) 
0 
 (0%) 
4%   
(+/-6)  15 
12 
(80%) 
3  
(20%) 
0  
(0%) 
2%    
(+/-4)   7 
5 
(71%) 
1 
(14%) 
1  
(14%) 
15%   
(+/-33) 
Rb 10 
3 
(30%) 
3 
(30%) 
4  
(40%) 
29% 
(+/-21)  15 
6 
(43%) 
7  
(50%) 
1  
(7%) 
16%  
(+/-17)   6 
0  
(0%) 
5 
(83%) 
1  
(17%) 
25%  
(+/-15) 
Signaling                                 
Cyt. β-
catenin 
10 4 (40%) 
6 
(60%) 
0  
(0%) 
15% 
(+/-18)  15 
2 
(13%) 
12 
(80%) 
1  
(7%) 
16%  
(+/-12)   8 
4 
(50%) 
4 
(50%) 
0 
 (0%) 
11%  
(+/-16)  
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Nuc. β-
catenin 10 
10 
(100%) 
0  
(0%) 
0 
 (0%) -  15 
15 
(100%) 
0 
 (0%) 
0  
(0%) -  8 
8 
(100%) 
0  
(0%) 
0  
(0%) - 
Membranous   
β-catenin 10 
10 
(100%) 
0 
 (0%) 
0 
 (0%) -   15 
15 
(100%) 
0  
(0%) 
0  
(0%) -   8 
8 
(100%) 
0  
(0%) 
0  
(0%) - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!! 182!
Appendix Table A6. Expression and distribution of cancer-related markers in ULMS 
A. Intensity                                     Primary ULMS                                                     Recurrent ULMS                                               Metastatic ULMS 
Marker Total n= absent weak moderate strong   
Total 
n= absent weak moderate strong   
Total 
n= absent weak moderate strong 
Survival                                    
Bcl-2  18 
1 
 (6%) 7 (39%) 
8  
(44%) 
2 
 (11%)  64 
8 
(13%) 
30 
(47%) 
17 
 (27%) 
9  
(14%)  122 
24 
(20%) 
49 
(40%) 
26  
(21%) 
23 
(19%) 
Cyt. survivin  18 
0 
 (0%) 
11 
(61%) 
7 
 (39%) 
0 
 (0%)  63 
0  
(0%) 
18 
(29%) 
45 
 (71%) 
0 
 (0%)  120 
0 
 (0%) 
37 
(31%) 
83 
 (69%) 
 0  
(0%) 
Nuc. survivin  18 
0 
 (0%) 
16 
(89%) 
2 
 (11%) 
0  
(0%)   63 
0 
 (0%) 
42 
(67%) 
20  
(32%) 
1  
(2%)   120 
0 
 (0%) 
82 
(68%) 
38 
 (32%) 
0 
 (0%) 
Invasion                                   
MMP-2  18 
18 
(100%) 0 (0%) 
0  
(0%) 
0 
 (0%)  65 
60 
(92%) 
3 
(5%) 
2 
 (3%) 
0 
 (0%)  118 
111 
(94%) 
2 
(2%) 
2 
 (2%) 
3  
(3%) 
MMP-9  18 
0 
 (0%) 7 (39%) 
6 
 (33%) 
5   
 (28%)   66 
1 
 (2%) 
23 
(35%) 
28 
 (42%) 
14 
(21%)   118 
0 
 (0%) 
53 
(45%) 
38 
 (32%) 
27 
(23%) 
Angiogenesis                                   
VEGF 18 
0 
 (0%) 9 (50%) 
6  
(33%) 3 (17%)   65 
1 
 (2%) 
28 
(43%) 
21 
 (32%) 
15 
(23%)   121 
0 
 (0%) 
32 
(26%) 
68  
(56%) 
21 
(17%) 
Oncoproteins and tumor suppressors               
MDM2  18 
15 
(83%) 1 (6%) 
2  
(11%) 
0  
(0%)  65 
53 
(82%) 
1 
(2%) 
7 
 (11%) 
4  
(6%)  117 
108 
(92%) 
4 
(3%) 
3 
 (3%) 
2  
(2%) 
p53 17 
6 
(35%) 6 (35%) 
5  
(29%) 
0  
(0%)  65 
19 
(29%) 
19 
(29%) 
27 
 (42%) 
0 
 (0%)  122 
62 
(51%) 
27 
(22%) 
32 
 (26%) 
1 
 (1%) 
p16  18 
2 
(11%) 6 (33%) 
3  
(17%) 
7  
(39%)  64 
3 
(5%) 
6 
(9%) 
20 
(31%) 
35 
(55%)  120 
8 
(7%) 
17 
(14%) 
39 
(33%) 
56 
(47%) 
Rb  18 
9 
(50%) 3 (17%) - 
6 
 (33%)   62 
38 
(61%) 
5 
(8%) - 
19 
(31%)   117 
70 
(60%) 
19 
(16%) - 
28 
(24%) 
Signaling                                    
Cyt. β-catenin 18 
1 
 (6%) 9 (50%) 
8 
 (44%) 
0 
 (0%)  64 
1  
(2%) 
20 
(31%) 24 (38%) 
19 
(30%)  120 
1  
(1%) 
40 
(33%) 
53  
(44%) 
26 
(22%) 
Nuc. β-catenin 18 
18 
(100%) 0 (0%) - 
0  
(0%)  64 
53 
(83%) 
0 
(0%) - 
11 
(17%)  121 
118 
(98%) 
0 
(0%) - 
3  
(2%) 
Membranous   
β-catenin 18 
17 
(94%) 0 (0%) - 
1 
 (6%)   64 
51 
(80%) 
0 
(0%) - 
13 
(20%)   121 
94 
(78%) 
0 
(0%) - 
27 
(22%) 
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B. Distribution 
  
 Primary ULMS       Recurrent ULMS       Metastatic ULMS   
Marker Total n= 
absent low high 
Average 
(+/- SD) 
 
Total 
n= 
absent low high 
Average 
(+/- SD)  
Total 
n= 
absent low high 
Average 
(+/- SD) 
Proliferation                                   
Ki67  18 
9 
(50%) 8 (44%) 
1 
(6%) 
11% 
(+/-18) 64 
9 
(14%) 
45 
(70%) 
10  
(16%) 
25% 
(+/-18) 123 
32 
(26%) 
76 
(62%) 
15 
(12%) 
23% 
(+/-18) 
Cyclin D1  18 
12 
(67%) 3 (17%) 
3 
(17%) 
18% 
(+/-29) 65 
47 
(72%) 
15 
(23%) 
3  
(5%) 
8% 
(+/-17) 124 
96 
(77%) 
23 
(19%) 
5 
(4%) 
7% 
(+/-14) 
Survival                                   
Bcl-2  18 
1 
(6%) 6 (33%) 
11 
(61%) 
54% 
(+/-28) 64 
8 
(13%) 
27 
(42%) 
29 
 (45%) 
43% 
(+/-34) 122 
26 
(21%) 
45 
(37%) 
51 
(42%) 
41% 
(+/-34) 
Cyt. survivin  18 
0 
(0%) 5 (28%) 
13 
(72%) 
59% 
(+/-21) 63 
0  
(0%) 
2 
(3%) 
61 
 (97%) 
73% 
(+/-11) 120 
2 
(2%) 
15 
(13%) 
103 
(86%) 
68% 
(+/-20) 
Nuc. survivin  18 
4 
(22%) 
10 
(56%) 
4 
(22%) 
26% 
(+/-20) 63 
0 
(0%) 
34 
(54%) 
29 
(46%) 
41% 
(+/-19) 120 
5 
(4%) 
63 
(53%) 
52 
(43%) 
40% 
(+/-18) 
Invasion                                   
MMP-2  18 
18 
(100%) 0 (0%) 
0 
(0%) 
0% 
(+/-0) 66 
61 
(92%) 
0 
(0%) 
5 
(8%) 
7% 
(+/-23) 118 
111 
(94%) 
1 
(1%) 
6 
(5%) 
4%  
(+/-19) 
MMP-9  18 
0 
(0%) 4 (22%) 
14 
(78%) 
73% 
(+/-25) 65 
0  
(0%) 
9 
(14%) 
56 
(86%) 
78% 
(+/-22) 118 
0 
(0%) 
19 
(16%) 
99 
(84%) 
76% 
(+/-23) 
Angiogenesis                                   
VEGF  18 
1 
(6%) 4 (22%) 
13 
(72%) 
56% 
(+/-26) 65 
3 
(5%) 
14 
(22%) 
48 
(74%) 
60% 
(+/-26) 121 
0 
(0%) 
25 
(21%) 
96 
(79%) 
66% 
(+/-21) 
Oncoproteins and tumor suppressors         
MDM2  18 
16 
(89%) 1 (6%) 
1 
(6%) 
6% 
(+/-17) 65 
59 
(91%) 
4 
(6%) 
2  
(3%) 
3% 
(+/-13) 117 
115 
(98%) 
1 
(1%) 
1 
(1%) 
1% 
(+/-6) 
p53 17 
8 
(47%) 3 (18%) 
6 
(35%) 
32% 
(+/-35) 65 
26 
(40%) 
14 
(22%) 
25 
 (38%) 
34% 
(+/-34) 122 
74 
(61%) 
15 
(12%) 
33 
(27%) 
22% 
(+/-31) 
p16  18 
4 
(22%) 1 (6%) 
13 
(72%) 
58% 
(+/-37) 64 
7 
(11%) 
4 
(6%) 
53 
 (83%) 
71% 
(+/-30) 120 
18 
(15%) 
6 
(5%) 
96 
(80%) 
65% 
(+/-32) 
Rb  18 
11 
(61%) 5 (28%) 
2 
(11%) 
13% 
(+/-21) 62 
46 
(74%) 
9 
(15%) 
7 
 (11%) 
11% 
(+/-22) 117 
91 
(78%) 
17 
(15%) 
9 
(8%) 
8% 
(+/-19) 
Signaling                                    
Cyt. β-catenin 18 
1 
(6%) 8 (44%) 
9 
(50%) 
52%  
(+/-31) 
64 1  
(2%) 
13 
(20%) 
50  
(78%) 
65%  
(+/-26) 
120 1  
(1%) 
30 
(25%) 
89  
(74%) 
61% 
(+/-26) 
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Appendix Table A7. Cancer-related biomarkers’ correlation to outcome. 
A. Biomarker distribution expression univariate correlation to recurrence-free (RFS) 
and metastasis-free (MFS) survival 
  RFS (univariable) MFS (univariable) 
Marker P Hazard Ratio (95% CI) P 
Hazard Ratio     
 (95% CI) 
Ki67 0.1909 - 0.2044 - 
Cyclin D1 0.5493 - 0.5559 - 
Bcl-2 0.3655 - 0.7220 - 
Cyt. survivin 0.1196 - 0.0680 - 
Nuc. survivin 0.0077 1.03 (1.01-1.05) 0.2683 - 
MMP2 0.9458   -  0.4031   - 
MMP9 0.7799   - 0.9543  -  
VEGF 0.4517 - 0.5928 - 
MDM2 0.7489 - 0.7840 - 
p53 0.0705 - 0.6729 - 
p16 0.4584 - 0.7786 - 
Rb 0.1351 - 0.6089 - 
Cyt. β-catenin 0.0045 1.02 (1.01-1.04) 0.2190 - 
Nuc. β-catenin  0.0001  5.81 (2.03-16.60) 0.6238  -  
Memb.  β-
catenin  0.1519  - 0.5537  - 
B. Biomarker distribution expression univariate and multivariate correlation to disease 
specific survival  
  DDS (univariable) 
Marker P Hazard Ratio (95% CI) 
Ki67  0.1240 - 
Cyclin D1  0.4388 - 
Bcl-2  0.0142 0.98 (0.97-1.00) 
Cyt. survivin  0.2564 - 
Nuc. survivin  0.6086 - 
MMP2  0.6272  -  
MMP9  0.9277 - 
VEGF  0.7665 - 
MDM2  0.8800 - 
p53  0.0680 - 
p16  0.8024 - 
Rb  0.3709 - 
Cyt. β-catenin  0.1403 - 
Nuc. β-catenin  0.3173   - 
Memb.  β-
catenin      0.5741 - 
All markers were calculated by Cox analysis. 
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Appendix Table A8. Expression and distribution of mTor componentry and tyrosine kinase receptors/ligands in controls. 
 GI Smooth Muscle  Myometrium  Leiomyoma 
A. Intensity                                
Marker Total n= absent weak moderate strong   
Total 
n= absent weak moderate strong   
Total 
n= absent weak moderate strong 
mTOR pathway componentry                     
pS6RP 10 
0  
(0%) 
6 
(60%) 
4  
(40%) 0 (0%)  15 
0  
(0%) 
12 
(80%) 
3  
(20%) 
0 
(0%)  8 
0 
 (0%) 
6 
(75%) 
2  
(25%) 
0 
 (0%) 
Cyt. 
p4EBP1 
10 0  (0%) 
7 
(70%) 
2 
 (20%) 
1 
(10%)  13 
0  
(0%) 
6 
(46%) 
7 
 (54%) 
0 
(0%)  7 
0 
 (0%) 
5 
(71%) 
2 
 (29%) 
0 
 (0%) 
Nuc. 
p4EBP1 10 
0 
 (0%) 
8 
(80%) 
2 
 (20%) 0 (0%)  13 
0 
 (0%) 
10 
(77%) 
2 
 (23%)  
0 
(0%)  7 
0 
 (0%) 
2 
(57%) 
3 
 (43%) 
0 
 (0%) 
pAKT 
10 0  (0%) 
10 
(100%) 
0 
 (0%) 
0  
(0%)  14 
0 
 (0%) 
14 
(100%
) 
 0 
 (0%) 
0 
(0%)  7 
0 
 (0%) 
7 
(100%) 
 0 
 (0%) 
0 
 (0%) 
PTEN 10 
2 
(20%) 
5 
(50%) 
3  
(30%) 
0  
(0%)  15 
0 
 (0%) 
7 
(47%) 
8 
 (53%) 
0 
(0%)  8 
1 
(13%) 
4 
(50%) 
3 
 (38%) 
0 
 (0%) 
Tyrosine kinase receptors/ligands                           
EGFR 10 
1 
(10%) 
8 
(80%) 
1  
(10%) 
0  
(0%)  15 
0 
 (0%) 
13 
(87%) 
2 
 (13%) 
0 
(0%)  8 
0  
(0%) 
6 
(75%) 
2 
 (25%) 
0 
 (0%) 
IGF-1R 10 
9 
(90%) 
1 
(10%) 
0 
 (0%) 
0 
 (0%)  15 
11 
(73%) 
4 
(27%) 
0 
 (0%) 
0 
(0%)  6 
6 
(100%) 
0  
(0%) 
0 
 (0)% 
0 
 (0%) 
PDGFR-α 10 
9 
(90%) 
1 
(10%) 
0 
 (0%) 
0 
 (0%)  15 
11 
(73%) 
4 
(27%) - 
0 
(0%)  8 
5 
(63%) 
3 
(38%) - 
0 
 (0%) 
PDGF-α 10 
1 
(10%) 
5 
(50%) 
0 
 (0%) 
4 
(40%)  15 
2 
(13%) 
7 
(47%) - 
6 
(40%)  8 
0  
(0%) 
3 
(38%) - 
0 
 (0%) 
PDGFR-β 10 
6 
(60%) 
4 
(40%) 
0 
 (0%) 
0 
 (0%)  15 
3 
(20%) 
12 
(80%) 
0 
 (0%) 
0 
(0%)  8 
4 
(50%) 
4 
(50%) 
0 
 (0%) 
0 
 (0%) 
PDGF-β 10 
2 
(20%) 
8 
(80%) 
0  
(0%) 
0 
 (0%)  15 
0  
(0%) 
13 
(87%) 
2 
 (13%) 
0 
(0%)  8 
0 
 (0%) 
8 
(100%) 
0 
 (0%) 
0 
 (0%) 
c-KIT 10 
10 
(100%) 
0  
(0%) 
0 
 (0%) 
  0 
(0%)   15 
15 
(100%) 
0  
(0%) - 
0 
(0%)  8 
8 
(100%) 
0  
(0%) - 
0 
 (0%) 
MET 10 
0  
(0%) 
4 
(40%) 
5 
 (50%) 
1 
(10%)  15 
0  
(0%) 
5 
(33%) 
9 
 (60%) 
1 
(7%)  8 
0  
(0%) 
2 
(25%) 
5  
(63%) 
1 
(13%) 
AXL 10 
2 
(20%) 
8 
(80%) 
0 
(0%) 
0 
 (0%)   15 
5 
(33%) 
10 
(67%) - 
0 
(0%)   8 
2 
(25%) 
6 
(75%) - 
0  
(0%) 
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B. Distribution             GI Smooth Muscle                                                      Myometrium                                                          Leiomyoma 
Marker Total n= absent low high Average 
(+/- SD) 
  Total n= absent low high 
Averag
e (+/- 
SD) 
  Total n= absent low high Average 
(+/- SD) 
mTOR pathway componentry                     
pS6RP 
10 0 (0%) 
2 
(20%) 
8 
(80%) 
63% 
(+/-14)  15 
0 
(0%) 
1 
(7%) 
14 
(93%) 
63% 
(+/-13)  8 
0 
(0%) 
2 
(25%) 
6 
(75%) 
64% 
(+/-14) 
Cyt. 
p4EBP1 10 
0 
(0%) 
0 
(0%) 
10 
(100%) 
70% 
(+/-12)  13 
0 
(0%) 
0 
(0%) 
13 
(100%) 
67% 
(+/-8)  7 
0 
(0%) 
1 
(14%) 
6 
(86%) 
61% 
(+/-23) 
Nuc. 
p4EBP1 10 
0 
(0%) 
0 
(0%) 
10 
(100%) 
73% 
(+/-5)  13 
0 
(0%) 
0 
(0%) 
13 
(100%) 
68% 
(+/-6)  7 
0 
(0%) 
1 
(14%) 
6 
(86%) 
66% 
(+/-26) 
pAKT 10 
0 
(0%) 
2 
(20%) 
8 
(80%) 
68% 
(+/-23)  14 
0 
(0%) 
7 
(50%) 
7 
(50%) 
44% 
(+/-22)  7 
0 
(0%) 
0 
(0%) 
7 
(100%) 
77% 
(+/-5) 
Tyrosine kinase receptors/ligands                           
EGFR 10 
0 
(0%) 
2 
(20%) 
8 
(80%) 
50% 
(+/-31)  15 
0 
(0%) 
8 
(53%) 
7 
(47%) 
39% 
(+/-22)  8 
0 
(0%) 
4 
(50%) 
4 
(50%) 
48% 
(+/-27) 
IGF-1R 10 
9 
(90%) 
1 
(10%) 
0 
(0%) 
4% 
(+/-13)  15 
11 
(73%) 
0 
(0%) 
4 
(27%) 
19% 
(+/-33)  6 
6 
(100%) 
0 
(0%) 
0 
(0%) 
0% 
(+/-0) 
PDGFR-α 10 
9 
(90%) 
1 
(10%) 
0 
(0%) 
1% 
(+/-3)  15 
11 
(73%) 
3 
(20%) 
1 
(7%) 
7% 
(+/-18)  8 
5 
(63%) 
2 
(25%) 
1 
(12%) 
9% 
(+/-17) 
PDGF-α 10 
2 
(20%) 
1 
(10%) 
7 
(70%) 
55% 
(+/-27)  15 
2 
(13%) 
5 
(33%) 
8 
(53%) 
46% 
(+/-29)  8 
0 
(0%) 
1 
(13%) 
7 
(88%) 
61% 
(+/-15) 
PDGFR-β 10 
6 
(60%) 
1 
(10%) 
3 
(30%) 
19% 
(+/-30)  15 
3 
(20%) 
8 
(53%) 
4 
(27%) 
29% 
(+/-21)  8 
4 
(50%) 
4 
(50%) 
0 
(0%) 
13% 
(+/-16) 
PDGF-β 10 
2 
(20%) 
5 
(50%) 
3 
(30%) 
30% 
(+/-28)  15 
0 
(0%) 
7 
(47%) 
8 
(53%) 
45% 
(+/-25)  8 
0 
(0%) 
6 
(75%) 
2 
(25%) 
34% 
(+/-24) 
c-KIT 10 
10 
(100%) 
0 
(0%) 
0 
(0%) -  15 
15 
(100%) 
0 
(0%) 
0 
(0%) -  8 
8 
(100%) 
0 
(0%) 
0 
(0%) - 
MET 10 
0 
(0%) 
0 
(0%) 
10 
(100%) 
79% 
(+/- 3)  15 
0 
(0%) 
0 
(0%) 
15 
(100%) 
80% 
(+/-9)  8 
0 
(0%) 
0 
(0%) 
8 
(100%) 
80% 
(+/-8) 
AXL 10 
2 
(20%) 
6 
(60%) 
2 
(20%) 
21% 
(+/-18)  15 
7 
(47%) 
7 
(47%) 
1 
(7%) 
16% 
(+/-22)  8 
4 
(50%) 
2 
(25%) 
2 
(25%) 
21% 
(+/-24) 
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Appendix Table A9. Expression and distribution of mTOR componentry and tyrosine kinase receptors/ligands in ULMS.  
 Primary ULMS  Recurrent ULMS  Metastatic ULMS 
A. Intensity                            
Marker Total n= absent weak moderate strong   
Total 
n= absent weak moderate strong   
Total 
n= absent weak moderate strong 
mTOR pathway componentry                     
pS6RP 18 0 (0%) 
12 
(67%) 
5 
(28%) 1 (6%)  62 0 (0%) 
15 
(24%) 
30 
(48%) 
17 
(27%)  120 
0 
(0%) 
28 
(23%) 
62 
(52%) 
30 
(25%) 
Cyt. 
p4EBP1 16 0 (0%) 
7 
(44%) 
8 
(50%) 1 (6%)  59 0 (0%) 
9 
(15%) 
40 
(68%) 
10 
(17%)  118 
0 
(0%) 
27 
(23%) 
66 
(56%) 
25 
(21%) 
Nuc. 
p4EBP1 16 0 (0%) 
12 
(75%) 
3 
(19%) 1 (6%)  58 0 (0%) 
19 
(33%) 
24 
(41%) 
15 
(26%)  118 
0 
(0%) 
44 
(37%) 
60 
(51%) 
14 
(12%) 
pAKT 16 0 (0%) 
7 
(44%) 
9 
(56%) 0 (0%)  57 0 (0%) 
22 
(39%) 
27 
(47%) 
8 
(14%)  113 
0 
(0%) 
47 
(43%) 
51 
(45%) 
15 
(13%) 
PTEN 18 1 (6%) 
3 
(17%) 
7 
(39%) 
7 
(39%)  64 4 (6%) 
10 
(16%) 
21 
(33%) 
29 
(45%)  121 
10 
(8%) 
12 
(10%) 
39 
(32%) 
60 
(50%) 
Tyrosine kinase receptors/ligands                           
EGFR 17 
7 
(41%) 
8 
(47%) 
2 
(12%) 
0 
(0%)  65 
15 
(23%) 
27 
(42%) 
20 
(31%) 
3 
(5%)  117 
17 
(15%) 
53 
(45%) 
38 
(32%) 
9 
(8%) 
IGF-1R 18 
9 
(50%) 
7 
(39%) 
2 
(11%) 
0 
(0%)  64 
27 
(42%) 
23 
(36%) 
11 
(17%) 
3 
(5%)  117 
68 
(58%) 
34 
(29%) 
14 
(12%) 
1 
(1%) 
PDGFR-α 18 
2 
(11%) 
14 
(78%) - 
2 
(11%)  63 
2 
(3%) 
4 
(6%) - 
57 
(90%)  120 
14 
(12%) 
82 
(68%) - 
24 
(20%) 
PDGF-α 18 
4 
(22%) 
12 
(67%) - 
2 
(11%)  65 
14 
(22%) 
43 
(66%) - 
8 
(12%)  120 
39 
(33%) 
74 
(62%) - 
7 
(6%) 
PDGFR-β 18 
1 
(6%) 
14 
(78%) 
3 
(17%) 
0 
(0%)  61 
2 
(3%) 
49 
(80%) 
10 
(16%) 
0 
(0%)  117 
5 
(4%) 
82 
(70%) 
29 
(25%) 
1 
(1%) 
PDGF-β 18 
0 
(0%) 
10 
(56%) 
7 
(39%) 
1 
(6%)  65 
2 
(3%) 
24 
(37%) 
28 
(43%) 
11 
(17%)  121 
3 
(2%) 
50 
(41%) 
24 
(20%) 
44 
(36%) 
c-KIT 18 
18 
(100%) 
0 
(0%) - 0 (0%)  65 
62 
(95%) 
3 
(5%) - 
0 
(0%)  124 
122 
(98%) 
2 
(2%) - 
0 
(0%) 
MET 17 
0 
(0%) 
6 
(35%) 
9 
(53%) 
2 
(12%)  64 
0 
(0%) 
18 
(28%) 
45 
(70%) 
1 
(2%)  123 
0 
(0%) 
49 
(40%) 
63 
(51%) 
11 
(9%) 
AXL 18 
6 
(33%) 
10 
(56%) - 
2 
(11%)  61 
12 
(20%) 
41 
(67%) - 
8 
(13%)  117 
25 
(21%) 
62 
(53%) - 
30 
(26%) 
 
 
!! 188!
 
B. Distribution                  Primary ULMS                                                 Recurrent ULMS                                              Metastatic ULMS 
Marker Total n= absent low high 
Average 
% (+/- SD) 
Total 
n= absent low high 
Average 
% (+/- SD) 
Total 
n= absent low high 
Average 
% (+/- SD) 
mTOR pathway componentry                     
pS6RP 19 
0 
(0%) 
5 
(28%) 
13 
(72%) 
53% 
(+/-22) 62 
0 
(0%) 
15 
(24%) 
47 
(76%) 
62% 
(+/-21) 120 
0 
(0%) 
27 
(23%) 
93 
(78%) 
61% 
 (+/-19) 
Cyt. 
p4EBP1 16 
0 
(0%) 
2 
(13%) 
14 
(88%) 
66% 
(+/-17) 59 
0 
(0%) 
4 
(7%) 
55 
(93%) 
73% 
(+/-16) 118 
0 
(0%) 
3 
(3%) 
115 
(97%) 
73% 
 (+/-13) 
Nuc. 
p4EBP1 16 
0 
(0%) 
2 
(13%) 
14 
(88%) 
64% 
(+/-13) 59 
1 
(2%) 
3 
(5%) 
55 
(93%) 
71% 
(+/-18) 118 
0 
(0%) 
4 
(3%) 
114 
(97%) 
72% 
 (+/-11) 
pAKT 16 
0 
(0%) 
5 
(31%) 
11 
(69%) 
59% 
(+/-22) 58 
1 
(2%) 
9 
(16%) 
48 
(83%) 
66% 
(+/-22) 113 
0 
(0%) 
16 
(14%) 
97 
(86%) 
68% 
 (+/-19) 
Tyrosine kinase receptors/ligands                           
EGFR 18 
7 
(39%) 
5 
(28%) 
6 
(33%) 
32% 
(+/-30) 66 
15 
(23%) 
28 
(42%) 
23 
(35%) 
34% 
(+/-29) 117 
17 
(15%) 
59 
(50%) 
41 
(35%) 
36% 
 (+/-28) 
IGF-1R 18 
12 
(67%) 
1 
(6%) 
5 
(28%) 
22% 
(+/-33) 64 
31 
(48%) 
7 
(11%) 
26 
(41%) 
35% 
(+/-38) 117 
76 
(65%) 
22 
(19%) 
19 
(16%) 
16% 
 (+/-27) 
PDGFR-α 18 
2 
(11%) 
10 
(56%) 
6 
(33%) 
33% 
(+/-25) 63 
9 
(14%) 
26 
(41%) 
28 
(44%) 
44% 
(+/-28) 120 
14 
(12%) 
45 
(38%) 
61 
(51%) 
44% 
 (+/-27) 
PDGF-α 18 
4 
(22%) 
9 
(50%) 
5 
(28%) 
29% 
(+/-25) 65 
14 
(22%) 
37 
(57%) 
14 
(22%) 
28% 
(+/-24) 120 
39 
(33%) 
57 
(48%) 
24 
(20%) 
24% 
 (+/-26) 
PDGFR-β 18 
0 
(0%) 
10 
(56%) 
8 
(44%) 
42% 
(+/-26) 61 
2 
(3%) 
12 
(20%) 
47 
(77%) 
59% 
(+/-22) 120 
5 
(4%) 
28 
(23%) 
87 
(73%) 
59% 
 (+/-23) 
PDGF-β 18 
0 
(0%) 
7 
(39%) 
11 
(61%) 
53% 
(+/-27) 64 
0 
(0%) 
19 
(30%) 
45 
(70%) 
57% 
(+/-24) 121 
1 
(1%) 
33 
(27%) 
87 
(72%) 
58% 
 (+/-24) 
MET 17 
0 
(0%) 1 (6%) 
16 
(94%) 
82% 
(+/-14) 64 
0 
(0%) 
0 
(0%) 
64 
(100%) 
86% 
(+/-7) 123 
0 
(0%) 
1 
(1%) 
122 
(99%) 
85% 
 (+/-8) 
AXL 
18 8 (44%) 
7 
(39%) 
3 
(17%) 
21% 
(+/-28) 
61 15 (25%) 
13 
(21%) 
33 
(54%) 
45% 
(+/-34) 
118 29 (25%) 
26 
(22%) 
63 
(53%) 
40% 
(+/-32) 
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Appendix Table A10. Biomarker distribution correlation to outcome. 
A. Biomarker distribution expression univariate correlation to recurrence-
free (RFS) and metastasis-free (MFS) survival 
  RFS (univariable) MFS (univariable) 
Marker P 
Hazard Ratio 
(95% CI) P 
Hazard Ratio     
(95% CI) 
pS6RP 0.2674 - 0.2294 - 
cyt. p4EBP1 0.8992 - 0.3479 - 
nuc. p4EBP1 0.9492 - 0.9846 - 
pAKT 0.3285 - 0.8661 - 
PTEN  0.9087  -  0.9308    
EGFR  0.5005 - 0.7279 - 
IGF-1R  0.1337 - 0.2411 - 
PDGFR-α 0.1903 - 0.0946 - 
PDGF-α 0.2263 - 0.0215 0.98 (0.97-1.00) 
PDGFR-β 0.0557 -  0.1556 - 
PDGF-β 0.6641 - 0.3909 - 
c-KIT 0.9570    0.1340    
MET 0.1222 - 0.0774 - 
AXL 0.3480 - 0.1671 - 
B. Biomarker distribution expression univariate correlation to disease 
specific survival  
 DDS (univariable)  
Marker P 
Hazard Ratio  
(95% CI)   
pS6RP 0.8796 -   
cyt. p4EBP1 0.0793 -   
nuc. p4EBP1 0.0494 1.03 (1.00-1.06)   
pAKT 0.4645 -   
PTEN  0.7488    
EGFR  0.9942 -   
IGF-1R  0.9531 -   
PDGFR-α 0.3775 -   
PDGF-α 0.3824 -   
PDGFR-β 0.0394 1.02 (1.00-1.04)   
PDGF-β 0.5717 -   
c-KIT  0.0284  5.28 (1.19-23.35)   
MET 0.4062 -   
AXL 0.7929 -   
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